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ABSTRACT 
There is good evidence that interleukin- I alpha (IL- I a) plays a key role in both the host 
response to bacteria and the tissue destruction associated with periodontal disease. This 
thesis investigated the interaction of bacterial, genetic and pharmacological factors in the 
regulation of IL-la in periodontal disease. To investigate the stimulation of IL-la by 
periodontal pathogens, human monocytes were challenged with a wide range of 
periodontal species. Most of the species tested stimulated high levels of IL-la. Induction 
by P. gingivalis was notably weak. Co-stimulation with P. gingivalis antagonised the 
ability of other bacterial species to induce IL-la, and this antagonism was due to the 
specific nature of its LPS. The association of periodontal. disease with host genetic 
variation was investigated by screening the IL-lA promoter region by direct sequencing 
in patients with aggressive periodontitis. Three single-nucleotide polymorphisms (SNPs) 
were identified including rs3783521 C>T, rs1800794 C>T, rs1800587 C>T. 
However, the prevalence of polymorphic alleles between patients and healthy subjects 
was similar. To test if any of these polymorphisms effect transcription of IL-IA, the 
polymorphisms of interest were introduced into an IL-lu luciferase reporter construct by 
site-directed mutagenesis. Only one of these polymorphisms, rs1800587 (-899), resulted 
in a significant change in transcription using transient transfection assays. The T allele of 
this SNP reduced both the basal activity and the response to LPS or periodontopathogens. 
Therefore, the rs1800587 SNP might play a role in the regulation of IL-lA gene 
transcription induced by bacteria. The central role played by IL-1 a in the pathogenesis of 
periodontal disease suggests that immunomodulation may offer a therapeutic option. 
Sub-antimicrobial concentrations of doxycycline inhibited IL-Ict production in response 
to bacterial stimulation by human monocytes. This effect appears to be at translational 
level rather than transcription. It does not appear to involve the regulation of NF-icB 
activity, or the suppression of IL-Ict transcription, or doxycycline chelation properties. In 
conclusion, IL-la is a pivotal cytokine involved in periodontal disease, and its regulation 
is a complex event governed by bacterial factors, host genetics and pharmacological 
agents. 
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CHAPTER1 
Introduction 
Chapter 1: Introduction 
"If it were notfor the great variability among individuals medicine might as well be a 
science and not an arto Sir WiMam Osler, 1892 
1.1 PERIODONTAL DISEASE 
Periodontal disease has been defined as any condition affecting the periodontium or tooth 
supporting tissues including the periodontal ligament, the gingival connective tissue and 
the alveolar bone. More than 40 different conditions have been classified as periodontal 
diseases at the International Workshop for the Classification of Periodontal Disease and 
Conditions in 1999 (Armitage, 1999) (Table 1.1). Several classification systems for 
periodontal diseases have been adopted over the years based on the understanding of the 
nature of these diseases. Advances in research methodologies have led to changes in 
disease paradigms. For the period from approximately 1870 to 1920, the diseases were 
classified on the basis of their clinical features. The concepts of classical pathology were 
used from 1920 to 1970 based on results from histopathological studies. Current 
classification systems for periodontal diseases are mainly based on the Infection/Host 
Response paradigm since the 1970s (An-nitage, 2002). 
Gingivitis and periodontitis are the most common forms of periodontal disease. The 
primary aetiology of both gingivitis and periodontitis is the presence of oral bacteria that 
accumulate as biofilm communities on tooth surfaces (Haffbjee and Socransky, 1994) 
and the majority of periodontal tissue destruction is caused by an inappropriate host 
response to those microorganisms and their products (Page and Kornman, 1997; 
Schenkein, 2006). 
Gingivitis is characterised by the presence of gingival inflammation, without loss of 
connective tissue attachment and can reverse to a healthy state after removal of the dental 
biofilm (Loe, 1965; Teles et al., 2006). Periodontitis results from a persistent bacterial 
infection, which causes chronic inflammation resulting in loss of gingival connective 
tissue and alveolar bone. Studies show that periodontitis is preceded by gingivitis and the 
duration of onset and the intensity of the inflammatory process vary considerably from 
person to person, as well as between teeth and tooth sites within the same person. 
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CURRENT CLASSIFICATION OF PERIODONTAL DISEASES AND CONDITIONS 
Gingival diseases 
A. Dental plaque-induced gingival diseases 
Non- plaque-induced gingival diseases 
11. Chronic periodontitis 
mild., 1-2mm CAL 
moderare: 34mm CAL 
severe: >5mm CAL 
A. Localized 
B. Generalized 
III. Aggressive periodontitis 
mild: 1-2mm CAL 
moderate: 3-4mm CAL 
severe: >5mm CAL 
A. Localized 
B. Generalized 
IV. Periodontitis as a manifestation of systemic diseases 
A. Periodontitis associated with hematological disorders 
a Periodontitis associated with genetic disorders 
C. Not otherwise specified (NOS) 
V. Necrotizing Periodontal Diseases 
A. Necrotizing ulcerative gingivitis (NUG) 
B. Necrotizing ulcerative periodontitis (NUP) 
Vi. Abscesses of periodontium 
A. Gingival abscess 
B. Periodontal abscess 
C. Pericoronal abscess 
VI 1. Periodontitis associated with endodontic lesions 
A. Combined periodontic-endodontic lesions 
Vill. Developmental or acquired deformities and conditions 
A. Tooth-related factors that modify or predispose to plaque-induced gingival 
diseases/periodontitis conditions 
B. Mucogingival deformities and conditions 
C. Occlusal trauma 
Table 1.1 Abbreviated version of the 1999 Classification of Periodontal Diseases. A new classification 
which was agreed upon at the International Workshop for a Classification of Periodontal Diseases and 
Conditions in 1999 on October 30-November 2,1999. Over 40 different gingival diseases and seven major 
categories of destructive pcriodontal diseases were listed. Adapted from Armitage (1999). 
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1.1.1 Chronic periodontitis 
Two main forms of destructive periodontal disease are currently recognized, chronic and 
aggressive periodontitis. Although prevalence figures vary with race and geographic 
region, chronic periodontitis is rather prevalent affecting about 35% of the population 
(Albandar et al., 1999; Gjermo et al., 2002; Sheiham and Netuveli, 2002). Chronic 
periodontitis is designated as localized or generalized depending on whether more or less 
than 30% of sites are affected (Goodson et al., 1982). In earlier literature this clinical 
form was referred to as adult periodontitis since it was believed that only adults 
developed the disease (Page and Schroeder, 1976). However, epiderniologic data clearly 
show that the disease can also be found in children and adolescents (Albandar and 
Tinoco, 2002). The main clinical features and characteristics of chronic periodontitis are 
listed in Table 1.2 (Armitage, 1999). 
Most prevalent in adults, but can occur in children and adolescents 
Level of destruction is consistent with the presence of local factors 
Subgingival calculus is a frequent finding (-40-60%) 
Can be associated with local predisposing factors (e. g., tooth-related or iatrogenic factors 
May be modified by and/or associated with systemic diseases 
Can be increased by diabetes mellitus, cigarette smoking and emotional stress 
Associated with a variable microbial pattern (i. e. no single bacteria] species ) 
Slow to moderate progression rate, but may have periods of rapid progression 
Tablel. 2 Main clinical features and characteristics of chronic periodontitis (1999 Classification). 
1.1.2 Aggressive periodontitis 
Aggressive periodontitis encompasses distinct types of periodontitis that affect people 
who appear otherwise healthy. Patients with aggressive periodontitis (formerly termed 
juvenile periodontitis, early onset periodontitis or rapidly progressive periodontitis) are 
characterized by a rapid and severe periodontal destruction in mainly younger individuals 
(Albandar and Tinoco, 2002; Caton and Lowenguth, 1993; Page et al., 1983). 
Epidemiological surveys have shown that the prevalence of aggressive periodontitis 
varies widely among races, regions and countries. The estimated prevalence of 
aggressive periodontitis ranges from 0.1% to 15% among Caucasians, Hispanics and 
African-Americans (Albandar et al., 1997a; Loe and Brown, 1991). 
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Aggressive periodontitis is subdivided into localized (LAP) or generalized (GAP) 
(Armitage, 2004; Ranney, 1993). In the case of generalized aggressive periodontitis, 
subjects display bone loss in at least three permanent teeth other than first molars and 
incisors. The localized form usually occurs in adolescence with characteristically high 
levels of antibodies against putative pathogens in serum, whereas GAP is usually 
diagnosed in people less than 35 years of age with low levels of antibodies against 
putative pathogens. However, GAP is not necessarily confined to individuals younger 
than 35 years of age. Generally accepted features of aggressive periodontitis are shown in 
Table 1.3 (Armitage, 1999). Currently, it cannot be concluded whether the localized and 
generalized forms of aggressive periodontitis are two different diseases, with distinct 
aetiological factors and pathogenesis, or whether they are two stages of the same disease. 
Primary features I 
Besides periodontitis, subjects are systemically healthy 
Rapidly progressing periodontal destruction 
Often show familial aggregation 
Secondary features (often but not always) 
No clear relationship between the amount of dental plaque and level of tissue destruction 
High prevalence of Aggregatibacter actinomycetemcomitans (formerly named Actinobacillus 
actinomycetemcomitans) and Porphyromonas gingivalis 
Hyper-responsive macrophage-phenotype with increased production of inflammatory mediators 
Progression of attachment loss and bone loss may be self-arresting 
Table 1.3 Features of aggressive periodontitis that are common to both the localized and generalized 
forms of the disease (1999 Classification). 
In summary, there is still uncertainty regarding the aetiological factors that might be 
involved and much is yet to be learned in order to explain why some individuals develop 
severe periodontal disease while others are relatively resistant to disease progression 
beyond marginal gingivitis. It is very likely that both chronic and aggressive periodontitis 
are a constellation of diseases rather than a single entity. The clinical manifestations of 
these diseases are altered by important environmental and host-modifying conditions 
including oral hygiene, smoking, emotional stress, and diabetes. With increased 
understanding of periodontal infections and increasing information about the genetic 
factors controlling host responses to these infections, it is may be possible to sub classify 
the forms of periodontitis into discrete microorganism/host genetic polymorphism groups 
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(Table 1.4). This thesis will focus on understanding the host response to bacteria and the 
genetic factors controlling host responses to these bacterial infections. 
" Group A- Set #I of microorganisms + Set #I of genetic polymorphisms 
" Group B- Set #2 of microorganisms + Set #2 of genetic polymorphisms 
" Group C- Set #3 of microorganisms + Set #3 of genetic polymorphisms 
Table 1.4 Hypothetical way of classifying periodontal diseases. Adapted from Armitage (2004). 
1.2 AETIOLOGY OF PERIODONTAL DISEASE 
Aetiology is defined as the study of causation of disease and includes both the direct 
cause and factors associated with cause. Two components can be defined within this; risk 
factors and risk determinants (or susceptibility factors). The term risk factor refers to an 
aspect of personal behaviour, an environmental exposure, or an inherited characteristic, 
which on the basis of epidemiological evidence is known to be associated with the 
increased rate of a subsequently occurring disease (Last, 1982). Risk factors are 
associated with a disease but do not necessarily cause the disease. Some risk factors may 
be modified to reduce one's risk of initiation or progression of disease, such as smoking 
cessation or improved oral hygiene while non-modifiable risk factors are usually intrinsic 
to the individual and therefore not easily changed such as genetic factors. A risk factor 
that cannot be modified is often referred to as a risk determinant (Albandar, 2002). 
Periodontal disease is considered to have multiple aetiological factors (Nunn, 2003). 
Microbial dental plaque biofilms are the principal aetiological factor of periodontitis, 
whereas several other local and systemic factors related to the host have important 
modifying roles in its pathogenesis. 
1.2.1 Bacterial risk factors 
The aetiology of various forms of periodontal disease has long been recognized to be 
related to bacterial accumulations and plaque composition. Microorganisms in dental 
biofilms are aetiological factors essential for the initiation of the inflammatory process 
locally at the infection site, and in the absence of these, the inflammatory response does 
not take place (Haffajee and Socransky, 2006; Moore and Moore, 1994). The evidence 
for the infectious nature of periodontal disease comes from several sources, including: 
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1. Clinical and microbiological data linking accumulated dental biofilms to the 
initiation, progression and recurrence of disease in periodontitis. 
2. Clinical studies which demonstrate that elimination of dental biofilms can be 
correlated with clinical improvement. 
3. Genetic and experimental data linking virulence factors possessed by different dental 
biofilm bacteria to pathogenic events known to occur during periodontitis. 
The role of bacteria in periodontal diseases was initially established in experimental 
gingivitis models (L6e et al., 1965) including studies on beagle dogs (Theilade et al., 
1966). Experimental gingivitis studies provided the first evidence that accumulation of 
dental plaque biofilms on clean tooth surfaces results in the development of an 
inflammatory process around gingival and periodontal tissues and that the inflammation 
may resolve subsequent to removal of the microbial biofilm (Silness and L6e, 1964). 
Since this advance, an enormous research effort has been devoted to the study of 
periodontal-disease-associated microflora, spanning from classic bacterial culture 
methods to modem approaches at the molecular, whole genornic and proteomic levels 
(Gmur and Thumheer, 2002; Griffen et al., 1998; Klein and Goncalves, 2003; Kumar et 
al., 2003; Lyons et al., 2000; Mayanagi et al., 2004). Early studies of the bacterial 
composition of subgingival plaque samples used cultural techniques (Nyvad and Kilian, 
1987; Socransky et al., 1977). These have yielded considerable insights into the 
colonizing micro-organisms that can be identified by means of cultivation. In the 
following years, poly or monoclonal antibodies were used to enumerate species directly 
in plaque samples (Wilson et al., 1993). More recently use of the checkerboard DNA- 
DNA hybridization techniques have provided not only information on these species, but 
also enabled the detection of unusual micro-organisms that are present in low numbers or 
those that are difficult to enumerate by culture (Ramberg et al., 2003; Ximenez-Fyvie et 
al., 2000b). 
Certain bacterial species have been associated with periodontitis. Specific genetic 
variants of A. actinomycetemcomitans have been shown to significantly correlate with 
aggressive forms of periodontal diseases and to be prevalent in aggressive periodontitis 
patients from certain geographic areas, particularly among subjects of African descent 
(DiRienzo ct al., 1994; Fine et al., 2006; Haubek et al., 2001; Kilian et al., 2006). There 
is also evidence showing that P. gingivalis is strongly associated with chronic 
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periodontitis (Holt and Ebersole, 2005; Slots and Ting, 1999). This bacterium is 
consistently detected in high levels in cross-sectional studies in persons with severe 
attachment loss and deep probing depths (Albandar et al., 1997b; Grossi ct al., 1994). 
However, evaluation of these pathogens as risk factors for identification of attachment 
loss over time has resulted in conflicting evidence. Some studies indicated that none of 
these pathogens were useful in predicting periodontal disease progression (Listgarten et 
al., 199 1; MacFarlane et al., 1988). 
Most recent evidence suggests that periodontal diseases have a multi-bacterial aetiology 
and therefore it is important to gain insight into the bacterial composition of dental 
plaque rather than the specificity of certain bacteria (Socransky and Haffajee, 2002). In 
the consensus report from the World Workshop in 1996, P. gingivalis A. 
actinomyretemcomitans and Tannerella forsythensis were described as being the most 
likely candidate organisms that could be referred to as risk indicators in periodontitis 
(Zambon, 1996). Once it became clear that no single pathogen was a causative agent for 
periodontal disease, studies shifted towards investigating how different organisms act in 
concert. Five sets of bacteria, or complexes that were consistently (>60%) found together 
in periodontitis were identified in 1998 (Figure 1.1) (Socransky et al., 1998). The most 
pathogenic complex designated as "the red complex", comprises of P. gingivalis, T 
forsyl, hensis, and Treponema denticola. The red complex bacteria exist in high numbers 
in lesions of chronic periodontitis (Umeda et al., 1996; Ximenez-Fyvie et al., 2006) and 
exhibit a strong relationship with inflammatory or other indicators of periodontitis such 
as pocket depth and bleeding on probing (Socransky et al., 1998). The other complex is 
designated as "the orange complex" including Fusobacterium nucleatum, Prevotella 
intermedia, Prevotella nigrescens, Peptostreptococcus micros, Campylobacter spp., 
Eubacterium nodatum, Streplococcus constellatus and is considered less pathogenic. The 
red complex is closely associated with the orange complex and bacteria belonging to "the 
orange complex7 have also been related to clinical parameters such as pocket depth 
(Socransky et al., 1998) but to a lesser degree than bacteria from the "red complex". 
There is also "the green complcx7', including Capnocytophaga spp., Campylobacter 
concisus, A. actinomyrelemcomitans (serotype a) and Eikenella corrodens. Moreover, 
Streptococcus spp including Streptococcus mitis, Streptococcus sanguis and 
Streplococcus oralis form "the yellow complex". Also "the purple complex! ' is made up 
by ActinomYces odontolyticus, and Vellionella parvula. Actinomyces naeslundii, 
24 
Chapter 1: Introduction 
Selenomonas noxia and A. actinomycetemcomitans (serotype b) are not clustered with 
other species. Species of the yellow, green and purple complexes together with A. 
naeslundii 2 are considered to be host compatible. 
A odm*o"kmn 
& mm$ 
& craft 
& »ngude a anwift C. r. cfiis 
S&OPeococcus lpý 
gordonfi 
kitennodius & 
A man& b 
a &%OW" 
a nocistum 
no3do 
ur-: Z= 
Figure 1.1 Diagrammatic representation of the microbial complexes in dental plaque. Socransky et al., 
(1998) carried out a studý to define species associations that occur in subgingival biofilms in vivo. Over 
13.000 subgingiNal biofilm samples from 185 subjects with different states of periodontal health and 
disease were tested. Associations between all pairs of species were measured by various similarity 
coefficients and the resulting similarity matrices subjected to cluster analysis. These analyses supported the 
hypothesis that there were distinct complexes of microorganisms in subgingival biofilms. Adapted from 
SocranskN and HaffaJee (2005). 
A large number of bacteria exist as a part of the normal ecology of the oral cavity, and 
these consist of diverse types of microorganisms that differ greatly in their virulence 
potential (Moore and Moore, 1994; Socransky and Haffajee, 2005). However, various 
bacterial species may have different effects on the pathogenesis of these diseases, and 
therefore may possess variable risk for periodontitis (Wolff et al., 1994; Zambon, 1996). 
The formation of a complex of periodontopathogenic bacteria is likely the result of the 
interactions between pathogenic and commensal organisms (Socransky and Haffajee, 
2005). Interactions among different bacterial cells have been proposed to drive the 
maturation of the dental biofilm. These interactions can occur at several levels including 
physical contact. metabolic exchange, and signal mediated communications 
(Kolenbrander et al.. 2006). The sequential nature of colonizing species is showed in 
Figure 1.2 (Courtesy of Dr. P. E. Kolenbrander). However, not all the bacteria present 
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might necessarily be part of transition from health to disease. Some longitudinal studies 
suggest that T forsythensis and C. rectus are the major species that characterized sites 
converting from health to disease (Tanner et al., 1998). It still remains unsolved as to 
how these shifts correlate with the appearance of gingivitis and in the susceptible host 
with the development of periodontitis. 
Figure 1.2 The model of oral bacterial colonization. This figure shows recognition of salivary pellicle 
receptors b) earl) colonizing bacteria. and coaggregations between early colonizers. fusobacteria and late 
colonizers ofthe tooth surface. Adapted from Kolenbrander et al. (2006). 
The characteristics of microbiological progression from periodontal health to gingivitis 
and eventually to periodontal disease are vast and complicated (Albandar et al., 1999; 
Haffajee et al., 2006; Socransky and Haffajee, 1994). The transition from health to 
disease in the periodontal tissues is accompanied by a change of the plaque microflora 
from predominantly gram-positive aerobic cocci to predominantly gram-negative rods 
(Listgarten, 1976). Total bacterial numbers also increase during microbial transition from 
health to disease. Approximately 1 02_ 103 bacteria are found in healthy subgingival 
plaque (Tanner et al., 1996), increasing to 104_ 106 organisms during gingivitis and 
escalating as high as 105-108 organisms during periodontitis (Darveau et al., 1997; 
Socransky et al.. 1963). However. it must be acknowledged that in some forms of 
periodontal disease the patients exhibit minimal levels of subgingival plaque (Brown et 
al., 1996). 
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Initial biofilm formation of up to 2 days of undisturbed plaque accumulation is 
predominated by streptococci (-63-86% of total bacterial number isolated), in particular 
S. mitis and S. oralis along with some Actinomyces, Veillonella (Nyvad and Kilian, 1987; 
Palmer et al., 2001; Socransky et al., 1994). As plaque matures, the bacterial population 
shifts to predominantly rods and filamentous bacteria (Listgarten, 1976; Tinanoff et al., 
1976). After 4 days of plaque accumulation, there is an increase in the numbers of F. 
nuclealum which facilitates biofilm development due to its coaggregation properties 
(Kroes et al., 1999). Subgingival plaque is probably formed by the spread of 
supragingival plaque down into the gingival sulcus (Theilade and Theilade, 1985). Few 
studies have examined the composition of subgingival and supragingival plaque samples 
in periodontal health and various states of periodontal diseases (Haffajee and Socransky, 
1994; Moore and Moore, 1994; Ximenez-Fyvie et al., 1999). The most commonly 
detected species in both health and disease are A. naeslundii and F. nucleatum. There are 
also other gram-negative periodontopathogenic bacteria such as P. gingivalis, T 
denficola in the both supragingival and subgingival plaque of healthy subjects and 
subjects with periodontitis. However, subjects with periodontitis seem to have higher 
proportions of these organisms in their supragingival plaque (Ximenez-Fyvie et al., 
2000a). 
It is likely that subject-specific factors such as genetic make-up prevent straightforward 
categorization of a microorganism as being absolutely causative of periodontal disease 
(Paster et al., 2006). There are studies that report inter-individual variation in dental 
plaque (Palmer et al., 2003; Palmer et al., 2001). It remains unclear whether the 
individual differences in flora composition are a result of different stages of disease 
progression, or are related to host, or environmental influences. It is possible that 
variation between individuals in the microflora of the oral cavity could be attributed to 
differences in host factors that modulate colonization of an individual by a specific set of 
species. Although periodontitis has been viewed for years as primarily the outcome of 
bacterial infection, it has become apparent that pathogens are necessary but not sufficient 
for disease activity to occur (Albandar, 2005; Page et al., 1997). 
1.2.2 Smoking 
Cigarette smoking has long been recognized as a risk factor for periodontal disease 
(Preber et al., 1980). The positive association between smoking and periodontal disease 
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has been reported in many epidemiological, clinical and in vitro studies (Albandar et al., 
2000). Cross-sectional and longitudinal data provide strong support for the statement that 
the risk of developing periodontal disease as measured by clinical attachment loss and 
alveolar bone loss increases with increased smoking between two and seven times 
(Johnson and Hill, 2004; Tomar and Asma, 2000). In a report derived from data of the 
United States Third National Health and Nutrition Examination Survey, it was calculated 
that 41.9% of periodontitis cases (6.4 million cases) in the adult population were 
attributable to current cigarette smoking and 10.9% (1.7 million cases) to former 
smoking (Tomar and Asma, 2000). A study of twins indicated that the degree of alveolar 
bone loss and the number of teeth lost were greater in the twins with a high smoking 
exposure when compared to their twin partners with a low smoking exposure (Bergstrom 
and Floderus-Myrhed, 1983). 
The study of genetic polymorphisms and smoking indicates that the interaction between 
polymorphisms and smoking may play a role in susceptibility to periodontal disease 
(McGuire and Nunn, 1999; Meisel et al., 2002). In a study of 323 maintenance patients, 
bleeding on probing was associated with a genotype of IL-I in those who had never 
smoked but the effect was not significant in smokers, where the authors suggest that the 
effect is overshadowed by the effect of smoking (Lang et al., 2000). 
Several studies have demonstrated that the severity of periodontitis appears to be related 
to the duration of tobacco use and amount of tobacco intake (Grossi et al., 1995). 
Periodontal treatment tends to result in a less successful outcome in smokers than in non- 
smokers (Hughes et al., 2006; Scabbia et al., 2001; Trombelli and Scabbia, 1997). A 
number of studies have established that smoking is associated with reduced gingival 
inflammation and bleeding (Bergstr8m and Bostrom, 200 1; Muller et al., 200 1). Reduced 
bleeding might reflect an underlying disruption of the immune response and that this may 
account for the increased loss of clinical attachment and alveolar bone (Barbour et al., 
1997; Palmer et al., 2005). Modulation of the host response by smoking will be discussed 
in the following sections. 
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1.2.3 Psychological factors 
A hypothesis of an increased risk for destructive periodontal diseases due to 
psychological disorders has long been promoted. Several studies have suggested that 
psychological stress may be associated with more acute forms of disease particularly 
necrotizing periodontal diseases (Homing and Cohen, 1995). Studies have demonstrated 
that individuals under psychological stress are more likely to develop clinical attachment 
loss and loss of alveolar bone (Hugoson et al., 2002; Pistorius et al., 2002; Wimmer et 
al., 2002). It is well established that psychological stress can down-regulate the cellular 
immune response (Rozlog et al., 1999). A recent study suggested that host response to P. 
gingivalis infection may be compromised in psychologically stressed individuals (Houri- 
Haddad et al., 2003). Another study assessed the effect of stress on the host immune 
system and showed that stimulation with P. gingivalis LPS significantly enhanced 
secretion of nitric oxide by macrophages, with the stressed animals showing significantly 
higher levels of nitric oxide than controls. Despite existing evidence from case control 
and cross sectional studies, no longitudinal studies have been published that confirm 
psychological stress as a risk factor for periodontal disease. Perhaps the relationship is 
due to the fact that individuals under stress are less likely to perform regular good oral 
hygiene and prophylaxis (Croucher et al., 1997). 
1.2.4 Systemic risk factors 
Periodontitis as a manifestation of systemic disease has been classified as separate 
periodontal disease category (Armitage, 1999) (Table 1.1). In fact, in most of these 
systemic diseases, there is either decreased host resistance to infections or perturbations 
in gingival connective tissue that increases its susceptibility to inflammation-induced 
destruction. It should be noted that diabetes mellitus is not on this list. Diabetes mellitus 
can be a significant modifier of all forms of periodontitis but there are insufficient data to 
conclude that there is a specific diabetes mellitus-associated form of periodontitis. 
Diabetes mellitus is one of the strongest systemic risk factors for periodontitis (Kinane 
and Chestnutt, 1997) and it is considered to be a modifier of existing periodontitis rather 
than a disease that causes periodontitis (L6e, 1993). Diabetes mellitus has been shown to 
be positively associated with clinical attachment loss (Genco, 1996). The severity of 
periodontitis in the diabetic patient appears to be related to the control of the diabetes 
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(Emrich et al., 1991; Tervonen and Oliver, 1993). In a longitudinal study of non-insulin 
dependent diabetics, severe periodontal disease at baseline was found to be a significant 
risk factor for poor glycemic control (Taylor et al., 1996). Similarly, poor glycemic 
control in non-insulin dependent diabetics has been shown to be associated with 
significantly greater alveolar bone loss compared to well-controlled non-insulin- 
dependent diabetics (Taylor, 2001). In addition, it has also been suggested that effective 
periodontal therapy can have a positive effect on the control of diabetes (Thorstensson, 
1995). 
Associations between periodontal disease and other systemic diseases such as 
osteoporosis, rheumatoid arthritis have also been reported, although it is not clear what 
role these relationships play (Mercado et al., 2001; Wactawski-Wende, 2001). With the 
discovery of emerging risk factors, inflammatory responses, and genetic regulators of 
these responses, it is quite possible that these associations actually reflect common 
underlying risk factors rather than any sort of causal relationship. The possible role of 
systemic diseases and systemic exposures in initiating or modifying the progress of 
periodontal disease is clearly a complex issue. 
1.2.5 Genetic factors 
A risk factor that cannot be modified is often referred to as a determinant (Genco, 1996). 
Risk determinants or susceptibility factors are demographic variables including age, 
gender and genetic factors. 
There is clear evidence that genetic factors affect the age of onset severity, and risk of 
developing periodontitis (Hart and Kornman, 1997; Hassell and Harris, 1995). While 
microbial and other environmental factors initiate and modulate periodontal disease, 
individuals are known to respond differently to common environmental challenges, and 
this differential response is influenced by the individual's genetic profile (Schenkein, 
2002). Evidence for a genetic contribution to periodontitis comes from several sources 
including familial aggregation of periodontal diseases (Boughman et al., 1988; Marazita 
et al., 1996), linkage studies (Hart et al., 2000b; Li et al., 2004b) and twin studies 
(Michalowicz et al., 1991; Michalowicz et al., 2000). Linkage studies of aggressive 
periodontitis have supported an autosomal dominant transmission (Hart et al., 2000b). 
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Studies comparing disease in monozygotic and dizygotic twins have suggested that about 
50% of the population variance in attachment loss could be accounted for by genetic 
factors (Michalowicz et al., 2000). Family studies of patients with aggressive 
periodontitis verify that there is a genetic contribution to this form of disease (Boughman 
et al., 1988). As well as clinical and epidemiological studies, animal models using 
susceptible and resistant mice have also provided strong evidence for a genetic 
predisposition to periodontal disease (Baker et al., 2000; Gemmell et al., 2003). 
However, studies of the prevalence of different bacterial species in human twins 
(Michalowicz et al., 1999) or in susceptible versus resistant mouse strains suggest that 
host genetics alone can not explain this variance in the incidence of P. gingivalis or P. 
intermedia (Baker, 2005). Thus, it seems that genetic factors have more influence on the 
host response to infection than on bacterial colonization itself (Baker et al., 2000). 
13 PATHOGENESIS OF PERIODONTITIS 
Periodontitis, a series of infections of the periodontal tissues arises from a complex 
biofilm of commensal and periodontopathic bacteria and their products, triggering an 
aberrant human inflammatory response. The bacteria colonizing the hard and soft tissues 
of the oral cavity are known to profoundly influence oral health and disease (Henderson 
and Wilson, 1998). Over 700 species have been identified in the human oral cavity 
(Kazor et al., 2003; Paster et al., 2001). These microorganisms produce several bioactive 
end products including endotoxins (lipopolysaccharides), exotoxins (e. g leukotoxin, 
cytolethal distending toxin) and proteases (e. g gingipains) (Curtis et al., 2001; Nishihara 
and Koseki, 2004; Potempa et al., 2000). 
These bacterial factors are more likely to challenge and disturb immune responses, and 
some of them may be chemotactic for polymorphonuclear leukocytes, activate the plasma 
proteinase cascade systems, or stimulate inflammatory and resident tissue cells to 
produce cytokines, including IL-la, IL-1p, TNF-a, platelet activating factor and 
prostanoids (e. g. prostaglandins, leukotrienes). Reactive oxygen species have also been 
implicated in the pathogenesis of periodontitis. The overproduction of reactive oxygen 
species may be a key component of hyper-inflammation associated with periodontitis 
(Chapple and Matthews, 2007). The pathogenesis of periodontitis is therefore largely 
attributed to localized inflammation which results from interactions between host and 
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microbial factors (Ishikawa, 2007). Understanding how the precise nature of host 
interactions with bacterial factors may clarify what determines the shift from health to 
periodontal disease. It is noteworthy that the consensus view of the host's involvement in 
the development of periodontal diseases comes over a hundred years later than when it 
was first mooted by Miller in 1890, in The InfectionlHost Response Paradigm (Armitage, 
2002). 
Although bacterially induced host responses may contribute to the progression of 
periodontal inflammation and tissue destruction, the intensity of the inflammatory 
process varies considerably from person to person (Schenkein, 2006). Resistant 
individuals successfully control the microbial challenge and the immuno-inflammatory 
pathways activated by bacteria, preventing periodontal destruction. Classic longitudinal 
studies have demonstrated the variation that exists in host susceptibility to a bacterial 
challenge. The vast majority of individuals (-80%) exhibit moderate attachment loss, 
whereas 7-10% develop severe generalized periodontitis, exhibiting rapid attachment loss 
(Loe et al., 1986). It is now considered that these variations may be related to 
complicated genetic, behavioural and environmental predisposing risk factors, including 
oral hygiene, smoking, emotional stress and diabetes (Brown and Loe, 1993; Kornman et 
al., 2000; Page, 1991; Schenkein, 2006) (Figure 1.3). 
A significant portion of the host predisposition to disease may relate to innate and 
acquired host defences, subsequent to inflammatory activation. Activation of immune 
responses occurs via a complex network of inflammatory mediators originating in both 
myeloid and non-myeloid cells. The variations in these host immune responses may in 
part be related to specific genetic polymorphisms (Kornman, 2001; Kornman and Duff, 
2001). 
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Figure 1.3 Fhe model ol'the pathogenesis ot'periodontal diseases. as deýeloped b) Kornman K (2001). 
1 his figure represents the interplay of' aetiologies. risk factors and risk determinants to play a role in the 
pathogenesis of'rwriodontal diseases. 
1.4 HOST RESPONSES TO PERIODONTAL MICROORGANISMS 
The host irninuric and inflarnmatorý response to the microbial challenge is a critical 
determinant of susceptibilitN to develop the destructive disease, under the influence of 
multiple behavioral. environmental. and genetic factors (Cohen, 2002; Jenner and Young, 
2005. Schumann. 2004). There is little doubt that patient susceptibility to periodontal 
disease plaNs a majJor role in determining the ultimate disease outcome (Meng et al., 
2007). Susceptibilitý to periodontal disease involves the interplay between bacteria, the 
host and environmental factors. It has been suggested that periodontitis is a continuous 
spectrum xN ith defined clusters of individuals presenting with a varying host 
susceptibilitý component (Chapple. 2002). The host employs a variety of defence 
strategies to control and protect itself against bacterial invasion. The oral epithelium 
represents the first barrier against the microbial biofilm. In addition to providing a 
physical barrier against invading pathogens. epithelial cells play an important role in 
innate host immune defences by producing a consortium of antibacterial peptides such as 
beta-defensins (Dale et al.. 2001: Hosokawa et al., 2006; Ouhara et al., 2006). 
Interactions between bacteria and epithelial cells lead to the activation of several complex 
signalling cascades. which ultimately regulate the immune responses. 
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Figure 1.4 Spectrum ot' periodontal diseases. This figure presents periodontitis as continuous spectrum 
ý%ith defined clusters of' indMduals presenting with a varying host susceptibility component. Patient 
susceptibilitN to periodontal disease plaNs a major role in determining the ultimate disease outcome. 
Adapted t"rom Chapple I. I. ý2002). 
The way in which the host responds to the bacteria is determined by the nature and 
control of both the innate and adaptive immune responses (Berglundh and Donati, 2005). 
Innate imrnunitý is responsible for initiation of the inflammatory process, acting as the 
first line of host defence and is critical for the successful eradication of an infection 
(Alexander and Rietschel. 2001: Bullard et al., 1996). It is also linked to the adaptive 
immune response. which helps clear the infection and builds specific immunity with a 
memor) component. Therefore it is difficult to separate their relative roles in the 
pathology of periodontitis (Dixon et al.. 2004). The innate processes of the host immune 
response primarily depend on the activity of macrophages and polymorphonuc fear 
leukocytes (PMNs) (Mathur and Michalowicz. 1997). Their shared role in the 
periodontium is the defence against the invasion of pathogens and the maintenance of 
local homeostasis and tissue integrity. These cells can respond to the bacteria by 
signalling thorough the Toll-like receptors (TLRs) which can directly initiate the innate 
immune response. which. in turn. may control the emergence and/or balance of the 
adaptive immune responses (Schroder et al., 2005). 
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1.4.1 Polymorpbonuclear leukocytes (PNINs) 
Polymorphonuclear (PMNs) leukocytes are an important line of defence against dental 
biofilms accumulated at the gingival margin. Bacterially activated neutrophils also 
produce chernotactic and vasoactive mediators that perpetuate the host inflammatory 
response. PMNs can be found within the gingival sulcus and migrate through the 
junctional epithelium in all stages of periodontal disease (Delima and Van Dyke, 2003; 
Tonetti et A, 1998). Their specific functions include adherence to host substrata, directed 
migration along chemical gradients, recognition and phagocytosis of microorganisms, 
followed by bactericidal activity. The importance of PMNs in protective responses 
against bacterial invasion is underlined by the prevalence and severity of periodontitis in 
patients with syndromes characterised by dysfunctional PMNs, such as leukocyte 
adhesion deficiency (Hart et al., 1994). Data suggests that the neutrophils of patients with 
localized aggressive periodontitis have abnormal functions (Lavine et al., 1979; Van 
Dyke, 1985) and it appears that a hyperresponsiveness of the neutrophil results in 
enhanced tissue destruction in periodontal disease (Kantarci et al., 2003). When 
activated, PMNs release lysosomal proteolytic enzymes such as Cathepsin G and matrix 
metal loproteinase-8 (MMP-8) and secrete arachidonic acid metabolites both of which can 
lead to periodontal tissue damage (Claesson et al., 2002; Pippin et al., 1995; Taichman et 
al., 1977). In addition, PMNs are capable of directly secreting pro-inflammatory 
mediators, as well as inducing the production of these cytokines from surrounding cells 
and tissues (Galbraith et al., 1997). Thus, they are able to directly contribute to the 
inflammatory response and attachment loss observed in periodontitis (Kantarci and Van 
Dyke, 2002). 
1.4.2 Monocytes/macrophages 
Monocytes arise from precursors in the bone marrow, which enter the peripheral 
circulation. At this point they are still considered immature cells, but upon entering the 
tissues, they differentiate into macrophages. Like PMNs, these cells are highly motile, 
but they are long-lived cells and are not terminally differentiated like neutrophils, 
meaning that they can undergo further proliferation once they exit the circulation and can 
form large multinucleated giant cells, or osteoclasts. Like PMNs they can respond to 
chernotactic gradients and share similar enzymatic systems to combat foreign antigens, 
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but because of their longer life spans macrophages usually predominate in chronic 
inflammation. 
Monocytes and macrophages both function as phagocytes, engulfing and destroying 
pathogens as well removing damaged tissues. Monocytes can enter the tissues and 
function as antigen-presenting cells, where they engulf foreign materials, digest them and 
display these antigens on their cell surface. Bacterial antigens such as lipopolysaccharide, 
can interact with monocytes/macrophage receptors including CD14 and TLRs to 
stimulate production of inflammatory cytokines and other mediators (Dixon et al., 2004; 
Ren et al., 2005). TLR-based recognition of pathogens enables the host to mount and 
maintain effective defence against pathogens. Monocytes as well as monocyte-derived 
dendritic cells are identified as the major TLR-expressing cells in human blood (Yang et 
al., 1998). Ten members of the TLR family (TLRI to TLRI 0) have been described (Du et 
al., 2000a; Takeda et al., 2003). Three of them, namely TLRI, TLR2, TLR4 are highly 
expressed in monocytes (Ozinsky et al., 2000). Human monocytes also express low levels 
of TLR3, TLR7, and TLR9 (Hornung et al., 2002). 
Monocytes both initiate and enhance the immune response by the secretion of a number 
of proinflammatory cytokines such as IL-la and TNF-a and a number of chemokines 
which influence the recruitment of additional monocytes, PMNs and lymphocytes into 
the gingival tissues (Amano, 2003; Taubman et al., 2005). The interaction of 
lipopolysaccharide with macrophages also stimulates production of prostanoids, in 
particular prostaglandin E2 (Blix and Helgeland, 1998; Shapira et al., 1994). 
Macrophages also act as antigen-presenting cells in the initial stages of the immune 
response and play a vital role in the effector stages as microbicidal cells (Ishikawa et al., 
1997). The presence of different subpopulations of macrophages in various forms of 
periodontal tissues may indicate participation of these cells in the local immune response 
in periodontal disease (Schlegel Gomez et al., 1995). 
1.5 MODIFIERS OF HOST RESPONSE 
While periodontopathic bacteria and the inflammation they provoke are essential for 
disease progression, environmental risk factors such as tobacco smoking, psychosocial 
stress and systemic diseases such as diabetes modify the host response and may be major 
determinants of the enormous variation in susceptibility (Page et al., 1997). It is likely 
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then that the amount of inflammatory mediators produced by an individual's monocytes, 
whether locally in the GCF or from isolated peripheral blood monocytes in response to 
periodontal microorganisms, is a characteristic of that individual's host response in 
periodontitis. Individuals with a normal response would have a sufficient level of 
inflammation which will have beneficial effects to fight the infection, and will not be 
sufficient to trigger periodontal tissue breakdown. Hyperresponsive individuals would 
produce much higher levels of inflammatory mediators than normal individuals at the 
same given challenge, and would exhibit disease expression at a lower microbial load 
threshold. This has been reported in studies of periodontitis in diabetic patients (Salvi et 
al., 1997; Takeda et al., 2006). When stimulated with lipopolysaccharide, monocytes 
isolated from diabetic patients produced higher levels of PGE,, IL-I and TNF-cc than 
those of nondiabetic patients with similar periodontal status (Salvi et al., 1998). There are 
also hyporesponsive individuals producing lower inflammatory mediator levels than 
normal individuals for a similar challenge (Molvig et al., 1988). Several factors might 
influence an individual's monocyte responsiveness, including genetic factors and 
environmental factors such as stress, smoking and systemic diseases (Medvedev et al., 
2006; Rallabhandi et al., 2006). Inter-individual differences in monocytic synthesis of 
cytokines have been reported in relation to different genetic backgrounds (Baker et al., 
2000). These genetic factors are intrinsic to the individual and do not vary with time. 
These behavioral and environmental factors may change over time and affect the 
individual's response differently at different time-points. This will be further discussed in 
the following sections. 
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Figure 1.5 Host response characteristics as a function of bacterial challenge level. This curve represents 
the host response levrels to lipopolysaccharide (LPS) There are three types of response including normal, 
hý po and h) per. Adapted from Champagne et al. (2003). 
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1.5.1 Systemic modifiers 
Systemic diseases can modify all forms of periodontitis through their effects on the 
normal immune and inflammatory defences. As discussed previously, 
polymorphonuclear leukocyte deficiencies and a number of genetic disorders such as 
Down's syndrome and chronic granulomatous disease confer increased susceptibility to 
periodontitis (Cohen et al., 1985; Gabre, 2000; Omer, 1976). Many of these cases are 
rare. 
Diabetes mellitus is a major systemic risk factor for periodontitis. There is a higher 
incidence and greater severity of periodontal disease in adults with either both type I and 
type 11 diabetics (Emrich et al., 1991; Tervonen and Oliver, 1993). A review found 
considerable evidence to suggest that diabetes and periodontitis are directly related 
(Kinane and Chestnuttý 1997). Other studies have also shown that the level of diabetic 
control is an important factor in this relationship and may modify the response to dental 
plaque (Aldridge et al., 1995; Guzman et al., 2003). It seems that a bi-directional 
relationship between periodontal disease and glycemic control exists (Nishimura et al., 
2003). Poorly controlled diabetic patients respond less successfully to periodontal 
therapy relative to well-controlled and non-diabetic patients (Westfelt et al., 1996). 
1.5.2 Smoking 
Tobacco smoking is among the most important risk factors in the aetiology and 
progression of periodontal diseases (Bergstrom, 1989; Bergstrom, 2003; Haffajee and 
Socransky, 2001a). Several mechanisms behind this relationship have been proposed 
including physiologic effects of smoking on vasoconstriction, re-vascularization of 
wounds, as well as host response alteration by smoking (Albandar et al., 2000; Barbour et 
al., 1997). Tobacco smoking increases the risk of periodontal destruction by stimulating 
inflammatory responses and impairing protective or reparative host responses (Ryder, 
2007; Sorensen et al., 2004). Smoking is associated with reduced gingival bleeding 
(Bergstr6m and Bostrom, 2001; Persson et al., 2001) and reduced bleeding may reflect an 
underlying disruption of the immune response. 
Inflammatory components in the GCF and serum have been studied in relation to 
smoking. Levels of inflarnmatory substances in smokers vary from levels in non-smokers 
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but the significance of this is not clear. Studies have shown altered gingival crevicular 
fluid inflammatory cytokine profiles such as IL-1, IL-8 (Ryder et al., 1998a; Ryder et al., 
1998b) and altered proteolylic regulation in smokers (Chang et al., 2003). However, 
smoking was not found to alter GCF levels of IL-lP and IL-Ira (Bostrom et al., 2000). 
Compared to non-smokers, smokers also have lower serum immunoglobulin and 
antibody levels against bacteria such as P. gingivalis (Quinn et al., 1996; Tangada et al., 
1997). Smoking has also been shown to influence polymorphonuclear leukocyte function 
including chemotaxis and phagocytosis (van der Vaart et al., 2004). In another study 
smokers had a lower level of IgG2, which may impair neutrophil function and in this way 
aggravate periodontal disease (Fredriksson et al., 1999). 
The relationship between some bacterial strains associated with periodontal disease and 
smoking has been studied (Haffajee and Socransky, 2001b; Preber et al., 1992; van 
Winkelhoff et al., 2001). The studies suggest that smoking could influence the host 
control of bacteria. In a study where bacteria were quantified, it was suggested that 
smoking favours a habitat for the establishment of bacterial species such as P. gingivalis, 
P. intennedia and A. actinomycetemcomitans in shallow pockets (Eggert et al., 200 1). In 
summary, the results of these studies do not suggest a single mechanism for the effects of 
smoking, but it is likely that smoking modifies the host immune response in a variety of 
ways and therefore influences disease expression (Wittebole et al., 2007). 
1.5.3 Genetic modifiers 
Periodontitis is associated with a variety of bacterial species; however, neither the type 
nor the proportion of bacteria fully explains the population variance in this disease 
(Johnson et al., 1988). Some individuals might be very susceptible and will develop 
aggressive forms of periodontitis at a relatively young age, while others might be 
resistant and will never develop periodontitis. If not everyone is equally prone to disease, 
this raises the question as to why some people arc more susceptible than others. Genes 
play a role in the predisposition to and progression of periodontal diseases (Hassell and 
Harr is, 1995; Sofaer, 1990). There is evidence that host genetics may affect the 
susceptibility to severity of periodontal diseases (Hodge and Michalowicz, 2001). The 
presence of microorganisms is required, but not sufficient, for the development of an 
infectious disease, such as periodontitis. A large body of published data suggests that in 
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humans. susceptibility to infectious diseases is influenced by the genetic make-up of the 
host (Casanova and Abel. 2004; Segal and Hill, 2003). Clinical phenotypes in the course 
of an infectious disease result from the complex interaction between environmental 
(microbial and non-microbial) and host (genetic and non-genetic) factors (Figure 1.5). 
Genetic epidemiological studies, studies of concordance rates between monozygotic and 
dizygotic t,. %ins and complex segregation studies have implicated human genetics as a 
central factor in susceptibility to infectious disease (Abel and Dessein, 1998; 
Kwiatko" ski. 2000). 
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Figure 1.6 A schematic sho%% ing the stages of the host-en% ironment interaction in the course of infection. 
The complex process that goes from exposure to an infectious agent to the development of a clinical 
infectious disease is under host and environmental control. Host factors might be genetic (for example, 
mutation in a gene in%ol%ed in immunity to infection) or non-genetic. Environmental factors might be 
microbial (for example. % irulence factors) or related to the mode of exposure (for example, smoking), and 
might haN, e an impact at each stage of the interaction. Adapted from Casanova and Abel (2004). 
To understand the potential clinical relevance of genetic variability on periodontitis it is 
necessary to understand how genes contribute to genetic diseases (Figure 1.6). Diseases 
can be divided in to two categories based on genetics; Mendelian diseases and 
multifactorial diseases (also called complex traits). With Mendelian genetics, the 
interaction between genes and environment that creates the phenotype is dominated by 
the genetic component (i. e. cystic fibrosis, Papillon Lefevre syndrome, amelogenesis 
imperfecta) (Hewitt et al.. 2004; Rommens et al., 1989). Diseases like atherosclerosis and 
AdaptW ArnmunNy 
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periodontitis are referred to as complex diseases because multiple genes contribute to the 
phenotype either individually or through interactions with each other or the environment 
(Hemminki et al., 2006; Rosenberg et al., 2002). In contrast to Mendelian diseases, 
multifactorial diseases do not follow a simple pattern of familial distribution or 
transmission. In the case of multifactorial diseases, what is inherited is a higher risk of 
developing the disease rather than the certainty of disease (Belmont and Leal, 2005). 
Phenotype i, Environment (i. e. 
smoking) 
Genotype 
Biological interactions 
Gene-gene or gene- 
environment 
Figure 1.7 The classic relationship of phenotype, environment, and genotype. For the periodontal disease 
phenotype, environmental risk factors include smoking status and plaque control. Adapted from Kinane et 
al. (2005). 
it is increasingly evident that genetic variance plays an important role in the 
determination of individual susceptibility to multifactorial diseases (Pritchard, 2001). 
There are several genetic alterations such as mutations and polymorphisms. Mutations 
are rare (less than 0.1%) and can have deleterious effects on protein functions, therefore 
mutations are the primary cause of a clinical phenotype or a disease. DNA sequence 
polymorphisms are usually defined as variation present at greater than 1% frequency in 
the population and that by itself is not sufficient to cause a disease (Nielsen, 2004; Wang 
et al., 1998). Nevertheless, DNA sequence polymorphisms may contribute to 
susceptibility to a disease or variation in functional properties of a protein. The most 
common are single nucleotide polymorphisms (SNPs) which occur on average every 
1000 nucleotides across the genome (Collins and Morton, 1998; Hinds et al., 2005; 
Sachidanandarn et al., 2001). A single nucleotide polyrnorphism defines two alleles for 
which there could be three genotypes amongst individuals in a given population (Figure 
1.8). A genotype is a description of the two alleles at a particular locus. Each individual 
will have one or maximum two forms of DNA. The latter is possible if the parents 
differed from each other at these alleles and the child inherited a different form from each 
parent. 
There are an estimated 7-10 million SNPs in the 3 billion-nucleotide human genome 
(Wheeler et al., 2005). SNPs are often inherited together as a consequence of their 
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physical proximit\ on a single chromosome and travel as blocks from generation to 
generation. \%hich is kno\%n as linkage (Stephens et al.. 2001). Linkage disequilibrium 
refers to the non-random association of alleles at different loci. Groups of co-inherited 
SNPs on the same chromosome are called haplotypes and identification of the state of 
one polý morph ism maý predict the state of the others (Judson and Stephens, 200 1). 
Figure 1.8 L\amplc of SNP comprising a C-* I substitution. Data generated from PCR product sequenced 
%Nith ABI BigD)c Terminator sequencing kit (Applied 13ios)stems). Electropherograrn shows the genomic 
DNA from indi\idual homo/ýgous for C at the site of the SNP (A) and individual homoz)gous for T (B). 
The base substitution is denoted bý a black arro%\. 
Npes of DN'A pokmorphisms such as minisatellite variab e number There are also other t. I 
tandem repeats (V\*]-Rs). microsatellite pol. N-morphisms and insertions or deletions 
(Reich et al.. 2001 ). VNTRs are not evenk dispersed in the genome and the majority of 
microsatellite polýmorphisms (xcur at di-nucleotide repeat sequences with very low 
frequenc\ 0 e%er\ 30000 base pairs). The role of VNTRs will not be discussed further 
due to their lo%k frequencý. 
Although the majoritN of DNA poINmorphisms are probably functionally neutral, a 
proportion of them can exert allele-specific effects on the regulation of gene expression 
or function of the coded protein. thus causing bemeen-individual differences in various 
biological traits and in susceptibilitý to disease (Hart et al.. 2000a; Toomes et al., 1999). 
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The precise location of a polymorphism within the gene can be important (Chakravarti, 
1999). SNPs are classified according to their position in genes into coding and noncoding 
polymorphisms. Noncoding SNPs may occur in the promoter region of the gene, within 
introns, and 5- and 3'- untranslated regions (Cargill et al., 1999; Sonenberg, 1994). 
Noncoding SNPs do not alter the base pair sequence in the part of the DNA that codes for 
the protein but may alter the rate of transcription, the processing or the stability of the 
mRNA. Polymorphisms occurring in promoter regions of genes may potentially affect 
the process of transcription whereby RNA polymerase, the enzyme responsible for 
transcribing the DNA into mRNA, is recruited to the gene and the mRNA synthesized 
(Hoogendoom et al., 2003). Polymorphisms occurring in promoter regions may also 
modulate or eliminate transcription factor binding, generate binding sites, or result in 
binding by a different transcription factor (Morley et al., 2004). Introns and the regions 
around the exons that do not code for proteins are also important, because they contain 
sequences that may dictate other attributes of how protein production is regulated (Roy 
and Penny, 2006). Coding SNPs are located in the exons of genes and classified into 
synonymous and nonsynonymous (Fallin et al., 2001; Tabor et al., 2002). Synonymous 
SNPs change the codon (set of three nucleotides in these exons code for the amino acids 
that are used to build proteins) into another that codes for the same amino acid. 
Therefore, there is no change in the amino acid. Nonsynonymous SNPs change the amino 
acid with functional consequences and may affect protein structure (Wray et al., 2003). 
Such coding polymorphisms have classically been implicated in monogenic Mendelian 
disorders (Sidransky, 2006). 
The reason for the current enormous interest in SNPs is the hope that they could be used 
as markers to identify genes that predispose individuals to common, multifactorial 
disorders (Loos et al., 2005). The human genes that contribute to these phenotypes can be 
sought following a hypothesis-driven or genome-wide approach. The hypothesis-driven 
approach selects candidate genes based on data obtained in animal models, on human 
data obtained in vitro, or on previous knowledge regarding disease pathogenesis (Fortier 
et al., 2005; Pharoah et al., 2004). Genome-wide association studies using large numbers 
of bi-allelic SNPs have been proposed as a potentially powerful method for identifying 
genes involved in complex diseases (Abel et al., 2006; Nelson et al., 2004). Other 
approaches have been applied such as linkage analyses using markers of genome 
variation in large families with multiple affected individuals (Terwilliger and Weiss, 
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1998). Different experimental designs can be used to conduct genetic association studies 
(Cardon and Bell. 2001). The most widely used are case-control and cohort studies. For 
complex disease susceptibility genes, direct association approaches that compare the 
distribution of genetic marker frequencies in individuals affected by a disease (case) and 
in those not affected by the disease (controls) are expected to have greater power than 
traditional linkage studies (Rees, 2002; Risch, 2000). A higher frequency of the SNP in 
cases than in controls is considered evidence that the allele/genotype is associated with 
increased risk. HmNever, both linkage analysis and association studies typically leave 
open the question of whether a disease-associated genetic variant is functionally 
important (Reich and Lander. 2001). 
There are a variety of experimental methodologies to investigate the functional 
significance of SNPs including DNA footprinting and gel-shift assays, allele-specific 
analysis of mRNA. assays of secreted protein and reporter gene assays (Figure 1.9) 
(Rebbeck et al.. 2004). The most commonly used assay to investigate the functional 
effects of SNPs on gene expression is reporter gene assay (Alam and Cook, 1990). This 
assay involves constructing a plasmid in which the putative regulatory region spanning 
the position of the SNP(s) from the gene of interest is linked to the coding sequence for a 
reporter gene whose expression can be measured (Figure 1.913). The reporter gene 
construct is then transfected into a cell and expression assayed and then constructs with 
the two allelic forms of the SNP are compared. 
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Figure 1.9 The approaches for imestigating the functional significance of SNPs A) Secreted protein 
assay: An approach is to compare le\els of protein produced From the gene of interest in indkiduals of' 
differing genotýpe- flor example. homoz)gous AA or B13 or heterozygous B) ) Reporter gene assay: The 
DNA sequence of interest. for example a promoter region spanning an SNP. is placed upstream of a 
reporter gene \Nhose expression can be measured. The reporter gene construct is then inserted (transfected) 
into a cel I and expression assaý ed. Adapted from Knight (2005). 
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1.6 CANDIDATE GENE APPROACH and PERIODONTAL DISEASE 
Since SNI's are the most common source of human genetic variation, (Suh and Vijg, 
2005). associating SNPs with human disease phenotypes has potential for direct clinical 
application by providing genetic markers for diagnostic and prognostic purposes and. 
possibly. novel therapeutic targets. Thus there has been enormous effort expended so tar 
to identify gene polymorphisms associated with risk for periodontal diseases (Kinane et 
al.. 2005). 
Large scale screening for SNPs is still very complex (Cantor and Nelson, 2005). 
Alternative approaches include selecting candidate genes coding for particular features of 
a disease (Goldstein et al.. 2003). This is in contrast to genome-wide scans and other 
approaches that relý on linkage disequilibrium between loci to identify genotype -d i sease 
associations. for which kno,. vledge of function is not required. A good candidate gene 
should have an expression pattern consistent with the disease phenotype and genes 
implicated in a disease maý be expressed to a different degree in patients and controls. 
There are three tý pes of candidate genes; functional candidate genes; positional candidate 
genes and expressional candidate genes (Hunter et al., 2005). Functional candidate genes 
are identified from an existing knowledge of the phenotype and the potential function of 
the gene involved after clinical or physiological studies of affected individuals (Tabor et 
al.. 2002). Positional candidate genes are based on the involvement of the gene to a 
marked chromosomal location after genetic linkage analyses (Cantor and Nelson, 2005). 
Expressional candidate genes are determined through differences in gene expression 
using microarraýs. 
The most promising approach for statistically powerful candidate gene association 
studies involves. i) the selection of candidate genes on the basis of different types of 
information. including available linkage results and results obtained with mouse models 
of the phenot-, pe ii) determination of the haplotype structures for these genes in control 
populations and testing for association between phenotype and haplotype status iii) 
assessing function of selected haplotypes using experimental systems, including in vitro 
systems and in vivo animal models (Collins et al., 1997, Goldstein and Weale, 2001; 
Johnson et al.. 200 1. Lohmueller et al., 2003; Rebbeck et al., 2004). 
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There has been a great interest in exploring SNPs in those genes involved in the control 
of the inflammatory response. To date many studies have focused on cytokine genes due 
to their significant role in orchestrating the immune response (Bidwell et al., 1999). 
Interindividual differences in cytokine profiles appear to be due, at least in part, to allelic 
polymorphism within regulatory regions of cytokine genes. Many studies have examined 
the relationship between cytokine gene polymorphisms, cytokine gene expression in 
vitro, and the susceptibility to and clinical severity of diseases. 
1.6.1 Candidate Genes in Periodontal Disease 
Genetic polymorphisms in a candidate gene approach have been explored as risk factors 
for periodontitis. There is a genetic basis to many aspects of the periodontal host 
response (Schenkein, 2006). Mutations of genes have been identified in Mendelian 
inherited syndromes that include significant periodontitis as a future clearly indicating 
that single gene defects can predispose to periodontitis (Hart et al., 2000b). This has 
facilitated studies to evaluate the association of an array of genetic polymorphisms with 
periodontitis. 
Pro-inflammatory and regulatory cytokines have been selected as possible candidate 
genes as a result of their direct involvement in the pathogenesis of periodontal disease 
(Gemmell et al., 1997; Landi et al., 1997; Oido-Mori et al., 2001; Taylor et al., 2004). 
Inflammatory cytokines including TNF-a, IL-lu, IL-1 P, IL-6, and IL-8 are present in the 
diseased periodontal tissues, and their uncontrolled production seems to play a role in 
tissue destruction (Bascones et al., 2005; Okada and Murakami, 1998). This approach is 
based on the hypothesis that increased or unregulated production of inflammatory 
cytokines in response to periodontopathogens occurs in subjects carrying functional 
polymorphisms in these genes. There are reports that some polymorphisms in the genes 
encoding IL-1, TNF, Fc gamma receptors (Fc gammaR), IL-10 and the vitamin D 
receptor, may be associated with periodontitis in certain ethnic groups. Table 1.5 
summarizes the results of a NbMed search on published gene polymorphisms and 
periodontitis (Takashiba and Naruishi, 2006). 
Polymorphisms in the IL-I system have been the main focus of attention because of an 
important regulatory role of IL-1 in inflammation and host response in periodontal 
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disease jaý lor et al.. 2004). Since TNF-ct plays an important role in both the immune 
and inflammatorý responses. several studies have investigated the role of genetic variants 
such as microsatellite polymorphisms and SNPs in the TNF-ct gene in relation to 
periodontal disease (Craandi. ik et al., 2002; Endo et al... 2001; Folwaczny et al., 2004; 
Kinane et al.. 1999). They have failed to find any significant associations between TNF-U 
gene polýmorphisms and periodontitis. However, other studies found a correlation 
between the TNF-ct -3308 genotype and levels of TNF-a production by neutrophils in 
periodontal disease (Galbraith et al.. 1998). IL-6 is expressed by a wide variety of cells in 
the periodontal lesion and in common with IL-I and TNF-ct, enhances bone resorption. It 
has been sugg , ested that polymorphisms in the IL-6 gene may be one of the protective 
factors associated %Nith lower susceptibility to chronic periodontitis (Holla et al., 2004; 
Komatsu et al.. 2005). Several other candidate genes have also been examined for 
association with periodontal disease. These studies have not supported a role for the 
tested polymorphisms in IL-10 (Hennig et al., 2000; Yamazaki et al., 2001) or IL-4 
(Michel et al.. 200 1: Pontes et al.. 2004, Scarel-Caminaga et al.. 2003). 
Categor,, (n) Gene (n) Correlation (n) 
Positive Negative 
Cvtokine (66) and its receptor IL-1 (36) 22 13 
TNF (14) 64 
allele 120) 15 2 
Immuno- receptor (2 1) FcR (14) 13 2 
Protease (6) MMP (3) 21 
I: n/,, mes and hormones Cathepsin C (6) 41 
Vitamin D-R (6) 51 
Others ( 16) 97 
Table 1.5 Reports of' literature search summarizing findings on the association betvveen periodontitis and 
pol)morphisms in genes affecting host response and metabolism. Adapted from Takashiba and Naruishi 
(2006). 
1.7 IL-Ict: A CANDIDATE GENE IN PERIODONTAL DISEASE 
The observation that severe periodontitis affects only 7-15% of individuals means that 
not all individuals are at equal risk for this disease. Therefore, it is important to establish 
who is at risk and what characteristics can be used to identify those individuals at the 
greatest risk. The association between the risk factor and the disease should be consistent 
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with current understanding of the disease process, and the factor should remain 
associated with the disease after controlling for other known risk factors and background 
variables. Such a factor could be used to screen individuals successfully and classify 
them accurately into high- and low-risk groups, and if this factor is targeted by specific 
interventions in high-risk individuals the probability of disease occurrence in these 
individuals should be lowered. Although it is likely that the IL-I genes are likely to be 
among many other such genes that contribute to risk for periodontitis, the biology of IL- I 
and the association of high innate levels of IL-1 with severe disease provide compelling 
evidence that this molecule is important in understanding periodontal destruction. This is 
discussed in the following sections. 
IL-la is a multifactorial proinflammatory cytokine that plays an important role in 
inflammation and host responses to infection. The IL-IA gene, a member of the large IL- 
I gene family is located in the region 2ql2-q2l of human chromosome 2, with 7 exons 
and 6 introns (Furutani et al., 1986; Lafage et al., 1989; March et al., 1985). The original 
identification of IL-I as an endogenous pyrogen, lymphocyte-activating factor, 
hemopoietin-1, and osteoclast-activating factor, serves to demonstrate its pleiotropic 
activity (Allan et al., 2005; Dinarello, 2002; Tanaka et al., 2005). 
The IL-I gene family of cytokines includes IL-la and IL-IP and IL-18 and six new 
members named IL-IF5 to IL-IFIO (Nicklin et al., 2002). The IL-1 family also has 
another member, IL-1 receptor antagonist (IL- I Ra), a natural competitive inhibitor to IL- 
I activity. Comparison of human IL-la, IL-IP and IL-IRA amino acid sequences yields 
< 25% identity (Dinerallo, 1996). IL-I family members act by binding to specific 
receptors. IL-la and IL-10 bind to IL-1 type I receptor (IL-IRI) and this results in 
recruitment of the IL-1 receptor accessory protein (IL-IRAcP) which is a required 
signalling component (Cullinan et al., 1998). A third member of the family, the IL-1 
receptor antagonist (IL-Ira), also binds to the type I IL-1 receptor but does not interact 
with IL- I RAcP. Therefore, IL- I ra functions as an antagonist preventing the action of the 
agonist IL-Is by blocking the receptor (Hannum et al., 1990). Additional regulation is 
provided by the type 11, or decoy, IL-1 receptor, which binds and sequesters the agonist 
IL-Is without inducing any signaling response of its own (Colotta et al., 1993). 
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1.7.1 Expression and synthesis of IL-la 
The IL-IA gene does not contain a classical transcription initiation motif or TATA box 
(Furutani et al., 1986). The main elements such as NFkB and NF-IL6 regulating IL-la 
expression are located upstream of transcription site (Figure 1.10) (Furutani, 1994; 
McDowell et al., 2005; Stylianou and Saklatvala, 1998). Several studies have shown the 
functional significance of the proximal promoter region in IL- Ia gene regulation (Alheim 
et al., 1996; Bailly et al., 1996a; McDowell et al., 2005; Zaldivar et al., 2002). 
Transactivation of the IL-la promoter in T cells by the T-lymphotropic virus type I tax 
(HTLV-1) protein suggests that NF-icB may be involved in the transcriptional regulation 
of IL-la (Mori and Prager, 1996). The NFicB sites are also likely to be involved in the 
induction of IL-Ig by other factors such as glucocorticoids (Awad et al., 2002; Miyazaki 
et al., 2000). Recently, an NF-IL-la binding site has been shown to be important for 
aberrant constitutive expression of IL-la in fibroblasts from patients with systemic 
sclerosis (Kawaguchi et al., 2003). There is also evidence that both NFKB and AP-1 may 
be induced by IL-la itself, suggesting a possible positive feedback loop (Niu et al., 2004; 
Werman et al., 2004; Zaldivar et al., 2002). 
DW 
-749 -740 
NFIIA 
. 1" -191 
NF11A 
-147 -139 
? TAC"A. 4 
-31 
-00ý NFUAAHEKA 
1 +19 +51 +716 
4- Exonl Intron 104 Exon2 IN. 
Fig. 1.10. A schematic representation of the structural Organisation of human ILIA gene including the 
proximal promoter, exons 1-2 and intron 1. The major transcription factor sites for NFKB (black), NF-IL6 
(hatched), are shown with numbers below each coloured box indicating the boundary of each region and 
the distance in base pairs from the transcriptional initiation site (shown as an arrow). Adapted from 
Stylianou and Saklatvala (1998) 
The transcription of IL-Ict is stimulated during inflammatory and infectious processes by 
the immune complexes, certain coagulation and complement cascade proteins, viral or 
bacterial products, in particular LPS (Calvano et al., 2005; Hazuda et al., 1988). It is also 
induced or enhanced by certain cytokines such as macrophage colony stimulating factor 
(M-CSF) (Hanamura et al., 1997) and interferon-gamma (IFN--t) (Kobayashi et al., 
1995). Other cytokines such as TNF-a stimulate the production of IL- Ia by keratinocytes 
(Kutsch ct al., 1993) and gingival fibroblasts (Kobayashi et al., 1999). IL-la also 
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stimulates its own production by monocytes (Manson et aL, 1989). In addition, 
stimulants of non-microbial origins such as phorbol esters, retinoic acid and stress can 
also stimulate transcription and synthesis of IL-la (Jarrous and Kaempfer, 1994; 
Mandinov et al., 2003; Murphy et al., 2003). 
After stimulation in vitro by LPS, mRNA for IL-la appears in the monocyte cells after 
15 minutes, accumulates over 4 hours and peaks at 6 hours then rapidly declines. The 
half-life of the IL-la mRNAs may vary depending on cell type but is generally in the 
range of 6-8 hours (Godambe et al., 1993; Perregaux and Gabel, 1998). 
1.7.2 Maturation and secretion IL-la 
Upon cell activation, IL-la is translated as 31-kDa precursor molecule (pro-IL-1a). Pro- 
IL-la remains in the cytosol after its translation and does not accumulate in organelles. 
Pro-IL-1 a is as fully active as the mature form, remains intracellular for the main part 
and acts at this level (Hu et al., 2003; Mosley et al., 1987; Werman et al., 2004). IL-I a is 
undetectable in the serum of patients with inflammatory diseases, with the exception of 
severe pathological states in which cell death likely allows release of the cytokine 
(Watanabe and Kobayashi, 1996). Under some circumstances, pro- IL-la is cleaved to 
yield a 17-kDa mature cytokine species that retains biologic activity; a calpain-like 
protease has been implicated in this cleavage (Carruth et al., 1991; Kobayashi et al., 
1990). Studies have demonstrated the existence of a transmembrane IL-la form of 23 
kDa (Bailly et al., 1990b; Brody and Durum, 1989; Kurt-Jones ct al., 1985). This IL-la 
form is bioactive and was demonstrated at the surface of monocytes and B lymphocytes. 
IL- Ia differs from most other cytokines by lacking a signal sequence, thus not trafficking 
through theendoplasmic reticulum (ER)-Golgi pathway; the precise mechanismsof IL-la 
secretion are thus largely unknown (Andrei et al., 1999; Minnich-Carruth et al., 1989). 
1.7.3 Biological and pathological properties of IL-1a 
Interleukin-la is one of the most potent proinflammatory cytokines involved both in 
physiological immune responses and in the development of various immuno-pathological 
disorders. IL- Ia is a multifunctional cytokine that plays a major role in acute and chronic 
inflammation. The importance of IL-Ia in the initiation and maintenance of adequate 
responses to bacterial invasion has been clearly established and reported in some detail 
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(Dayer et al., 2001; Dinarello, 1996; Dinarello, 1998; Dinarello, 2002; Dube et al., 2001). 
Data obtained from studies using IL-IRI-deficient mice suggest that IL-la is an 
important factor in response to tissue damage and infection, but is not required for 
normal development and homeostasis (Labow et al., 1997). 
The biological effects of IL-la are multiple and directed at many cell types and organs, 
but its principal role is considered the initiation of the defence reaction. IL- Ia is made by 
a variety of cells, in particular monocytes, macrophages and epithelial cells, 
keratinocytes, gingival and dermal fibroblasts, neutrophils and endothelial cells (Bailly et 
al., 1990a). Major differences are observed in the amount of secreted IL-la from these 
different cell types (Kobayashi et al., 1999; Kong et al., 2006; Lonnemann et al., 1989; 
Murphy et al., 2003; Roubenoff et al., 1998; Sugano, et al., 2004). 
IL-la regulates major innate immune processes by modulating the production of potent 
inflammatory molecules, such as nitric oxide (NO), type 11 phospholipase (PL) A2, 
cyclooxygenase (COX)-2, prostaglandins, leukotrienes, platelet-activating factor and 
other cytokines (Clausen et al., 1996) (Figure 1.10). The metabolites of arachidonic acid, 
prostaglandins and leukotrienes in turn are also endogenous regulators of IL-la (Endres 
et al., 1989). IL-la can also up-regulate adhesion molecules (ICAM-1) on endothelial 
cells (Scholz et al., 1996). IL-1a is likely to play a pivotal role in the pathogenesis and 
maintenance of chronic diseases by augmenting the transcription of other pro- 
inflammatory genes such as IL-8 and IL-6 (Werman et al., 2004). 
IL-Ia is also a major inductive factor in osteoclastic; bone resorption and can 
simultaneously inhibit osteoblastic activity (Suda et al., 2004; Tanabe et al., 2005; Wei et 
al., 2005; Yu and Ferrier, 1993). Connective tissue remodelling occurs in growth and 
development and is regulated by the interplay of cell-cell and cell-matrix interactions 
involving the production of enzymes, activators and inhibitors and cytokines and growth 
factors (Reynolds and Meikle, 1997). Proteinases such as the metalloproteinases (MMPs) 
are key enzymes in tissue degradation and IL-Ia can directly activate MMPs thereby 
contributing to tissue destruction (West-Mays et al., 1995). 
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I L- I 
III -A-01). COX-2. 
iNOS. Endothelial adhesion Molecules. 
Sýnthesis ot'Chemokincs 
PGF, Leuk-otrienes. NO, Neutrophil Endothelial 
Adhesion. Emigration of Neutrophils, Activation of 
Neutrophils 
Intlarnmation. Fissue Destruction. Loss of 
Function 
Figure 1.10 I-he inflammatorý ca: cade triggered bý I L- Ia (iNOS =inducible NO synthase), Adapted from 
Dinarcilo (2000). 
As listed in Table 1.6. IL-la induces the expression of genes associated with 
inflammation at the transcriptional level. It is clear that IL-la has been associated with a 
wide range of vital functions including immune cell recruitment, cell proliferation, 
angiogenesis and invasiveness of different tumour cells, tissue destruction, bone 
resorption. blood pressure and central nervous cell functions (Dinarello, 2000; Dinarello, 
2002: Voronov et al.. 20033). Moreover, clinical studies show that IL-la is a significant 
modifier of inflammation in vivo. as exemplified by patient responses to IL-I inhibitors 
(Choý and Pana,, i. 200 1: Daver et al., 2005). With all these capabilities, IL- Ia appears to 
act as key cytokine in many chronic diseases ranging from rheumatoid arthritis (Buchan 
et al.. 1988: Niki et al.. 2001), Alzheimer's disease (Hayes et al., 2004). juvenile 
osteoarthritis. systemic sclerosis (Du et al., 2000b) to periodontitis (Dayan et al., 2004). 
1.8 IL-la versus IL-lp 
IL-la and IL-lp displaý amino acid and nucleotide homologies of 26 % in humans 
(Dower et al.. 1986). IL-la and IL-lp bind to the same receptors, and it generally has 
been assumed that the two forms of the cytokine elicit similar responses (Dinarello, 
1996. Patarca and Fletcher. 1997). However, there is evidence that distinguishes specific 
roles for ll, -I(x and IL-lp causing inflammatory disease and that IL-la is an essential 
mediator of Yersinia entcrocolitica- induced intestinal inflammation that cannot be 
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compensated for bN the endogenous levels of IL-IP (Dube et al., 2001). Endogenously 
produced IL- Ia and I L- IP differ dramatically in the subeellular compartments in which 
they are active. Unlike pro IL-Ict. pro IL-IP only has marginal biological activity and 
needs to be c leaved by the I L- I -converting enzyme (IC E) or caspase- I to yield the active 
IL-IP peptide (Cerretti et al.. 1992). IL-la is mainly active as an intracellular precursor 
(31 kDa) or as a membrane-associated form (23 kDa), but is only marginally active as a 
secreted 17 kDa molecule. IL-Ict is only rarely secreted by living cells, except for 
activated macrophages. and in contrast to IL- I P, I L- Ia is not commonly detected in blood 
or in bod\ fluids. except during severe disease, in which case the cytokine may be 
released from dying cells. Despite the fact that in vitro IL-I(X apparently shares the vast 
majority of effects of IL-10. its physiological role remains unclear (Dinarello, 1996). 
Although there is a significant amount of data supporting the role of IL- I in the initiation 
and progression of periodontal disease. most studies have focused on the role of IL- IP in 
periodontal disease (Delaleu and Bickel, 2004; Figueredc, et al., 1999; Graves and 
Cochran. 200-3). Hou et al.. 1995; Jandinski et al., 1991). Little is known about the role of 
IL-Ict in inducing an inflammatory response to periodontopathogens. Its relative 
pathogenic contribution during the progression of periodontitis remains to be fully 
elucidated. 
Cytokines 
I I. - I a. IL- I [I. I L- I Ra, IL-12. IL-3). 11-6.11,12. GM-CSF. 11-8 and other chemokines 
Cytokine receptors 
11-1 (PýS) 
11. -2, GIM-CS1 
Proinflammatory mediators 
i\pe-2 
c\ to.., ol ic xid sccrctorý plios2hol ipase A, 
Endothelin-I 
GaIll 
Growth factors 
IIDGI : fibroblast gro\\th factor: keratinocýtc groýkrth factor 
llcpjtocýtc ýroýQh factor 
Ner\e groMh t, actor 
*vlclanoma , ro\ý th stiniulator\ acti\ it\ 
Insulin-like , ro\\th factor 
Tissue remodelling 
Stroinclý,, irl. , -, clatitlascs. elastase. collagenases. tissuc 
inhibitor of metal loproteinases I 
Adhesion molecules 
H-A\l. \ CANI- 1.1, \mphocýte L-selectin 
Table 1.6 Increased Expression of Various Genes b) 11--lu. [t, -I(x induces the expression of several genes 
associated %% ith inflammation. Adapted 
from Dinarello ( 1996). 
53 
Chapter 1: Introduction 
1.9 IL-lu in periodontal disease 
A number of lines of evidence support a pivotal role for IL-la in mediating the host 
response to periodontal pathogenic bacteria and the associated tissue damage. Firstly, 
levels of IL-la are undetectable in the gingival crevicular fluid (GCF) of healthy teeth 
but are highly elevated in severe periodontal disease (Ishihara et al., 1997; Mathur et al., 
1996; Rasmussen et al., 2000). Secondly, successful treatment results in the reduction of 
IL-la concentration to pre-disease levels (Holmlund et al., 2004). Tbirdly, in a primate 
model of acute periodontal disease the use of IL-I receptor antagonists to block IL-I 
activity is able to significantly reduce inflammation and tissue damage (Delima et al., 
2002; Graves et al., 2000; Graves and Cochran, 2003). Finally, the ectopic expression of 
IL- Ia in the oral epithelia of transgenic mice shows that expression of IL- Ia is sufficient 
to induce all the cardinal features of periodontal disease even in the absence of bacteria 
(Dayan et al., 2004). 
1.9.1 The role of IL-1a in bone resorption 
IL-la is produced in response to periodontal pathogens mainly by monocytes in the 
periodontal tissues but is also produced by other cells including gingival keratinocytes, 
gingival fibroblasts, human polymorphonuclear leukocytes (Henderson et al., 2002; 
Johnson and Organ, 1997; Kobayashi et al., 1999; Matsuki et al., 1993; Stouft et al., 
1987; Takeichi et al., 1994; Zhou et al., 2005). 
Alveolar bone resorption is a hallmark of periodontitis. IL-l a is one of the most potent 
bone-resorbing factors associated with inflammation. A number of studies have found 
IL-la can simultaneously inhibit osteoblast and promote osteoclast activity (Nakamura 
and Jimi, 2006; Tanabe et al., 2004; Wang and Stashenko, 1993). Further studies 
demonstrate that increased IL-la synthesis by bone marrow cells may play an important 
role in the differentiation and survival of osteoclasts induced by Aggregatibacter 
(Actinobacillus) actinomycelemcomitans LPS (Ueda et al., 1998). In vivo periodontal 
disease models show that regulation of receptor activator of nuclear factor kappaB ligand 
(RANKL) and osteoprotegerin (OPG) expression is important for the control of alveolar 
bone destruction (Teng et al., 2000). Recent studies have shown that IL-la induces 
RANKL expression by stromal cells (Wei et al., 2005) and decreases OPG production by 
osteoblasts (Tanabe et al., 2005) and thus stimulates bone resorption. Moreover, the 
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degradation of collagen is a key step in bone resorption and MMPs have long been 
implicated in collagen degradation (Song et al., 2006). IL-la increases the expression of 
several MMPs including MMP-I, MMP-3 and MMP-7 (Wisithphrom et al., 2006). 
Collectively, the literature on IL-la suggests that it is involved in the regulation of bone 
resorption generally and that includes alveolar bone resorption. 
1.10 IIAA gene polymorphisms and periodontal disease 
It has been reported that genetic polymorphisms at the IL-I gene locus including IL-la 
may identify individuals who are susceptible to periodontitis, although there is 
disagreement about which variantof the IL-I gene confers susceptibility. The IL-IA gene 
demonstrates interindividual differences in protein production rates in response to 
stimulation and these high and low producer phenotypes have a molecular basis (Endres 
et al., 1989). A number of polymorphisms have been reported in the lL-lA gene (Bailly 
et al., 1996b; Bensen et al., 2003; Dominici et al., 2002). Although many single- 
nucleotide polymorphisms (SNPs) have been identified in the coding and regulatory 
regions of the IL-IA gene ttp: //www. ncbi. nim. nih. gov/entrez , most clinical studies 
have used only one or two of the SNPs that are reported to exist in this region (Kaijzel et 
al., 2002; McDowell et al., 1995). The IL-IA gene variations have been associated with 
earlier onset or more severe disease expression of Alzheimer disease (Dominici et al., 
2002), cardiovascular disease (Um et al., 2003), osteoporosis (Duncan et al., 1999), 
polycystic ovary syndrome (Kolbus et al., 2006), primary open angle glaucoma (Wang et 
al., 2006) and gingival overgrowth (Bostanci et al., 2006). 
The possible role of IL-IA gene polymorphisms in the periodontal diseases was first 
suggested in 1997 (Komman et al., 1997a). In that study, the IL-I composite genotype 
formed by the carriage of allele 2 at both IL-IA -889 and IL-113 +3953 was found to be 
associated with an increased risk for severe chronic periodontitis with an odds ratio of 6.8 
(95% confidence interval: 1.01- 45.95). Since then, several studies have evaluated the 
association of IL-I genotypes with the severity of periodontal disease (Kornman et al., 
1997a; McDevitt et al., 2000), increased bleeding on probing (Lang et al., 2000) and 
tooth loss (McGuire and Nunn, 1999). The composite genotype has also been reported to 
be correlated to the bacterial composition of plaque from periodontitis patients (Agerbaek 
et al., 2006; Socransky et al., 2000). However, contradictory reports showed that the 
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simultaneous presence of allele 2 at the ILIA-889 and ILI B +3953 loci is not positively 
associated with severity of chronic periodontitis (Meisel et al., 2002; Papapanou et al., 
2001) or tooth loss (Cattabriga et al., 2001). The IL-I composite genotype is also limited 
to specific racial groups. Whilst this genotype is apparently predictive of periodontal 
disease severity in people of European population, it is so infrequent among people of 
Chinese subjects that correlation with disease severity cannot be made (Armitage et al., 
2000). 
1.10.1 Interleukin-lA gene polymorphisms in aggressive periodontitis 
lL-lA gene polymorphisms, including IL-IA-889 and IL-IA+4845 have been studied by 
different groups in various ethnic populations (see Table 1.7). Since there is strong 
linkage disequilibrium between IL-IA-889 SNP and IL-IA+4845 SNP in exon 5 (G to C 
transition) some of the studies have chosen to test the latter (Gore et al., 1998; McGuire 
and Nunn, 1999). 
Regarding the relationship between IL-IA genotype and aggressive periodontitis 
susceptibility, conflicting results have been presented based on different ethnic 
populations, including Caucasian-American, African-American, European-Caucasian and 
Asian populations (Anusaksathien et al., 2003; Brett et al., 2005; Gonzales et al., 2003; 
Hodge et al., 200 1; Moreira et al., 2007; Rogers et al., 2002; Walker et al., 2000). Studies 
on early-onset periodontitis found that allele I (C) of IL-IA-889 and IL-IB+3953 was 
transmitted more frequently with this clinical phenotype. In addition, both 
polymorphisms were in strong disequilibrium with each other in Caucasians but not in 
African Americans (Diehl et al., 1999). When the association of these polymorphisms 
with aggressive periodontitis was investigated in a Chinese population, the frequency of 
allele 2 at the IL-IA+4845 has been correlated with an increased risk in male patients (Li 
et al., 2004a). 
In contrast, studies on generalized early onset periodontitis in Scottish Caucasian patients 
failed to find any association between aggressive periodontitis and genotype with respect 
to the IL-IA-899 genotype (Hodge et al., 2001). An investigation of this genotype in 
Brazilian and Japanese populations did not reveal any association with aggressive 
periodontitis (Tai et al., 2002). The contradictory results found in several studies may 
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also be explained bý differences in the diagnostic criteria used to define populations, the 
lo%N number of subjects studied. and the characteristics of the control population (Table 
1.7). Since aggressive periodontitis is a complex, oligogenic disorder, IL-1A genetic 
variations may have an important but not exclusive influence on disease risk. 
Reference 
Diehl et al.. 
1999 
Genotype Subjects 
reported 
889 
56 GEOP patients and 56 controls Cross- No assoc. 
with Caucasian heritage sectional 
Principal findings 
Al Me I of I L- IA -889 
28 African-American and se%cn Linkage ýNas transmitted more 
Caucasian American analysis frequently with the HOP 
phenotype 
Hodge et al., 
IL-IA- 
2001 
889 
Rogcrs ct aL. 
2002 
889 
Walker et al., IL- 
2000 1+4845 
Tre\ ilatto et 
al.. 2002 
I[--IA- 
889 
Gonzales et 
al.. 2003 
11-- 
1+4845 
Quappe et a] - 889 
2004 
1 19 Caucasian EOP patients and 
oo hcalth\ controls in Perth 
Cross- 
No assoc. 
scetional 
37 African-Americans with UP 
Study 
design 
Cross- No assoc. sectional 
Braziliant'amik. 14 indiN iduals) Famik 
i th A P-P stud\ 
No assoc. 
28 North European AgP patients 
and 33 controls. 16 Central Cross- No assoc. American AgP patients and 14 sectional 
controls 
30 AgP patients. 75 healthý 
controls and 75 subjects of Cross- No assoc. 
unknoN%n periodontal status sectional 
(reference population) in Chile 
IL- 47 GEOP patients and 97 healthy Cross- 
Tai et al.. 2002 I A+4845 controls in Japan sectional 
No assoc. 
Liu et al.. I L- 
2004 IA-4845 
Anusaksathien 
et a].. 21003 
IIAA - 
881) 
122 GAgP and 90 hcalthý controls Case- 
in Chiese control 
123 Thai suýjects. including CP. Cross- 
A91, and healthý controls sectional 
Association in trale 
No assoc. 
Moreiraetal.. IL-IA- 55 GAgP and 41 healthy controls 
Case- No assoc 
2006 889 control 
Table 1.7 Reported IL-JA gene pol\morphisms in aggressive periodontitis. GAP. (generalized) aggressive 
periodontitis. (i-FOP. (generalized) early onset periodontitis. No assoc.. not related to 
disease 
susceptibi I itN - 
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1.10.2 IL-IA gene polymorphisms in chronic periodontitis 
In contrast to aggressive periodontitis, several reports on chronic periodontitis indicate 
that the IL-IA genotype is associated with this form of periodontal disease (Laine et al., 
2001; McDevitt et al., 2000; Papapanou et al., 2001; Shirodaria et al., 2000). However, 
other studies failed to find an association between IL-IA genotype and chronic 
periodontitis (Armitage et al., 2000; Lopez et al., 2005). IL-IA gene polymorphisms have 
been investigated with respect to chronic periodontitis, smoking, ethnic group, oral 
microbial pathogens present in the plaque biofilm and other periodontal clinical 
parameters related to inflammatory status or to the progression of the disease (Cattabriga, 
et al., 2001; Cullinan et al., 2001; Komman et al., 1997a; Laine et al., 2001; Moreira et 
al., 2007). It has been suggested that the IL-lA allele 2 (T) genotype is correlated with 
the levels of specific bacterial complexes including T forsythensis, P. gingivalis, T 
denticold and suggests that there may be a correlation between a tendency of genotype- 
positive people to harbour these bacteria in their plaque (Socransky et al., 2000). A 5- 
year longitudinal study of a group of subjects of almost exclusively European heritage 
showed an interaction between the IL-IA periodontitis-associated genotype and age, 
smoking and presence of P. gingivalis (Cullinan et al., 2001). Studies including Chinese, 
Greek, Japanese and Thai populations did not find a relationship between IL-1 genotypes 
and chronic periodontitis disease susceptibility or severity (Anusaksathien et al., 2003; 
Armitage et al., 2000; Sakellari et al., 2006). Overall, the results appear contradictory and 
it is difficult to draw any firm conclusion concerning the association of IL-lA gene 
polymorphisms with chronic periodontitis. Besides ethnic differences, it appears that 
confounding factors, such as smoking, gender or age may collectively complicate the 
study outcomes on IL-IA polymorphisms in chronic periodontitis. 
Polymorphisms in the IL-IA gene linked with periodontitis appear to be dependent upon 
ethnic background, and also may indicate that different genetic polymorphisms are 
associated with different forms of periodontitis, namely chronic periodontitis or 
aggressive periodontitis (Hodge et al., 2001; Parkhill et al., 2000). 
1.11 'The functional importance of HAA gene polymorphisms 
The suggestion that IL-IA gene polymorphisms influence the pathogenesis of 
periodontal disease needs to be supported by evidence from studies at the molecular and 
58 
Chapter 1: Introduction 
cellular level. However, the number of studies describing the functional importance of 
IL-IA polymorphisms is relatively few. There is evidence supporting the hypothesis that 
various combinations of alleles on the IL-IA gene differ in the way they produce IL-la 
cytokine in vivo. A study reported that significantly elevated levels of IL-la in plasma 
were detected with the IL-IA-899 (TI) homozygous as compared to the IL-IA CC or CT 
(Hulkkonen et al., 2000). Another study reported that carriage of the IL-IA-889 allele 2 
(T) resulted in increased IL-10 plasma levels in healthy individuals (Kilpinen et al., 
2002). 
There is evidence that the presence of allele 2 (T) at position IL-IA-899 was associated 
with a four-fold increase of GCF IL-1a protein levels in non-smoker chronic 
periodontitis patients (Shirodaria et al., 2000). Furthermore, periodontitis patients 
carrying the IL-IA-889 T allele had significantly increased serum levels IL-6 and C- 
reactive protein (D'Aiuto et al., 2004). However, it is not clear whether these promoter 
polymorphisms are causally related to the regulation of IL-la transcription. A single in 
vitro study has tested the effect of the IL-IA-889 polymorphism on transcriptional 
activity in reporter gene assays (Dominici et al., 2002). This study reported that allele 2 
(T) at position IL-IA-899 was associated with a 1.8-fold increase at basal transcription 
rate compared with a construct containing the allele I (C) in PCIJ cells (human 
pancreatic cell line). The same TT genotype was also associated with five fold higher 
levels of secreted IL-la compared with the CC genotype when PMBC cells were 
stimulated with LPS for 3 hours. Interestingly, those differences disappeared after 6 
hours of cell stimulation. The basis for such observations will be further discussed in 
Chapter 5. 
1.12 AIMS OF THE STUDY 
As mentioned in this review, the available evidence suggests that IL-la is an important 
mediator of periodontal disease. Furthermore it appears that genetic polymorphisms in 
the lL-lA gene may play an important role in influencing susceptibility to disease by 
regulating transcription and thereby increasing IL-la production. Therefore the 
hypothesis to be tested here is that polyrnorphisms in the lL-lA gene promoter regulate 
lL-lA transcriptional activity induced by a range of periodontopathogens. This in turn 
provides a mechanism to directly influence pathogenesis of periodontal disease by 
59 
Chapter 1: IntroductioI2 
increasing the IL-la associated bystander damage. The studies proposed here aim to 
identify polymorphisms in the promoter region of the lL-lA gene, to investigate their 
effect on transcriptional activity, and to investigate their interaction with a range of 
periodontopathogens. 
The specific objectives of the studies include: 
1. To investigate how periodontopathogens may regulate IL-la production through 
multiple pathways 
2. To identify the common IL-1 A gene promoter polymorphisms present inpatients with 
aggressive periodontitis 
3. To test the detected polymorphisms to ascertain whether there was a significant 
difference between patients with aggressive periodontitis and unrelated healthy 
individuals in tenns of allele frequencies or genotype frequencies 
4. To test functional impact of identified polymorphisms on transcriptional activity 
using in vitro reporter gene assays and in silico analysis 
5. To investigate if different periodontopathogens interact with specific IL-la 
polymorphisms 
6. To identify the mechanism by which doxycycline modulates inflammation including 
IL-la production including: 
9 The regulation of IL-la production in monocytes by doxycycline 
The effect of metal ions on IL-la production and if doxycycline regulates 
cytokine response via the chelation of metal ions 
To test the specificity of the response to doxycycline for IL-la and other 
cytokines 
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2.1 INTRODUCTION 
a rirF r ula I VUL)FIL 
As mentioned previously, the initiation and progression of periodontal disease depends 
on the presence of bacterial plaque. Tissue destruction is an indirect result of the presence 
of bacteria and their ability to trigger a host inflammatory response. The local host 
response to periodontal bacteria includes the recruitment of polymorphonuclear 
neutrophils and monocytes/macrophages (Dixon et al., 2004; Kornman et al., 1997b). 
Monocytes are a major part of the inflammatory infiltrate and can be found within 
gingival connective tissues of patients with periodontitis (Zappa et al., 199 1). These cells 
play a critical role in regulation of the local inflammatory host response, in part through 
their ability to secrete pro-inflammatory cytokines including IL-la in response to gram- 
negative bacteria and their products (Matsuki et al., 199 1; Stoufi et al., 1987). 
The stimulation of IL-1a production by bacterial products has been studied by several 
groups. However, there has not been a systematic comparison of the effects of a full 
range of periodontal pathogenic bacterial species. Previous studies using primary 
monocytes or cell lines have investigated only either a single species, a number of strains 
of a single species or compared relatively small number of different species (Henderson 
et al., 2002; Sugano et al., 2004). Therefore, the aims of these pilot studies were to 
investigate how different bacteria may induce IL-1a production by monocytes and 
categorize bacteria in classes of response. In preliminary studies the aim was to compare 
a range of culture conditions for IL-la production by monocytes. Different bacterial 
species were compared to identify qualitatively different classes of bacterial stimulants. 
Characterization of bacterial factors within the supernatants was carried out including 
heat treatment, LPS depletion. These results served for the basis of experimental work 
described in later chapters. 
2.1 MATERIAL & METHODS 
2.1.1 Cell Culture 
Monomac-6, THP-1 and U-937 cell lines were obtained from the German Collection of 
Microorganisms and Cell Cultures (Mascheroder, Braunschweig, Germany). MonoMac-6 
cells were cultured in RPMI-Glutamax (Gibco BRL Life Technologies, UK) 
supplemented with 10% fetal bovine serum, 1% non-essential amino acids (Gibco BRQ, 
1% sodium pyruvate (Gibco BRL) and 9 99/ml bovine insulin (Sigma-Aldrich). THP-1 
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and U-937 cells were cultured in RPMI-Glutamax (Gibco BRL Life Technologies, UK) 
supplemented with 10% fetal bovine serum. All cell lines were cultured as a suspension 
in humidified conditions containing 5% C02 at 37*C. They were sub-cultured at 2xI 06/ml 
every 2-3 days. This was followed by centrifugation of suspension at 10OOrpm for 5min. 
The cells were then seeded in T75cm 2 flasks as required. 
Cells were cultured at the density of IX 106 cells per ml in 96-well flat-bottom plates and 
challenged with bacterial supernatants. The bacterial supernatants were added to the 
monocytes (200gl/well) at dilutions of 1: 250,1: 100,1: 50 and were incubated at 371C 
in a 5% C02 humidified atmosphere. Control cultures were incubated in the absence of 
bacterial supernatant. At the end of each study all plates were simultaneously thawed and 
exposed to three freeze-thaw cycles to lyse the cells. The cell free culture supernatants 
were collected by centrifuging at 1000 rpm for 5 minutes and stored at -80'C until the 
cytokine assays were performed The IL-la concentrations were measured in the 
supernatant (secreted compartment) and in the lysate (cell-associated compartment). All 
experiments were carried out in triplicate. 
2.1.2 Bacterial strains and growth conditions 
Bacterial supernatants were from cultures of P. gingivalis W50 and W83,381, F 
nucleatum ATCC 25586, C rectus ATCC 33238, A. actinomycetemcomitans Y4, P. 
intermedia NCTC 93 3 6, V atypica NCTC 1183 0, and P. nigrescens Mu 14. Supernatants 
from a culture of S sanguis NCTC 7863 were used as a negative control and LPS from 
the non-oral bacterium Escherichia coli 026: B6 (Sigma-Aldrich) was used as a positive 
control. Bacterial cultures were grown in the appropriate growth medium either 
aerobically in a 5% C02 incubator or in an anaerobic chamber containing an atmosphere 
of in 80% N2,10% H2, and 10% C02 (Table 2.1). Cultures were grown to the same 
density (approximately 5xI 07 colony forming units/ml) and harvested by centrifugation at 
10000 xg for 15 min at 4*C. The culture supernatants were collected, filter-sterilized and 
stored at -800C until used. 
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Bacterial strains Growth Medium 
A. actinomycelemcomitans (A. a) Y4 Tryptic soy broth with 0.6% yeast extract 
S. sanguis (S. s) -NCTC 7863 
S. mutans(S. m) -NCTC 10449 
Tryptic soy broth containing 5% defibrinated 
sheep blood 
F. nucleatum (F. n) -ATCC 25586 Schaedler broth (Difco) 
P. gingivalis (P. g) -W50 and W83 Tryptic soy broth (Difco) supplemented with 5g 
of hernin 
C rectus (C. r)-FDC285 YPD broth with 1%yeast, 2% peptone and 2% 
dextrose 
V. atypica (Va) -NCTC 11830 Veillonella agar plates (Difco) 
P. intermedia (P. i)-NCTC 9336 
P. nigrescens (P. n) - Mu 14 
Tryptic soy broth (Difco) supplemented with 5g 
of hemin and vitamin K3 
T denficold (T. d)-ATCC 35404 Trypticase-yeast extract-gelatin-volatile Fatty 
acids broth with 5% rabbit serum 
Table 2.1 Bacterial strains and growth conditions. Bacterial cultures were grown in the appropriate growth 
medium either aerobically in a 5% C02 incubator or in an anaerobic chamber containing an atmosphere of 
in 80% N29 10% H2, and 10% C02. 
2.1.3 Total protein assay of bacterial culture supernatants 
Protein quantitation was performed by the Bradford method using Bio-Rad colorimetric 
protein assay (Bradford, 1976). To quantify total protein, bacterial culture supernatants 
were defrosted and 50 pl was taken for measurement of protein concentration by Bio-Rad 
colorimetric protein assay. Bradford Assay is an accurate method commonly used to 
determine the total protein concentration of a sample. According to the principle of this 
technique the binding of the acidic dye solution Coomassie Brilliant Blue G-250 with the 
proteins in the supernatants results in a qualitative colorimetric reaction that can be read 
in a microplate reader at 595 mn, and compared against a standard curve of bovine 
albumin of known concentrations. 
2.1.4 Endotoxin removal by Polymyxin B 
To assess the relative role of LPS of periodontal pathogens on IL-la production by 
Monomac-6, bacterial supernatants were passed through polymyxin B coated columns to 
remove endotoxin components according to the manufacturer's protocol (Detoxigel, 
Pierce Biochemicals). Detoxi-Gel AffinityPak Columns were regenerated by washing 
with 5ml of 1% sodium deoxycholate (Sigma-Aldrich, UK) followed by 5ml of pyrogen- 
free water to remove detergent. 500pI of bacterial supernatants were applied to the 
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column. and 500p I of pýrogen-free water were added. Bottom and top caps were replaced 
after the sample had entered the gel bed and incubated for 2 hours at room temperature. 
Samples %%ere eluted with Iml pyrogen-free water and stored at -70'C until use in 
experiments. Columns %%ere regenerated as before and stored in 25% ethanol at 2-8'C. 
2.1.5 Endotoxin Testing 
To confirm that polýmýxin B coated columns had removed LPS from supernatants, the 
endotoxin content of elutriated supernatants "as measured by the Limulus Amebocyte 
LNsate (LAL) (Cambrex Biotech). The Limulus Ameboc,, -te Lysate (LAL) test is a 
qualitati%e test for Gram-negati%e bacterial endotoxin. The principle is as below. 
Proenzyme 
Coagulase 
Coagulogen 
+ 
Coagulin 
Endotoxin 
FigureIll rhc Limulus Amehoc)te L,. sate (LAI. ) assay. Gram-negati%e bacterial endotoxin catalyzes the 
actkation of a proenzyrnc in the Limulus Ametx-)c,, -te L. Nsate (Young et al.. 1972). The initial rate of 
acti%ation is determined bý the concentration of endotoxin present. The actkated enzyme (coagulase) 
hNdrol)scs specific tx)nds %%ithin a clotting protein (coagulogen) also present in Limulus Amebocyte 
L%satc. once hýdroll zed. the resultant coagulin self-associates and forms a gelatinous clot. 
The use of LAI. for the detection of endotoxin was performed according to the 
manufacturer's instructions. Briefly, samples were tested to check the pH was between 
7.0 and 7.5. Sterile Water for Injection (USP) was used to reconstitute E. coli Control 
Standard Endotoxin. The %ial %%as vortexed for 15 minutes. The standard endotoxin was 
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diluted to give concentrations ranging from I EU/rnI to 0.01 EU/ml. The lysate was 
reconstituted by addition of 0.25 ml of the negative control (USP), positive sample 
control, control standard endotoxin dilution or sample to be tested to the Iyophilized 
lysate in the test vial. The vials were incubated one hour in a 37'C water bath. Care was 
taken to avoid any microbial endotoxin contamination. 
At the end of the incubation period, each vial was carefully removed and inverted 1800. 
The sample vials were compared to the control vials. A positive test was characterized by 
the formation of a solid gel, which remains intact after inversion. This was observed in 
the positive control vials and in the positive sample control vials. The lysate sensitivity 
was 0.0 1 EU/ml. All test sample vials failed to form a solid clot after inversion and were 
therefore scored as endotoxin negative. 
2.1.6 Statistical analysis 
Student's 1-test and a one-way analysis of variance were used and data were considered 
significant at P<0.05. 
2.2 RESULTS 
2.2.1 Induction of IT. -la production in Monomac-6, THP-1 and U-937 cells 
A variety of established cell lines exist that exhibit monocyte-like characteristics. The 
ability of the three cell lines including human Monomac-6, THP-1 and U-937 to 
synthesize and secrete IL- Ia in response to E. coli LPS was examined at 6 hours. 
The cell lines were cultured with a range of Escherichia coli (E. coll) LPS doses between 
10 ng/ml and 100 ng/ml for 6 hours. Detectable levels of IL-la were measured from all 
cell lines. In all cases unstimulated cells produced very low levels of IL-la. Monomac-6 
and THP-1 cell lines produced IL-la in a dose dependent manner as can be seen in 
Figure 2.2. However, Monomac-6 cells produced four times more IL-la than THP-1 
cells. U-937 cells did not respond to LPS, which is consistent with previous studies (Hass 
et al., 199 0. 
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Figure 2.2 If, la production b,, monocNtic cell lines stimulated Nvith EC-oli LPS. Monomac-6. TI IP- I and 
1'-937 ý%ere exposed to Ecoli LPS (10 and 100 ng/ml) for 6 hours. The cell-associated and secreted 
amounts of ll, -lu %%ere quantified bý EIASA. The data are the mean ± standard deviations (S. D. ) of 
triplicate assaý s. 
2.2.2 Nlonomac-6 cells as a model for IL-la production 
Monomac-6 cells %%ere stimulated with E. coli LPS in the presence or absence of fetal 
bovine serum. Ec-oli LPS induced a dose dependent increase in 11--la production (Figure 
2.33). The addition of fetal bovine serum significantly increased the production of IL-Ici, 
in a dose dependent manner. Un-stimulated cells produced very low levels of 11--la 
compared to stimulated cells. Cell-associated levels in unstimulated cells were higher 
than secreted levels (p<0.05). Although a considerable proportion of IL-la protein is 
cell-associated. determination of both cell associated and secreted compartments is 
necessarý in order to assess overall cytokine synthesis to approximate the in vivo 
conditions. Therefore further experiments tested total IL-Ict levels. 
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Figure 2.3 I'he effects of' LPS concentration and fetal bovine serum levels on H. -I(I production by 
Monomac-6 cells. Monomac-6 cells %Nere exposed to 1.10 and 100 ng /mI of'E. coli LPS for 6 hours. The 
cell-associated and secreted amounts ot'IL-la %kere quantified bý ELISA. The data are the mean : i- standard 
de-, iations (S. D. ) oftripi icate assaý S. 
2.2.3 Determination of the optimal number of Monomac-6 cells 
To investigate the source of variation bet%Aeen experiments, the effect of cell number on 
IL-Ict production was analysed. Three different concentrations of cells were tested; 
1X105. )- 
-xlWand 
WOO cells per mi. In these experiments E. coli LPS (IOng/ml) was used 
as a stimulant. The highest concentration of cells produced approximately 7 times more 
I L- Ia than others (Figure 2.4). 
Hence. a concentration of W06 cells per ml was chosen for subsequent experiments. 
These data suggest that variation in cell plating could be a key factor in variation between 
different experiments. 
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Figure 2.4 I'he effect ot'cell density of Monomac-6 cells on IL-la production. Monomac-6 cells xNere 
exposed to P_ coli LPS (I OOng/m I) for 6 hours. The cel I -associated and secreted amounts of I L- Ia "ere 
quantified b\ FIASA. The data are the mean ± standard deviations (S. D. ) oftriplicate assays. 
2.2.4 Time-dependent production of IL-Ict by Monomac-6 cells 
Previous studies reported that the half-life ofthe IL-la mRNAs may vary depending on 
cell type being in the range of 6-8 hours (Godambe et al., 1993; Perregaux and Gabel. 
1998). To determine which time was likely to give the clearest results in this system, 
levels of 11--la production were compared at 1,2,4 and 6 hours. Monomac-6 cells were 
stimulated with E coli LPS (100ng/ml) for the indicated time periods. The results 
indicated that production of IL-la increases over 2 hours and peaks at 6 hours (Figure 
2.5). Therefore all subsequent experiments were studied at 6 hours. 
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Figure 2.5 Kinetics of' IL-lu production bý Monomac-6 cells. Cells "ere exposed to E. coli ITS (100 
ng, m]) 1'()r 1.2.4 and 6 hours. After incubation the cells were lysed by subjecting those to three cycles of 
freezing and tha\\ing to assess total IL-let by ELISA. The data are the mean ± standard de\ iations (S. D. ) of 
triplicate assa) s. 
In summary. the present findings indicate that under the experimental conditions assayed, 
maximum IL-la production by Monomac-6 is obtained once these cells are stimulated in 
the presence of 10% FCS for 6 hours at density of IxI O"/ml. 
2.2.5 IL-la production by Monomac-6 cells in response to periodontopathogens 
This studý aimed to examine the production of 11--la by Monomac-6 cells exposed to 
different concentrations of supernatants from oral bacteria. The effect of nine different 
types of bacterial supernatant on the production of IL-la was tested. The bacterial 
supernatants from A. actinonijcelenicomilans (A. a), F nuclealu"I (F. n), C. rectus (C. r), 
P. interntedia (P. O. V atipica (Va), T denticola (Td), P. gingivalis (P. gW50 and W83), 
P. nigrescens (P. n) and S. sanguis (S. s) were tested. The supernatants were added to 
culture medium at dilution ratio of 1: 250.1: 100 and 1: 50. 
Total protein levels differed between different bacterial cultures but levels appeared to be 
significantlý higher for P. intertnedia (Figure 2.6). As expected, there was a significant 
difference bet\%een inoculated bacterial media and bacterial culture supernatants 
(p<0.05). 
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Figure 2.6 Total protein concentrations in the culture supernatants expressed as ýLg/ml. Samples were 
defrosted and 50 ul was taken for measurement of protein concentration by Bio-Rad colorimetric protein 
assay. QuantitatiNe colorimetric reaction was read in a microplate reader at 595 nm. and compared against 
a standard cur, e ofboý ine albumin of known concentrations. 
To assess the importance of concentration of supernatant components on cytokine 
production a wide range of doses were tested. The results indicated that despite varying 
the concentrations added (1: 250,1: 100 and 1: 50), levels of cytokine production 
increased by at most 4-39 % at highest dosage (Figure 2.7). Minimal IL- I Ct was measured 
in cultures with inoculated media (10M). All bacterial supernatants significantly 
increased IL-la production. Amongst the different species tested A. 
actinomycelenicomilans (A. a), F. nucleatuni (F. n), C. reclus (C. r), P. iniermedia (P-i) 
and V aýypica (Va) were high inducers of IL-Ict production consistent with a previous 
report (Zubery et al., 1998). In contrast, T denticola (Td), P. gingivalis (P-g W50 and 
W83), P. nigrescens (P. n) and S. sanguis (S-0 consistently induced lower levels. There 
was no significant differences between the two strains of P. gingivalis (p=0.67). 
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Figure 2.7 Dose-response studý of the effect of periodontal pathogen(s) supernatants on IL-I(x production 
b\ Monomac-6 cells. Monomac-6 cells were plated at a density of lxlO' cells/ml in 96-well dishes. Cells 
were exposed to a range of periodontopathogens. Bacterial supernatants were added to cell culture media at 
various dilutions (1: 250.1: 100 and 1: 50). After 6h incubation the cells were lysed by subjecting those to 
three cý cles of freezing and tha\% ing to assess total IL- I a. The supernatants were harvested and assayed for 
ll_-J(xhý HASA. The data are the mean -j- standard 
deviations (S. D. ) of triplicate assays. 
2.2.6 Effect of heat treatment of bacterial supernatants 
In previous studies it has been shown that different periodontal bacterial species or 
different fractions of the same bacteria have different heat vulnerability profiles (Choi et 
al.. 2001). To further reveal differences between bacterial supernatants on IL-la 
production. the supernatants were subjected to heat treatment. Ecoli LPS (IOng/ml) was 
used as a positive control. The supernatants were heated to boiling for 30 minutes. They 
were added to cell culture media at 1: 100 dilutions and compared to unheated 
supernatants. 
Fig. 2.8 shows the impact of heat treatment on the supernatant's capacity to stimulate 
cytokine production. As expected, Ecoli LPS was resistant to heat treatment. Our data 
show an important interspecies heat vulnerability profile from different bacterial 
supematants. Heat-treatment of culture supernatants of A. actinomyceteniconlitans, P. 
intermedia, and T denticola resulted in significant decline in their capacity to induce 
cytokine production (Figure 2.8). In contrast, IL-Ict-inducing capacity of C. reclus, P. 
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gingivalis and f. at-ipica was significantly increased (p<0.05). In addition, F. nucleuluin 
cýtokine-inducing capacitý %N as not significantly affected by heat-treatment. 
4500 
4000 
3500 
3000 
2500 
2000 
1500 
1000 
500 
0 
I 
1 
A. a V. 11 U. 1 PA 
* 
I 
0 nontreated 0 heated 
* 
Is 
I 
V. a P. n P. gw50 T. d 
Figure 2.8 The effect of heat treatment on peri odon to pathogen induced IlAct production by Monomac-6 
cells. fhe bacterial supernatants kNere heated to boiling for 30 minutes. The cells were exposed to unheated 
or heated bacterial supernatants for 6 hours and the cells were lysed by sulýjecting those to three cycles of 
freezing and tha\Ning to assess total IL-la bý ELISA. The data are the mean ± standard deviations (S. D. ) of' 
triplicate assaýs- . P<0.05 
2.2.7 The effect of LPS depletion 
To assess the relative role of LPS of periodontal pathogens on IL-la production by 
Monornac-6. bacterial supernatants were passed through polymyxin B coated columns to 
remove endotoxin components. LPS-clepleted supernatants were then assessed for their 
abilitN to stimulate IL-la production. LPS-depleted supernatants were added to cell 
culture media at 1: 100 dilutions and compared to un-treated supernatants. As expected, 
E. coli LPS completek lost its activity by polymyxin B treatment. In cultures stimulated 
by C. rectits. P. interinetlia, V atypica and P. gingivalis approximately 99 %, 99.3%, 
99.7% and 86% of the IL-la production was abrogated by polymyxin B, respectively. 
Treatment with polymyxin B inhibited the IL-la-inducing capacity of A. 
actinonij, cetemeoinitans and F nucleamm by 52 % and 71 % respectively (Figure 2.9). 
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Figure 2.9 The effect of LPS depletion from per i oclontopath ogen(s) supernatants on ll, -Iu production, 
The supernatants \%ere passed through polvmýxin B coated columns and the cells were exposed to un- 
treated or LPS-depleted bacterial supernatants for 6 hours. After 6h incubation the cells were 1ýscd b) 
subjecting those to three cýcles of freezing and thawing to assess total IL-Ia. The supernatants were 
har\ested andassa\ed for IL-la bN ELISA. Thedataarethemean± standard cleýiations (S. D. ) oftriplicate 
assaýs. 'P<0.05. 
These studies suggest that bacteria can induce IL-la production by a range of 
mechanisms. At least three different classes of bacterial stimulants can be identified: 
1. Those partly affected by depletion of LPS and heat-labile, F nucleatum and 
A. actinomyceleniconfilans 
2. Those requiring LPS and heat-labile; P. interniedia, P. nigrescens 
3. Those requiring LPS and enhanced by heat treatment; C. reclus, V. atypica, P. 
gingivalis 
2.3 DISCUSSION 
monocytic cell line. Monomac-6 (Ziegler- This stud,, demonstrated that the more mature 
Heitbrock et al., 1994) is more susceptible to bacterial stimulation than THP-1 or U-937 
cell lines (Schwende et al., 1996). These results extend the finding of others showing that 
Monomac-6 does not need to be pre-cultured with PMA to show significant IL-la 
secretion in response to LPS or periodontal pathogens (Hass et al., 1991 ; Pradines- 
Figueres and Raetz. 1992). These results imply that Monomac-6 is a more efficient and 
time saving model system to study monocyte activation in periodontal disease. The 
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present results also confirmed previous studies that the amount of IL-la production is 
highly dependent upon monocyte culture conditions and under the experimental 
conditions assayed. maximum IL-I(x production by Monomac-6 is obtained once these 
cells are stimulated in the presence of 10% FCS for 6 hours at density of IxI 06/ml (Danis 
et al.. 1990). Un-stimulated cells did not produce detectable levels of secreted IL- Ia but 
did produce low but significant levels of cell-associated IL-la. These results are similar 
to previously published reports and confirm that under normal conditions, 94-95% of IL- 
Ict remains cell-associated (Matsushima et al., 1986; Watanabe and Kobayashi, 1994) 
Although a considerable proportion of IL-la protein is cell-associated, determination of 
both cell associated and secreted compartments is necessary in order to assess overall 
cytokine synthesis to approximate the in vivo conditions. 
This study also demonstrated that a broad range of oral bacteria stimulate the expression 
of IL- I cc in Monomac-6 cells as previously reported (Henderson et al., 2002; Reddi et al., 
1995; Sugano et al.. 2004). Previous studies have investigated only either a single 
species. a number of strains of a single species or compared relatively small number of 
different species. In this thesis bacterial culture supernatants were used as a stimulant. 
One problem with this type of strategy is that culture supernatants from each bacterial 
species will contain a mixture of bacterial endotoxin, bacterial waste products and 
bacterial enzymes. The exact content is likely to change not only between species but 
also between batches of bacterial cells. This would reflect slight variation of culture 
medium and incubation period of bacteria. Indeed, total protein levels differed between 
different bacterial cultures but levels appeared to be significantly higher for only P. 
inlermedia. However, the results indicated that despite P. inierniedia having the highest 
protein concentration, levels of IL- I ct production were lower than others which had lower 
protein. 
The results here also indicated that a range of periodontal pathogens have the capacity to 
induce IL-I(x production in Monomac-6 cells; nevertheless the nature of the responsible 
component for this effect may vary among them. This capacity may be attributed to 
either LPS or to proteinaceous component depending upon the specific species. In 
support of this data. Monomac-6 cells have been shown to produce cytokines in response 
to an extract of A. actinomycelenicomitans surface associated proteins. This cytokine 
inducing activity was heat sensitive suggesting that the active components were 
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proteinaceous (Reddi et aL, 1996; Reddi et al., 1995). Different bacterial virulence 
factors may act through a range of distinct signalling mechanisms to stimulate the 
production and release of cytokines (Darveau et al., 2002; Saklatvala, 1995). Toll-like 
receptors 2 and 4 have recently been identified as possible signal transducers for various 
bacterial ligands (Bainbridge and Darveau, 2001; Yoshimura et al., 2002). To further 
clarify the mechanisms involved the ability of different bacterial virulence factors to 
interact with different TLRs to stimulate IL- Ia production could be investigated further. 
In summary, this study demonstrates that a broad range of oral bacteria stimulate the 
expression of IL- Ia in Monomac-6 cells and the nature of the responsible component for 
this effect may vary among them. 
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Antagonistic Effects of Porphyromonas gingi*valis 
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3.1 INTRODUCTION 
As mentioned previously more than 700 species can colonize the oral cavity (Aas et al., 
2005) and approximately 500 species may be detected in subgingival plaque (Paster et 
al., 2001). Evidence suggests that the most pathogenic complex is "the red compleX7 
which includes P. gingivalis, T forsythensis, and Treponema denticold (Lakshmyya et 
al., 2007; Socransky et al., 1998). Although there are strong indications that certain 
species are the likely aetiological agents of periodontal diseases, there are almost 
limitless possibilities for bacterial interactions in the ecology of the oral cavity 
microflora, including synergism, commensalism, and antagonism. The mixed nature of 
the bacterial infection in periodontal disease will have a direct influence on the nature 
and extent of the host response to the bacterial challenge. Cytokines are central to this 
response and appropriate production of cytokines results in development of protective 
immunity. However inappropriate production of cytokines can lead to tissue destruction 
and disease progression. P. gingivalis has been reported to be a major component of the 
pathogenic microbiota in various periodontal diseases (Holt et al., 1999). Despite a 
profound inflammatory response, the host immune system is usually not able to eliminate 
P. gingivalis infection. P. gingivalis might have the potential to suppress the normal 
immune response to a wide range of periodontal pathogens. This chapter will focus on 
P. gingivalis and its properties of modulating cytokines in ways that evade the innate host 
immune response, and permit its colonization and propagation in the oral cavity. 
3.1.1 Porphyromonasgingivalis 
P. gingivalis is a gram-negative, black-pigmented anaerobe and is characterised as a 
bonafide periodontal pathogen within "the red complex" (Holt and Ebersole, 2005). 
Several approaches for identifying P. gingivalis strains have been reported, including 
serotyping and whole genomic digest (Genco and Loos, 1991; Parent et al., 1986). More 
recently, 22 unique but closely related P. gingivalis types have been identified using 
heteroduplex analysis (Leys et al., 1999). The effects of different strains of P. gingivalis 
have been compared in several animal studies, indicating a range of host responses 
(Evans et al., 1992; Genco et al., 1991; Laine and van Winkelhoff, 1998). In most animal 
studies, P. gingivalis strains W50 and W83, which are indistinguishable from one 
another, proved to be particularly virulent and strongly associated with human 
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periodontitis (Griffen et al.. 1999). Other strains, such as 381,49417, A7AI-28, are also 
considered as virulent strains (Ebersole et al., 1995; Lin et al., 2005). 
PorIAlvi-onionas gingivalis expresses several virulence factors including capsular 
polýsaccharide (K-antigen). fimbriae, the cysteine proteases (the Arg- and Lys- 
gingipains) and lipopolysaccharide (LPS). Studies have been performed to determine the 
distribution of the specific serotypes of P. gingivalis strains. P. gingivalis has been 
classified into serotypic groups based on antisera binding to the capsule (K-antigen, KI 
to K6) (Aduse-Opoku et al.. 2006; Laine et al., 1996), fimbriae (filamentous component, 
t)pes I to V) (Nakagawa et al.. 2000) or outer membrane antigens (A, B, C) of 
Rgingivalis (Ebersole and Steffen, 1995). Rgingivalis strain 381 is reported as K 
antigen negative (K-neg) or capsule deficient (van Winkelhoff et al., 1993). Some 
P. gingivalis strains and their serotypes are shown in Table 3.1. 
Strain Capsular serotype Fimbrial scrotype Outer membrane serotype 
PC U 
W83 KI v C 
391 K-ýýý I A 
A7A 128 
(ATCC53977) 
K3 II B 
FAY 19m- I 
ATCC 49417 K4 11 
A7A 1 -18 
(A RV53977) 
B 
ATCC 49417 K4 11 
116 1690 K5 - 
FIG 1691 K6 
11G184 K2 
= 
- - 
Tablell P. gingivalis strains and serot)pes 
3.2 Major virulence factors of A gingivalis 
Bacterial pathogens are highly evolved and have developed strategies to enable them to 
survive and groNN within their specific hosts. These specialized survival strategies are 
dependent upon the co-ordinated expression of appropriate genes which facilitate the 
processes of colonization. acquisition of growth nutrients, evasion of host defences. and, 
in some cases. invasion of host tissues prior to transmission to a new host environment 
(Hornef et al.. 2002). These gene products can be broadly referred to as the virulence 
determinants of the pathogen. In the following sections, some of the maClor virulence 
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factors of P. gingivalis that may have particular relevance to the survival of the organism 
in an inflammatory site and the potential consequences of these factors to the aetiology of 
periodontal disease will be reviewed. 
3.2.1 Effects of A gingivalis LPS on host innate and immune mechanisms 
Gram-negative bacteria are protected from their environment by the outer membrane, 
which contains the unique glycolipid, LPS. LPS consists of three regions: a 
phosphorýlated glucosamine disaccharicle substituted with fatty acids known as lipid A 
that possesses the majority of the activity inducing an inflammatory response. a highly 
variable O-polysaccharide, and a conserved core oligosaccharide (Seydel et al., 2000). 
The LPS of P. gingivalis differs from that of other Gram-negative bacteria in that the 
protein structure of P. gingivalis LPS lacks heptose and 2-keto-3-deoxyoctonate, (Koga 
et al.. 1985) and P. gingivalis LPS has weak endotoxic activity, although it is 
significantlý mitogenic (Mayrand and Holt, 1988; Ogawa et al., 1994). 
P. gingivalis LPS is a significant antigen in periodontitis patients and may account for a 
significant proportion of the immune response directed towards this organism (Farida et 
al.. 1986). P. gingivalis LPS has several properties which are associated with the 
bacterium's role in the pathogenesis of periodontitis. Recent studies indicate that P. 
gingivalis LPS can activate mononuclear phagocytes to induce proliferation, cytokine 
production. and CD14 expression. This provides evidence that this bacterial component 
can act as a critical regulatory factor in the chronic inflammatory response associated 
with periodontitis (Roberts et al., 1997). 
P. gingivalis ITS induces a variety of cytokines from a number of different cells. Human 
gingival fibroblasts secrete the pro-inflammatory cytokines IL-1p, IL-6 and IL-8 in 
response to incubation with P. gingivalis lipopolysaccharide. In addition, P. gingivalis 
lipopolysaccharide also induces monocytes-macrophages to secrete TNF-Q, IL-1, nitric 
oxide. prostaglandin E, at higher concentrations compared to the equivalent dose of E. 
coli LPS (Bramanti et al.. 1989; Shapira et al., 2000; Zhou and Amar, 2006). Neutrophils 
exposed to P. gingivalis lipopolysaccharide show increased expression of the 
transcription factors NF-KB and AP-1 and the pro-inflammatory cytokine IL-8 (Sugita et 
al.. 1998). Models of murine periodontitis have been used to show that P. gingivalis 
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lipopolysaccharide induces bone resorption via the stimulation of local production of IL- 
Ia and IL- 10 (lino and Hopps, 1984; Nishida et al., 200 1). P. gingivalis LPS can interact 
with CD14 on osteoclasts to induce the expression of IL-IP and IL-6, which in turn 
initiates bone resorption (Miyata et al., 1997). 
Lipopolysaccharide of P. gingivalis evokes a highly unusual host cell response. Unlike E. 
coli LPS which interacts with Toll-like receptor 4 (TLR4), P. gingivalis LPS interacts 
mainly with Toll-like receptor 2 (TLR-2) (Wang and Ohura, 2002). Macrophages have 
recently been shown to be stimulated by P. gingivalis LPS via TLR-2 to secrete pro- 
inflammatory cytokines (Hirschfeld et al., 2001). In addition, P. gingivalis LPS appears 
to be able to antagonise TLR-4 and competes with other bacterial proteins for TLR-4 
(Hajishengallis et al., 2002; Wang et al., 2001; Yoshimura et al., 2002). Interactions 
between TLR-2 and TLR-4 agonists may be important in the regulation of inflammatory 
reactions in periodontitis (Bainbridge and Darveau, 2001). Although the precise effect of 
antagonistic LPS on the pathogenesis of periodontitis remains to be elucidated, this 
antagonistic activity would allow the microorganisms to escape from the innate immune 
system. It has been suggested that although LPS is generally considered a bacterial 
component that alerts the host to infection, LPS from P. gingivalis may selectively 
modify the host response as a means to facilitate its pathogenic effects (Darveau et al., 
2002). 
3.2 2 Extracellular proteolytic enzymes and their role in periodontitis 
p. gingivalis produces a variety of proteinases with the ability to degrade host proteins 
and modulate the immune response (Curtis et al., 2001). While the precise roles of the 
cysteine proteases of P. gingivalis in these processes are still under investigation, there 
are a plethora of host target proteins with critical functions in host defence and tissue 
integrity that are susceptible to proteolytic inactivation by these enzymes. This has led to 
the suggestion that cysteine proteinases may be important virulence factors in the 
periodontal diseases (Lamont and Jenkinson, 1998). Although, gingipains are the major 
cysteine proteinases synthesized by P. gingivalis, there are other proteases of P. 
gingivalis such as a protease-hemagglutinin, a dipeptidyl peptidase and periodontain. At 
least one of these proteinases, periodontain can inactivate the human serpin al proteinase 
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inhibitor, which is the primary endogenous regulator of human neutrophil elastase 
(Nelson et al., 1999). 
The Arg-gingipains (RgpA/B) and Lys-gingipain (Kgp) cysteine proteases are believed 
to be the main endopeptidases produced by the bacterium (Kesavalu et al., 1997b). 
Current data suggests that the Arg-gingipains and Lys-gingipains represent the majority 
of surface exposed protein on P. gingivalis W50 (Veith et al., 2002). Three genes encode 
the major extracellular Arg-X and Lys-X specific cysteine proteinases of P. gingivalis. 
The extracellular and cell-associated protease activity with specificity for arginine 
peptide bonds is derived from two genes, rgpA and rgpB (for Arg-gingipain A and B). 
The gene encoding gingipain R associated with hemagglutinin/ adhesion domains is 
referred to as rgpA and the gene that encodes gingipain R without this C-terminal 
hemagglutininladhesion extension is referred to as rgpB. The extracellular and cell- 
associated cysteine protease activity with specificity for lysine peptide bonds is derived 
from a single gene, Kgp (for Lys-gingipain) (Figure 3.1). 
The construction and phenotypic analysis of isogenic protease mutants of P. gingivalis 
have confirmed putative functions for these enzymes. In P. gingivalis rgpA isogcnic 
mutants, protease activity is reduced to about 50% of the wild type. Otherwise, the 
mutants are phenotypically similar to the wild type (Fletcher et al., 1995; Rangarajan et 
al., 1997; Tokuda et al., 1998). Similarly, an rgpB mutant of P. gingivalis W50 retains 
only 50% of total Arg-X activity (Rangarajan et al., 1997b). The double mutant lacking 
both rgpA and rgpB abolishes all Arg-X activity (Nakayama et al., 1995; Aduse-Opoku 
et al., 2000). Inactivation of the kgp of P. gingivalis leads to total loss of lysine specific 
protease activity confirming that this gene is the sole source of this activity in P. 
gingivalis (Okamoto et al., 1998; Barkocy- Gallagher et al., 1999; Lewis et al., 1999; Shi 
et al., 1999; Aduse-Opoku et al., 2000). 
82 
Chapter 3: Antaqonistic Effects of Raingivalis 
Arginint specific proteases 
- CMWytlc 
Cat*ft - 
Lysine specific protesse 
P""modde - CaUftlic - 
AdhwOv%ýrftmggkWrAn 
RgpA 
RgpB 
Adhooln*4dmnnboWubrdn 
Kgp 
Figure 3.1 Sclicinatic i-ci-ve,, cmation of' the R9pA B and Kgp PI-oleascs of P. gingkalis. propeptide. 
cataktic domain. haemagglutinating adhesion act i \, ity. Adapted 1rom Curtis MA (1999). 
Clinical studies support the role of gingipains in periodontitis (Figure 3.2). Several 
studies have demonstrated that periodontal infection by P. gingivalis leads to the 
development of a significantly elevated antibody response to the gingipains. In a survey 
of patients with chronic periodontitis, 92% showed a serum IgG response to the RgpA- 
Kgp proteinase-adhesin complexes (O'Brien-Simpson et al., 2000). Patients with 
generalized aggressive periodontitis also possess elevated levels of both arginine and 
iysine-gingipain-specific IgG in their sera, suggesting that gingipain-specific antibodies 
may be important for the control of P. gingivalis infections (Gibson et al., 2005). 
It, vivo studies in a mouse model using specifically engineered protease mutants have 
reinforced the vievý that the cýsteine enzymes play a key role in the infection process. 
(Fletcher et al.. 1995: Kesavalu et al.. 1997a; Tokuda et al., 1998). More recently. the 
contribution of rgpA. rgpB and kgp to the virulence of P. gingivalis W50 has been shown 
in the murine lesion model using isogenic mutants lacking each proteinase (O'Brien- 
Simpson et al.. 2001). These data are also supported by studies which have examined the 
protecti%e effect of immunization by means of purified preparations of cysteine enzymes. 
A recent studý reported that mice immunized with the RgpA proteinase and its associated 
adhesins protected against P. gingivalis-induced periodontal bone loss whereas the RgpB 
proteinase did not result in a protective immune response (Gibson and Genco. 2001). 
Ho%Never. these studies suggest protease gene inactivation can elicit pleiotropic effects in 
P. gingivalis. and hence the decrease in virulence observed in the above studies may not 
solely be a function of decreased proteoly'sis. 
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P. gingivalis gingipains also activate a broad range of host proteins and are considered 
key virulence factors in the onset and development of chronic periodontitis and host 
defence evasion (Imamura, 2003). Gingipains stimulate expression of matrix 
metalloproteinases (MMPs) in fibroblasts and activate secreted latent MMPs that can 
destroy periodontal tissues (Potempa et al., 2000). P. gingivalis proteinases degrade 
several plasma host proteinase inhibitors including a-antitrypsin, a2-macroglobulin, 
antichymotrypsin, antithrombin III and antiplasinin (Grenier, 1996). 
The RgpA/B proteinases can directly degrade CD14 on the surface of monocytes thereby 
inhibiting lipopolysaccharide activation (Sugawara et al., 2000). Gingipains can also 
degrade components of the complement system and inactivate other receptors including 
TLR-2 and TLR-4 (Jagels et al., 1996; Kishimoto et al., 2006). Thus gingipains can 
perturb the host-defence systems and thereby facilitate sustained colonization by P. 
gingivalis. The cysteine proteases of P. gingivalis can degrade TNF-a, IL-6, and IL-8 and 
probably other cytokines (Baba et al., 2002; Banbula et al., 1999; Calkins et al., 1998; 
Kobayashi-Sakamoto et al., 2003; Mezyk-Kopec et al., 2005; Mikolajczyk-Pawlinska et 
al., 1998; Oleksy et al., 2002). Thus the proteases can directly disrupt the normal function 
of the cytokine network. 
While these studies suggest that gingipains could have a catastrophic effect on the 
cytokine network in the periodontal tissues through degradative effects, it is also clear 
that these products of P. gingivalis can stimulate the production of cytokines. The 
arginine-specific proteases from P. gingivalis activate protease-activated receptors on 
human oral epithelial cells and induce IL-6 secretion (Lourbakos et al., 2001). In 
addition, P. gingivalis infection induces gene expression of IL-6 and MMP-13 in stromal 
cells/osteoblasts, and gingipains may be involved in inducing several other 
proinflammatory factors (Ohno et al., 2006). Indeed, while arginine-specific protease can 
functionally inactivate IL-1, an internal peptide derived from RgPA can stimulate IL-6 
synthesis by human fibroblasts and mononuclear cells (Sharp et al., 1998). The conflict 
between up-regulation of synthesis and proteolytic degradation of cytokines complicates 
the interpretation of the true biological significance of proteolysis in this system. 
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Figure 3.2 1 fie suggc..,, ted role ot'gingipains in the pathogenesis of periodontitis. 
3.2.3 Capsule 
Bacterial capsules are accepted as important virulence determinants and the interaction 
bemeen capsule and the host's immune system in invasive infections may decide the 
outcorne of infection (Moxon and Kroll, 1990). The capsule of P. gingivalis is a major 
surface antigen and it consists of a polysaccharide heteropolymer that surrounds the outer 
membrane. Capsular polysaccharides of gram-negative bacteria play an important role in 
maintaining the structural integrity of the cell in hostile environments (Aduse-Opoku et 
al.. 2006). Based on the antigenicity of the polysaccharicle K antigens of the capsule, 6 
different capsular serotypes have been reported (Laine et al., 1996). P. gingivalis strain 
381 has no capsular-polysaccharide layer and lacks K antigen and does not induce a 
capsular-specific antibody response (Fan et al.. 2001). The presence of capsule has also 
been correlated NN ith virulence of P. gingivalis using in vivo model systems. Encapsulated 
strains of P. gingivalis such as W50 are also more resistant to phagocytosis by 
polymorphonuclear cells than strain 381 (Sundqvist et al., 199 1). 
3.2.4 Fimbriae 
Fimbriae plaý an important role in the adherence of P. gingivalis to oral surfaces and 
maý also trigger host responses (Amano et al., 2004). P. gingivalis fimbriae have been 
sho%Nn to stimulate the release of IL-la. IL-IP TNF-a, IL-6 from macrophages and 
85 
aDter j: aaonistic r-rT 11 in ivali, 
fibroblasts and TNF-c4 IL-6 and IL-8 from polymorphonuclear cells (Hamada et al., 
2002; Hanazawa et al., 1992). Furthermore, P. gingivalis fimbriae have been shown to 
stimulate bone resorption in a murine embryonic calvarial bone resorption assay by 
activating osteoclasts (Kawata et al., 1994). Five P. gingivalis firnbrial types (types I-V) 
have been described based on their antigenicity (Nakagawa et al., 2000). Recent clinical 
investigations have demonstrated the close relationship between the organisms with type 
11 fimA and the development of periodontitis (Kato et al., 2006). 
3.2.5 GroEL beat shock protein 
GroEL, a homologue of the Heat shock protein 60 family, is a major HSP in various 
bacterial infections and is widely recognized as an important molecule in periodontitis 
(Maeda et al., 2000; Nair et al., 1999). GroEL of P. gingivalis can stimulate the 
expression of pro-inflammatory cytokines in macrophages (Kesavalu et al., 2002; Ueki et 
al., 2002). The P. gingivalis heat shock protein GroEL is highly antigenic and antibodies 
to p. gingivalis GroEL are detectable in gingival tissue extracts (Tabeta et al., 2000). 
3.3 SUMNIARY AND AIMS 
There is good evidence that P. gingivalis is one of the key bacterial species involved 
periodontal diseases in humans (Holt et al., 1999). The substantial rise in the numbers 
and proportions of P. gingivalis in subgingival plaque samples from diseased sites in the 
periodontium suggests that this organism is well-adapted to and benefits from the hostile 
conditions which prevail subgingivally during the inflammatory disease (Socransky et 
al., 1999). Despite a profound inflammatory response, the host immune system is usually 
not able to eliminate P. gingivalis infection. 
The production of pro-inflammatory cytokines including IL-I, by host cells upon sensing 
bacterial products is crucial to the innate and adaptive immune responses to infection. 
These cytokines enhance the bacteriacidal capacity of phagocytes, recruit additional 
innate cell populations to sites of infection, and direct the ensuing specific immune 
response to the invading microbes. A number of lines of evidence support a pivotal role 
of IL-la in mediating the host response to periodontal pathogenic bacteria (Dayan et aL, 
2004; Wang and Stashenko, 1993). So far the studies have demonstrated that most 
periodontopathogens induced a significant level of IL-la release from both Monomac-6 
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and primary monocytes, while P. gingivalis induced IL-la to only a minimal level. It is 
puzzling that P. gingivalis is strongly associated with disease but does not induce IL-la 
production. The stimulation of IL-I(x at the site infection by other periodontopathogens 
could be antagonised by P. gingivalis. 
As reviewed in detail above, P. gingivalis seems to have the ability to perturb the innate 
immune response rendering the host susceptible to disease via its virulence factors such 
as LPS and gingipains. P. gingivalis LPS exhibits unusual characteristics and can interact 
with TLR-2 and is able to antagonize the effects of other bacteria. P. gingivalis also 
produces proteases that may directly degrade CD14 and lead to further reduction in 
response to LPS from other bacteria. Therefore, it was hypothesized that P. gingivalis 
may directly alter IL-la activities via either inactivation or degradation, and its major 
virulence factors may play an important role in the deregulation of IL-la at the site of 
inflammation. 
The aims of the studies described in this chapter are: 
" To compare the ability of supernatants from a number of the major periodontal. 
pathogens including A actinomycetemcomitans, P. gingivalis, F. nucleatum, C 
rectus, P. intermedia, V atypica and P. nigrescens for their ability to stimulate 
IL- Ia production in both the MonoMac-6 cell line and primary monocytes. 
" To investigate if P. gingivalis culture supernatants can antagonize IL- 
Ia production stimulated by other pathogens, when cells were exposed to 
combinations of supernatants. 
" To investigate the underlying mechanisms of antagonism of cytokine production 
by P. gingivalis. 
3.4 MATERIALS & METHODS 
3.4.1 Bacterial strains and growth conditions 
Bacterial supernatants were obtained from cultures of P. gingivalis WJO and W83,381, 
F nuckatum ATCC 25586, C. rectus ATCC 33238, A. actinomycetemcomilans Y4, P. 
intermedia NCTC 9336, V atypica NCTC 11830, and P. nigrescens Mul4. Supernatants 
from a culture of S sanguis NCTC 7863 were used as a negative control and LPS from 
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the non-oral bacterium Escherichia coli 026: B6 (Sigma-Aldrich) was used as a positive 
control. P. gingivalis W50 protease mutant strain (kgp, Lys-gingipain) and the protease 
(Arg-gingipain)-double defective mutants (rgpA, rgpB) were kindly supplied by Prof. 
M. A. Curtis, Molecular Pathogenesis Group, Queen Mary, University of London (Aduse- 
Opoku et al., 2000). To investigate the role of P. gingivalis gingipain cysteine proteinases 
on cytokine production, P. gingivalis supernatant was pre-treated with ImM proteinase 
inhibitor Na-p-Tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK) (Sigma- 
Aldrich) for lh at 4'C. Bacterial cultures were grown in the appropriate growth medium 
(see Chapter 2, Table 2.1) either aerobically in a 5% C02 incubator or in an anaerobic 
chamber containing an atmosphere of in 80% N2,10% H2, and 10% C02. Cultures were 
grown to the same density (approximately 5xI 07 colony forming units / ml) and 
harvested by centrifugation at 10000 xg for 15 min at 41C. The culture supernatants 
were collected, filter-sterilized and stored at -80'C until used. For some studies, culture 
supernatants were heat-inactivated at 100'C for 20 min. The supernatants of bacteria 
were directly diluted in culture medium to final dilutions of 1: 250 and 1: 50. 
3.4.2 Stimulation of human primary monocytes and Monomac-6 
Peripheral blood was obtained from three healthy individuals by venous puncture and 
collected in EDTA vacutainers (Becton Dickinson). All participants signed a written 
consent form. Protocols for the study were approved by the East London and City Health 
Authority London Research Ethics Committee. Human peripheral blood mononuclear 
cells (PBMQ were separated by density gradient centrifugation using Ficoll-Paque Plus 
(Amersham Biosciences) according to the manufacturer's instructions. The cells were 
washed twice with PBS containing EDTA (2mM) and bovine serum albumin (2%), pH 
7.3. Cell viability was determined by Trypan blue exclusion. PBMC count was 
performed with a haernocytometer and processed for magnetic purification. The 
Monocyte Isolation Kit 11 (Miltenyibiotec, Germany) was used. This technique relies 
upon an indirect magnetic labelling system allowing the isolation of unstimulated 
monocytes from human peripheral blood mononuclear cells (PBMQ (Hafsi et at., 2004). 
The purity of isolated monocytes was evaluated by flow cytometry on a FACScan flow 
cytometer (Becton Dickonson) using a CD14 FITC-conjugated antibody (Figure 3.3). 
Purified monocytes were re-suspended in RPMI-Glutamax (Gibco BRL Life 
Technologies, UK) supplemented with 10% heat-inactivated fetal bovine serum (Bio- 
88 
apter 3: Antagonistic Effects Of P- n ivalis 
Whittaker. Mar\land). Monoc\-tes \%ere then seeded in 96-well microtitre, plates at a 
densitý of IxIOcells per ml and stimulated with bacterial culture supematants at 370C 
for 6 hours in a 5% CO, atmosphere. 
The mNelomonocNtic cell line Monomac-6 was obtained from the German Collection of 
Microorganisms and Cell Cultures (Mascheroder, Braunschweig, Germany). MonoMac-6 
cells "ere cultured in RPMI-Glutamax (Gibco BRL Life Technologies, UK) 
supplemented %% ith 10% fetal bovine serum. I% non-essential amino acids (Gibco BRL), 
1% sodium p)ruvate (Gibco BRL) and 9 gg/ml bovine insulin (Sigma-Aldrich). 
MonoMac-6 cells %%ere cultured at a density of Ix 10" cells per ml in 96-well flat-bottom 
plates and challenged %% ith bacterial supernatants. The bacterial supernatants were added 
to the monoc%ics (200pl/%%ell) at dilutions of 1: 250 (0.8pl) and 1: 50 (4gl) and were 
incubated at 37C in a *50,6 CO, humidified atmosphere. In preliminary experiments, a6 
hour incubation period %%as found to be suitable for detection of IL-la production. To 
assa-v total IL-la (cell associated and secreted) cells were lysed by three freeze-thaw 
cycles. The cell free culture supernatants were collected by centrifuging at 1000 rpm for 
5 minutes and stored at -80'C until the cytokine assays were performed. Control cultures 
were incubated in the absence of bacterial supernatant. All experiments were carried out 
in triplicate. 
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Figure 3.3. I: lo%% c%tometric anal%sis of isolated PBMCs. PBMCs were isolated using a Monocyte 
Isolation Kit 11. Non-monocyles %%ere indirectl,. magneticall) labeled using a cocktail of biotin-conjugated 
antibodies against CD3. CD16. CD19. CD56 (specific for T cells. NK cells. B cells. NK and CD3- T cells, 
respecti%el%) and Anti-Biotin MicroBeads. The dot plots shoN% nucleated live cells gated according to LDS 
and propidium iodide staining. Enriched cells %%ere stained with antibiotin-PE and CD14-FITC. A) Gated 
on ('D45- e%cnt% onl) CD3. CD19 and CD56-PE. B) Gated on CD45+ events only CD14-PE. 
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3.4.3 Cell viability assays 
Cell viability was determined by measurement of lactate dehydrogenase (LDH) release 
using the CytoTox96 non-radioactive cytotoxicity assay (Promega, USA). In brief, 
Monomac-6 cells or primary human monocytes were exposed to bacterial culture 
supernatants and then incubated for 6 hours at 37*C. A sample of (50 gl/well) 
supernatant was carefully removed and transferred into an optically clear 96-well plate. 
Reaction solution was added to each well and incubated for 30 min in darkness. The 
enzyme reaction was then stopped by the addition of IM HCI. The absorbance at 490nm 
was measured using an ELISA reader (Model 680, Bio-Rad Laboratories). The activity 
of the enzyme released from damaged cells into the supernatant was measured, and the 
activity was expressed as a percentage of the total LDH activity released from cells lysed 
by exposure to 0.1% Triton X-100 for 45 min. Values shown represent the mean 
standard deviation of three wells. 
3.4.4 Protease Assays 
P. gingivalis wild type (W50) and protease gene knockouts (E8 and KIA) were grown in 
131-11 broth with haemin and menadione under identical conditions to achieve maximal 
Arg-X and Lys-X active proteases. The enzyme assays for Arg-X and Lys-X protease 
activities using the synthetic substrates N-a-benzOyl-DL-arginine-p-nitroanilide (DL- 
BRpNA) and N-a-acetyllysine-p-nitroanilide (Ac-LyspNA) respectively, were performed 
according to the published protocols (Rangarajan et al., 1997). 
3.4.5 Determination of cytokine production 
Cytokine production from the different experiments was determined in the cell free 
culture supernatant by commercially available specific ELISA (R&D Systems, 
Minneapolis, MN, USA) according to standard procedures. The absorbance at 450 nm 
was read using a microplate reader (Model 680, Bio-Rad Laboratories) with a 
wavelength correction set at 570nm. A standard curve was generated using a four 
parameter logistic (4-PL) curve-fit (Microsoft Office Excel) for each set of samples 
assayed. The cytokine concentrations of the samples were calculated using the standard 
curve. 
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3.4.6 Determination of cytokine degradation 
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To control for any effects of degradation of IL-la by P. gingivalis supernatants, 
recombinant human (rh) IL-la (50 ng/ml) was added to cultures. The cytokine 
concentration in the supernatants was determined by ELISA and compared to the basal 
levels of a control incubated for 6 hours in the absence of bacterial supernatant. 
3.4.7 Preparation of LPS from P. gingivalis 
P. gingivalis was a gift from Dr. Minnie Rangarajan (Molecular pathogenesis Group, 
ICMS). It was prepared as follows. P. gingivalis W50 was grown anaerobically in brain- 
heart infusion supplemented with haernin (5 gg/ ml) for 24 hours. The cells were 
harvested, washed with water and freeze-dried. P. gingivalis LPS was prepared by the 
cold MgC12-ethanol procedure as described previously (Darveau and Hancock, 1983). 
LPS was lyophilized to determine the yield and stock solutions were prepared in 
pyrogen-free distilled water (I mg/ml) and vortexed prior to use. No protein was detected 
in LPS preparations as determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and staining for protein using the enhanced colloidal gold 
procedure. 
3.4.8 Determination of endotoxin levels in the bacterial supernatants 
Bacterial endotoxin was assessed using The Chromogenic Limulus Amebocyte Lysate 
(LAQ Test (QCLIOOO, Cambrex Bio Science, and Walkersville). Purified P. gingivalis 
LPS and bacterial supernatants were dissolved in pyrogen-free water and serial dilutions 
were made. The absorbance of the sample was determined spectrophotometrically at 405 
nm and the concentration of endotoxin was calculated from a standard curve. In the case 
of polymyxin B treatment, endotoxin was removed from bacterial supernatants using a 
polymyxin B column (Detoxigel, Pierce Biochemicals) according to the manufacturer's 
instructions (see in Chapter 2). As assessed by LAL assay (using the purified LPS as a 
standard), the concentration of LPS in P. gingivalis and C. rectus supernatant was 35.7 
and 38 pg/ml, respectively. In addition, pretreatment of bacterial supernatants with 
polymyxin B resulted in a dramatic reduction in LPS amount of both supernatants (0.55 
and 0.39 gg/nil, respectively). 
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3.5 Statistical analysis 
Student's 1-test and a one-way analysis of variance were used and data were considered 
significant at P<0.05. 
3.6 RESULTS 
3.6.1 Stimulation of IL-1a production by culture supernatants from periodontal 
pathogens 
When the monocytic cell line, Monomac-6 was exposed to bacterial supernatants of 
cultured periodontal pathogens a significant up-regulation of the total level of IL-I a was 
seen after 6 hours (Figure 3.4A). Unstimulated Monomac-6 cells or those exposed to 
noninoculated culture media showed very low levels of IL-la. production. The most 
pronounced inducers were A. actinomycelenicomitans, F. nucleatum, C rectus and V 
atypica, whereas P. gingivalis was consistently the least potent treatment. Some putative 
pathogenic species including P. intermedia and P. nigrescens produced only a modest 
induction of IL-la. When primary CD14 positive monocytes were stimulated with 
bacterial supernatants in a similar manner, IL-la production was significantly up- 
regulated after 6 hours (Figure 3.413). The pattern of IL-la production was somewhat 
different to Monomac-6 cells with responses to A. actinomycetemcomitans and F. 
nucleatum being relatively lower and responses to P. intermedia and P. nigrescens being 
significantly greater. However, the response to P. gingivalis was still lowest. 
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Figure 3.4 Production of IL-la by human monocytes in response to bacterial stimuli. Monomac-6 cells 
(A) and freshly isolated human monocytes (B) were plated at a density Of IX106 cells/ml in 96-well dishes. 
Cells were exposed to culture supernatants from periodontopathogens. Bacterial supernatants were added 
to cell culture media at 1: 250 dilution. After 6h incubation the cells were lysed and cell-free supernatants 
were harvested to assess total IL-la (secreted and cell-associated) by ELISA. The data are the 
mcan±standard error of mean (SEM) n=3. 
Monomac-6 cells and isolated human monocytes showed almost no toxic effects in the 
presence of bacterial supernatants except A. actinomycetemcomitans (Figures 3.5A and 
3.513, respectively). Whilst A. actinomycetemcomitans induced some toxicity it was still 
able to significantly elevate levels of IL- I a. In the present study, most supernatants were 
diluted no less than 1: 250 and for P. gingivalis in combination with other supernatants it 
was diluted 1: 50 in medium. 
The toxicity testing demonstrated that the inability of P. gingivalis to elicit a significant 
IL-la response was not related to its toxicity to the Monornac-6 cells or isolated human 
monocytes (Figure 3.5A and B). Interestingly the levels of LDH release in cells treated 
with both Crectus and P. gingivalis were not increased compared to cells treated with 
either bacterium alone. It has been previously shown that P. gingivalis can partially 
neutralize the leukotoxicity of A. actinomycetemcomitans (Johansson et al., 2000) and it 
is possible a similar mechanism is involved in this situation. Although the amount of 
leukotoxin in the A. actinomycetemcomitans supernatants used was not defined, 1: 250 
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dilution induced similar cytotoxicity to <5ng/mi of purified leukotoxin shown in a 
previous study (Kelk et al., 2003). 
3.6.2 Antagonism of IL-la production by P. gingivalis 
To investigate if P. gingivalis could affect the IL-la stimulating activity of other 
periodontal species a 5-fold excess of P. gingivalis supernatant was mixed with other 
bacterial supernatants before addition to monocytes. Several species showed an altered 
capacity to induce IL-Ia in the presence of P. gingivalis supernatant (Table 3.2A). A 
small (21±4%) but significant (P<0.05) synergistic effect was seen in combination with 
A. actinomycetemcomilans whilst all the other bacteria showed a reduction in IL-la 
production. The C rectus induction of IL-la production appeared to be the most 
sensitive to the presence of P. gingivalis showing a 72±7% reduction in total IL-la 
levels. 
One possible explanation for the antagonistic effects and the low IL-la production by P. 
gingivalis supernatant is that the proteolytic activity of the supernatant acts to degrade 
any IL-la produced. To evaluate the direct degradation of IL-la by P. gingivalis 
supernatant, recombinant human IL-1a (50 ng/ml) was incubated with culture 
supernatant (at 1: 250 and 1: 50) at 37*C in PBS for 6 hours. Subsequent ELISA analysis 
was able to detect 96% of the added IL-la protein. This confirms that the proteolytic 
degradation of IL-la was not a significant factor in this experimental system and did not 
account for the low cytokine production seen in the presence of P. gingivalis supernatant. 
Similar effects of co-stimulation with P. gingivalis and other pathogens were also seen in 
primary monocytes (Table 3.213). In all cases the addition of P. gingivalls significantly 
decreased total IL-la production of between 69 and 84%. Interestingly the stimulating 
effect of A. actinomyvetemcomitans in combination with P. gingivalis seen in Monomac- 
6 cells was not seen and instead in primary monocytes IL-Ia production was reduced by 
84%. 
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Figure 3.5 Effects of bacterial supernatants on cell viability. Monomac-6 (A) and freshly isolated human 
monocytes (B) were exposed to culture supernatants from periodontopathogens; for 6 hours. Cytotoxicity 
was determined by the release of the cytosol enzyme lactate dehydrogenase (LDH). The activity was 
expressed as a percentage of die total LDH activity released from cells lysed by exposure to 0.1% Triton X- 
100 for 45 min. The data are the mean±standard deviations (S. D. ) n=3. *P<0.05 
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A) 
Bacteria 
Control 
P. gingivalis (P. g) 
A. actinomycetemcomitans (Aa) 
F. nudeatum (F. n) 
C. rectus (C. r) 
V. atypica (V. a) 
P. intermedia (P-J) 
P. nigrescens (P. n) 
E coli LIDS (E. c) 
Singles 
30.11±7.56 
35.89 ± 4.23 
1874.89 189.45 
3423.25 ± 344.99 
1754.78 ± 138.16 
3103.12 ± 641.74 
284.45 ± 84.21 
121.24 ± 15.74 
1109.86 ± 89.87 
Co-stimulation 
45.15118.05 
2272.88 * 47.90 
2468.141405 
500.27 174.48 
2423.10 ± 364 
159.57 38.42 
64.40 32.80 
464.90 39.83 
change 
B) 
Bacteria Singles co-stimulation 
26.84 ± 12.4T 
21.22 ± 16.5*T 
27.90 ± 16.0*1 
71.49 ± 7.43*1 
21.91 ± 9.89 1 
43.90 ± 9.26 1 
46.33 ± 1.44*1 
64.80 ± 2.59*1 
change 
Control 
P. gingivalis (P-9) 
A. actinomycetemcomitans (Aa) 
F. nucleatum (F. n) 
C. rectus (C. r) 
V. atypica (V. a) 
P. intermedia (PJ) 
A nigrescens (P. n) 
117.72±0.87 
208.54± 27.79 255.28±34.57 
559.22 ± 88.06 88.78 37.51 
417.77 ± 113.8 123.17 11.81 
594.66 ± 90.11 144.49 64.17 
1242.16 ± 268.84 206.81 25.52 
1209.46 16.34 239.52 10.86 
1369.58 140.96 346.22 37.83 
22.41 ± 6.2t 
83.86 ± 2.49*1 
69.19 ± 7.30*1 
75.20 ± 7.43*1 
82.82 ± 4.14*1 
80.19 ± 2.60*1 
74.56 ± 2.40*1 
Table 3.2 Overall changes in total IL-la levels in Monomac-6 (A) and human monocytes (B) treated with 
a range of bacterial supernatants in the presence of P. gingivalis supernatant Monomac-6 or freshly isolated 
monocytes were plated at a density of Ix 106 cells/ml in 96-well dishes (1001il/well). Cells were treated 
with a range of periodontopathogens or LPS from E. coli (10 ng/ml) with (co-stimulation) or without 
(single) supernatant from P. gingtvalis for 6 hours. After 6h incubation the cells were lysed and cell-free 
supernatants were harvested to assess total IL-la (secreted and cell-associated) by ELISA. Changes 
induced by co-stimulation represent mean changes in three separate experiments with mean±standard error. 
Figures for co-stimulation were adjusted for the stimulating effect of P. gingivalis alone. T% increase, 1% 
decrease, * P<0.05. 
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3.6.3 The effect of different A gingivalis strains on the antagonistic activity 
vali 
Before testing the ability of mutants to antagonise the effects of C rectus-mediated IL-la 
production it was necessary to confirm that the other pathogenic strains produced similar 
effects. The antagonistic activity of P. gingivalis was not restricted to the W50 strain. A 
comparison of the antagonistic ability of this strain with W83 and 381 (nonencapsulated) 
showed no significant differences when used in combination with C reclus (Figure 3.6). 
Subsequent experiments used strain W50 which is the parental strain for the mutants that 
were tested in later experiments. 
Figure 3.6 Effects of different P. gingivalis strains on the antagonistic activity. Monomac-6 cells were 
plated at a density of Ix IV cells/ml in 96-well dishes. Cells were exposed to C. rectus with or without 
supernatant from P. gingivalis (W50, W83 or 38 1). After 6h incubation the cells were lysed by subjecting 
those to three cycles of freezing and thawing to assess total IL-la. The supernatants were harvested and 
assayed for IL-la by ELISA. The data are the mean ± standard deviations (S. D. ) of triplicate assays. 
0 P<0.05 
3.6.4 Mechanism of immune suppression 
Since the most dramatic antagonistic interaction in Monomac-6 cells was between C 
reclus and P. gingivalis this combination of bacterial supernatants was used to investigate 
further the mechanism of antagonistic activity. Removal of LPS from P. gingivalis and 
C reclus supernatants by polymyxin B almost completely eliminated the ability to 
stimulate IL-la production by 94 and 99% respectively. Heat treatment of supernatants 
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resulted in an increase in the stimulating ability of the supernatants by 44 and 48% 
respectivelý and suggests that the active components are not heat-sensitive (Figure 3.7). 
Figure 3.7 ]'he effiect of ITS depletion and heat treatment on periodontopathogen induced IL-la 
production bý %lonomac-6 cells. The bacterial supernatants were passed through polyrnyxin B columns or 
heated to boiling for 30 minutes. rhe cells were exposed to un-treated or LPS-depleted or heated bacterial 
supernatants for 6 hours. After 6h incubation the cells were Iýsed and cell-free supernatants were 
har\ested to assess total ll, -Iu (secreted and celi-associated) by ELISA. rhe data are the mean±standard 
de\ iations (S. D. ) n=3. 
Role of gingipains of P. Aingivalis in inhibition of IL-lu stimulation by C reclu. v 
The LPS and protease content of P. gingivalis cultures are known to vary significantly 
%kith time in culture (Rangarajan et al., 1997). Thus cultures grown between I and 6 days 
were compared for their ability to induce IL-Ict from Monomac-6 cells and antagonize C. 
rectus activity. Samples or cells were withdrawn throughout the course of logarithmic 
growth. These investigations were performed by examining growth in appropriate 
medium as detailed in Materials & Methods. Growth of P. gingivalis W50 was 
significantl) increased over four days followed bý reduced cell proliferation (Figure 3.8 
A). The levels ofprotem in culture supernatants increased steadily throughout the course 
of growth (Figure 3.8 B). HoNNever. culture supernatants did not show any significant 
change in the abilitý to induce IL-Ict over the culture period (Figure 3.9 A) but showed a 
significant progressive increase (R-0.95) in their ability to antagonize C. reclus activity 
(Figure 3.9 B). 
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Figure 3.8 Gro\\th assay of P. gingivalis W50 (A) and effect of cu I ture length on total protein I e\e Is (B) 
Culturcs \Nere grov\n as described in Materials and Methods. A) Bacterial growth at the indicated time 
points \Nas evaluated via measurement of the optical densitN at 540nm with a (JV-\isible 
spectrophotometer. B) Supernatants withdrawn at the indicated time points (1-6 da,, -old). Total protein 
concentrations \%ere measured bý Bio-Rad colorimetric protein assa). Quantative colorimetric reaction was 
read in a microplate reader at 595 nm. and compared against a standard curve of bovine albumin ofknown 
concentrations. The data are the mean±standard deviations (S. D. ) n=3 
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Figure 3.9 I: tl'ect of culture length on stimulation of' IL-lu (A) or inhibition of 11-1(1 production 
stimulated bN C. rectus in kionomac-6 cells (B). Cultures were grown as described in Materials and 
Methods. Supernatantswithdrax%n atthe indicated time points (1-6 day-old). Monomac-6cells k%cre plated 
at a density of Ix 10' cells/ml in 96_Nvell dishes. Cells "ere exposed to P. gingivalis with and %% ithout C. 
rectus for 6 hours. After incubation the cells were lysed and cell-free supernatants %kere harvested to assess 
total 11, la (secreted and cell-associated) bN ELISA. The data are the mean: i: standard deviations (S. D. ) riý3 
Using specific protease mutants lacking the Lys-gingipain kgp (K I A) or Arg-gingipains 
rgpA rgpB expression (E8) it NNas possible to test their role in the antagonism of C. reclus 
activity. Enzyme assaý s for Arg-X and Lys-X protease activities using N-()E-benzoyl-[)I. - 
arginine-p-nitroanilide (BAPNA) and N7-a-acetyllysine-p-nitroanilide (AcKpNA), 
respectively. were performed to confirm the phenotypes of these mutants as described in 
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Materials & Methods. Compared to P. gingivali. v W50, P. gingivalis E8 mutant (rgl)A 
rgl)B) had Arg-X protease activity below the detection limit of the assay without any 
significant effect on the Lys-X protease activity in culture supernatants. In contrast, Arg- 
X activity in culture supernatants of KIA (kgp) only reached a maximum of z 40% of 
levels in W50. 
A complementary approach used the proteinase inhibitor TLCK or heating to block 
protease activity in the wild-tYpe P. gingivalis supernatants. Treatment with 1111M TLCK 
completely abolished both Arg-X and Lys-X activity (Table 3.3). Both KIA and F8 11. 
gingivalis protease-mutant strains remained capable of antagonizing C. rectus mediated 
IL-la production by respectively 68.4±4.9% and 49.6±2.8% (wild type inhibition was 
68.9±4.7%). In addition. heat-treatment or chemical blockage of cysteine protease 
activity of P. gingivalis did not remove the inhibitory activity. Together this data 
suggests that protease activity does not play a significant role in the antagonistic activity 
of P. gingivalis. 
Strain Genotype Enzyme activities U/mI/mg protein 
Arg-X Lys-X 
W50 wild-type 5.36±0.14 1.70 ± 0.18 
KIA kgp:: enn 1.90±0.27* 0.20 ± 0.11 * 
E8 rgpA:: tetQ 0.30±0.07* 1.74 ± 0.19 
TLCK-treated wild-type 0.48±0.1 1* 0.18 ± 0.02* 
*P<0.05 compared toKild-type W50 
Table 3.3 . Ar&)-X and 
LN s-X protease acti\ ities in isogenic mutants of P. gingi%, alis. Culture supernatants 
ofP, gingivalis W50 and KIA and E8 were assayed for Arg-X and Lys-X activity using the substrates DL- 
BAIINA and Ncr-acetykl. -Iý sine-p-nitroanilide (Ac-l, yspNA) respectively. Arg-X and Lys-X activities 
\Nere normalized vvith respect total protein in the culture supernatants and activities are expressed as units 
ml-' per mg protein. The figures shovvn are the mean±standard deviations (S. D. ) oftriplicate assays and 
statistical differences vvere calculated by Student*s i test. 
Role of Agingivalis LPS in inhibition of IL-Ia stimulation by C rectuN 
LPS is another important component of the bacterial supernatant. The ability of purified 
P. gingivalis LPS to stimulate IL-1a production by Monomac-6 cells was tested. P. 
gingivalis LPS caused a significant concentration-dependent stimulation of IL-Ict 
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production (Figure 3.10). Purified LPS was a relatively poor inducer of IL-1a from 
Monomac-6 cells. P. gingivalis supernatant was able to induce slightly higher IL- Ia than 
100 ng/rril of its purified ITS. In addition, measurement of P. gingivalis culture 
supernatants býr the LAL assay showed that the 1: 250 dilution used to stimulate cells 
contained approximatelý 142 ng/ml. 
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Figure 3.10 The leýels of total IL-la in Monomac-6 cells treated \\ith 11. gingivalis supernatant or its 
1, PS. Monomac-6 cells \\ere plated at a densit) of Ix 10" cells/ml in 96-\ýclj dishes. Cells xNere exposed to 
P. gingivalis supernatant or ITS from P. gingivalis (10.100.1000 ng/ml). At-ter 6h incubation the cells 
\Nere I\sed and cell-free supernatants were har,, ested to assess total B. -la (secreted and cel I -associated) bN 
FLISA. I he data are the mcanmstandard errors (SI-M) of three independent experiments. *p<0.05 
Since purified LPS has only a limited ability to induce IL-Ict it was possible to test its 
antagonistic activity when mixed with C. reclus supernatant. Whilst 10 ng/ml purified 
LPS had no significant effect the addition of 100 or 1000 ng/ml was able to significantly 
antagonize stimulation of IL-la by C. rectus (Figure 3.11). The level of IL-I(X inhibition 
seen with 100-1000 ng/ml LPS was not significantly different from P. gingivalis culture 
supernatant (1: 50) containing 714 ng/ml LPS (p=0.16 and p=0.07, respectively). In 
addition. polyrnyxin B treatment of P. gingivalis supernatant reduced LPS concentrations 
from 714 ng/ml to 11.2 ng/ml at the (1: 50) dilution used, and subsequently inhibited the 
C. rtclus-stimulated IL-Ict production by only 10% (Figure 3.11). Collectivel, -" these 
findings provide evidence that the LPS in P. gingivalis culture supernatants appears to be 
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essential and present in sufficient quantities to account for the observed inhibition of C. 
rectus-induced IL-la production by Monomac-6 cells. 
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Figure 3.11 1-he role ot'P. gingivalis LPS in C. rectus mediated I L- Ia production by Monomac-6cel Is. 
klonomac-6 cells ý%ere plated at a density of' IxIO" cells/ml in 96-\\ell dishes. Cells \\ere exposed to C. 
rectus NNith purified P. gingivalis LPS (10.100.1000 ng/ml) or P. gingivalis supernatant. After 6h 
incubation the cells \%ere I)sed and cell-free supernatants were harvested and assayed Ior total IIA(z 
(secreted and cell-associated) b) FIASA. The data are the mean±standard errors (SEM) of' three 
independent experiments. *p<0.05 
To learn more about the possible mechanisms by which P. gingivalis LPS acts to 
antagonize C. reclus activity. Monomac-6 cells were pre-treated with I ýLg/ml purified P. 
gingivalis LPS. Priming of Monomac-6 cells with P. gingivalis LPS largely abolished 
responsiveness to C. rectus (Figure 3.12). There was no obvious effect when pre-treated 
cells "ere exposed to a combination of C. reaus and P. gingivalis compared to C. reclus 
alone. The result of LPS pre-treatment suggests that Monomac-6 cells were rendered 
either directly or indirectly unresponsive to C. reclus. 
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Figure 3.12 1 he role ot'priming ot'Monomac-6 cells with P, gingivalis LPS in C recius mediated I L-I a 
production. Monomac-6 cells \krere pretreated for Ih x%ith P. gingivalis LPS (I Pg/ml) or medium alone. 
Monomac-6 cells \%ere plated at a densitN of lxlO' cells/ml in 96-\\rell dishes and subsequently challenged 
\kith C. rectus or P. gingivalis or both supernatant for 6 h. After 6h incubation the cells were lysed and 
cell-free supernatants ýýere har\ested to assess total IL-la (secreted and cell-associated) by ELISA. The 
data are the mean=: standard de\ iations (S. D. ) of triplicate assays. **p<0.05 
3.7 DISCUSSION 
This stud) demonstrated that a broad range of oral bacteria stimulate the expression of 
IL-la in Monomac-6 cells and primary monocytes as previously reported (Henderson et 
al.. 2002-, Reddi et al., 1995, Sugano et al.. 2004). The weakest stimulators of IL-10C were 
the non-pathogenic S. sanguis and surprisingly P. gingivalis. Most previous studies 
considered the stimulation of cytokine production for each bacterial species in isolation. 
Therefore. IL-lot production b) monocytic cells was compared when treated with single 
bacterial supematants to those treated with mixtures. A number of previous studies 
suggested that P. gingivalis might evade the normal responses through its ability to 
suppress the normal innate immune mechanisms (Darveau et al., 1998). In the present 
study P. gingivalis supernatants inhibited the capacity of most studied pathogens to 
stimulate IL-IcE production b) monocytes. The most pronounced inhibition was seen in 
combination with C. rectus. where the overall level of IL-I(X production was reduced by 
approximatel. ', 72% in the presence of P. gingivalis. In the case of A. 
aclinomycelenicomilans. co-stimulation of the cells with P. gingivalis caused a 
synergistic effect in IL-Ict production by Monomac-6 cells, but a reduction in primary 
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human monocytes. The basis for this difference is not clear but could reflect increased 
sensitivity to P. gingivalis stimulation by primary monocytes compared to Mononlac-6 
cells. There is no reason to believe that all oral bacterial species that are weak stimulators 
of cytokine production act to suppress immune responses. In preliminary experiments 
with Treponenia denticola. we have shown that culture supernatants elicit only a very 
small level of IL-Ict production on their own but are highly synergistic when combined 
with other periodontal pathogenic species (Javier Fernandez, M Clinic Dent Thesis, 
2006). 
P. gingivalis expresses a number of potential virulence factors. In this study the culture 
supernatant contains a mixture of bacterial endotoxin, bacterial metabolic products and 
enzymes. The most frequently studied components are the LPS and the Arg- and Lys- 
gingipain cysteine proteinases which are found in large quantities in culture supernatant 
(Curtis et al.. 2001: Shapira et al.. 1998). In previous studies it has been shown that 
proteolytic cleavage bý P. gingivalis can degrade and inactivate cytokines including IL-6, 
IL-8 and TNF-a (Banbula et al.. 1999; Calkins et al., 1998-, Mezyk-Kopec et al., 2005; 
Oleksy et al.. 2002) and the CD14 receptors (Duncan et al., 2004. Sugawara et al., 2000). 
However, the possibility that the antagonistic actions of P. gingivalis reported here were 
the result of proteolytic breakdown of the IL-la is not supported by our data. When 
cultures containing P. gingivalis supernatant were supplemented with IL-la protein at 
known concentrations almost all could be detected by ELISA after 6 hours. The reasons 
that we did not observe proteolytic degradation in our system could reflect the presence 
of serum proteins. including protease inhibitors and the relatively short (6 hour) period of 
incubation. Moreover. the P. gingivalis protease-mutant strains still retained their 
capacity to antagonize C. rectus-mediated IL-la production. In addition, heat-treatment 
or chemical inhibition of protease activity in the wild-type P. gingivalis strain 
supernatant did not abolish its inhibitory capacity, but were in fact slightly enhanced. 
This may reflect the normal complexing of the gingipains with LPS in the supernatant 
which acts to mask LPS activity. The act of heating unmasks the LPS and results in 
increased inhibitory activity (Takii et al., 2005). Overall the data suggests that gingipains 
do not play a significant role in the antagonism of activity of C. rectus by P. gingivalis as 
measured by changes in I L- I ct production. 
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To investigate the involvement of LPS in the observed inhibition of IL-la production the 
activity of purified P. gingivalis LPS was tested. This purified LPS could not stimulate 
high levels of IL-la production by monocytes which is in agreement with previous 
findings (Roberts et al., 1997). In contrast, depletion of LPS from C rectus culture 
supernatants using polymyxin B columns largely abolished its ability to stimulate IL-la 
production. Adding purified P. gingivalis LPS was sufficient to suppress IL-la 
stimulation in response to the C rectus. Interestingly LPS concentrations in P. gingivalis 
supernatants are similar to the level of purified LPS needed to inhibit IL-la production. 
In addition, P. gingivalis supernatant depleted of LPS using polymyxin B was unable to 
block C rectus induced IL- Ia production. 
One possible explanation for the observed antagonistic effect is that although P. 
gingivalis LPS is a weak stimulus for proinflammatory cytokines it is a potent inducer of 
IL-IReceptor antagonist (IL-IRA) (Ogawa et al., 1994). Indeed, it has been shown that 
high levels of IL-IRA may down-regulate IL-Ia production in response to LPS in 
monocytes (Granowitz et al., 1992). Alternatively, the antagonistic effect could be 
attributed to competition of the two species for common signalling receptors, such as 
CD14 and Toll-like receptors (TLRs) (Darveau et al., 2004; Hajishengallis et al., 2002; 
Yoshimura et al., 2002; Zhou et al., 2005). Although it has not been conclusively shown 
that P. gingivalis and C. rectus possess any components that initiate common signalling 
pathways, the present work supports a putative LPS cross-talk between these two species. 
We have shown that priming of Monomac-6 cells with P. gingivalis LPS results in a 
significant decrease in the capacity for C rectus to stimulate IL-la production either 
alone, or in combination with P. gingivalis. Previous studies have demonstrated that P. 
gingivalis LPS can antagonize the LPS of E. coli as well as other species (Yoshimura et 
al., 2002). There is evidence that binding of P. gingivalis LPS to both TLR2 and TLR4 is 
involved in this inhibition (Coats et al., 2003; Darveau et al., 2002; Nassar et al., 2002). It 
is also important to draw a distinction between the phenomenon of endotoxin tolerance 
which is normally thought to require a prolonged stimulation of immune cells and this 
study which involves a more acute short term assay (Muthukuru et al., 2005). It is 
possible that the same mechanisms are involved, but equally studies suggest that the 
observed antagonism could reflect direct signalling by P. gingivalis LPS rather than a 
generalized suppression of immune responsiveness (Coats et al., 2003; Darveau et al., 
2002). 
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In summary, this work demonstrates an antagonism between P. gingivalis and C rectus 
in terms of IL-la production that appears to rely on the integration of positive and 
negative signals through cell signalling rather than any direct interaction between 
components in the supernatants. This study suggests that P. gingivalis appears to play a 
role in the short term inhibition of innate immune responses. Although P. gingivalis LPS 
exhibits a. weak cytokine stimulating capacity, it may cause an early inactivation of 
immune cell responses to other bacteria. In this situation the other periodontal bacterial 
species may be more likely to persist therefore favouring the establishment of chronic 
inflarnmatory lesion typical of periodontitis. 
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CHAPTER4 
Aggressive Periodontitis and IL-lA SNPs 
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4.1 INTRODUCTION 
As described in Chapter 1, the association of IL-1 genotypes with periodontal disease has 
been widely studied. In 1997, Kornman and co-workers found an association between 
carriage of two alleles in the IL-IA-889 and IL-113+3953 genes, and an increased severity 
of chronic periodontitis (Kornman et al., 1997a). This has resulted in the production of a 
commercially available periodontal susceptibility test (PST, Interleukin Genetics). The 
composite IL-1 genotype has been extensively investigated with respect to both chronic 
and aggressive periodontitis, smoking, ethnic group, oral microbial pathogens present in 
the plaque biofilm and other periodontal clinical parameters related to inflammatory 
status or to the progression of the disease (Shapira et al., 2005). However, there is 
conflicting data in the literature regarding the specific role of IL-1 polymorphisms in 
periodontal disease (Kinane et al., 2005). It has been suggested that these polymorphisms 
are a useful marker in specific populations (Armitage et al., 2000; Walker et al., 2000) 
but unlikely to be relevant in aggressive periodontitis (Hodge et al., 2001). 
The contradictory results found in several studies may be explained by differences in the 
diagnostic criteria used to define populations, the low number of subjects studied, 
difficulties in selecting a control group (due to the continuous variability of chronic 
periodontitis and the different age of onset of disease between individuals) (Greenstein 
and Hart, 2002). In contrast, identifying the role played by genetics in generalized 
aggressive periodontitis patients may be easier since it has a widely accepted definition in 
terms of phenotype and age of onset compared to chronic periodontitis (Hodge and 
Michalowicz, 2001). 
A number of techniques are available for rapid SNP genotyping. A key requirement of a 
SNP genotyping method is that it distinguishes unequivocally between the allelic variants 
present in homozygous and heterozygous forms. The choice of technology depends on 
whether a few SNPs are to be screened in many individuals or many different SNPs are to 
be examined in a few individuals. There are several methods to discriminate alleles 
including by differential hybridization, primer extension, ligation and cleavage of an 
allele-specific probe (Twyman and Primrose, 2003; Wang et al., 1998). The most reliable 
system for re-sequencing genes in multiple individuals is still nucleotide sequencing 
itself (Chan, 2005; Sanger et al., 1977). Pre-screening methods have been widely used for 
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the discovery of SNPs or mutations in human disease populations and are especially 
useful to identify SNPs that are rare (Table 4.1). The available high-throughput methods 
make genotyping of a large number of samples fast and inexpensive. The TaqMan assay 
(Applied Biosystems) is one of high-throughput methods. However, TaqMan analysis 
requires basic information regarding the existence and abundance of different 
polymorphisms. The information available in public data bases is currently incomplete to 
allow all potential polymorphisms to be identified using this technique in patients with 
periodontitis. 
Method 
Sequencing 
Single-strand conformation polymorphism (SSCP) 
Cleavage fragment length polymorphism (CFLP) 
Denaturing high-performance liquid chromatography 
(DHPLC) 
Accuracy, Reference: 
Higý' rLiývin; siý; ei 1., 
56641; 
Low (Wang et al., 2003) 
Medium (Casadei et al., 2001) 
Medium (Glatt et aL, 2001) 
Table 4.1 Pre-screening methods for SNP discovery. Listed pre-screening methods for SNP discovery, 
broadly categorized according to their principles of SNP detection, and comparing their accuracy under one 
set of conditions, excluding human error. Sequencing was Adapted as the gold standard. Assuming one set 
of conditions, no human error, and a 100% accuracy of sequencing as the arbitrary standard; high = 100%, 
medium = 90-100%, low = 60-90% Adapted from (Suh and Vijg, 2005). 
There are several web-based resources available for assessment of single nucleotide 
polymorphisms (Table 4.2). The NCBlEntrez SNP database (httt): //www. ncbi. nim. 
nih. izov/entrez currently lists 15 polymorphisms in 5' upstream region of the IL-IA gene 
of which five are located in the putative promoter (2.1 kb of the genomic sequence 
upstream of the transcriptional start site). Many of the reported polymorphisms are based 
on studies of relatively small numbers of individuals (often only 46) and in all cases 
periodontal status is unknown. Surveys of the abundance of polymorphisms generally 
aim to identify those polymorphisms with a frequency above about 4%. However, since 
severe periodontal disease has an incidence of about 8% in the general population, it is 
possible that any given polymorphism abundant in this sub-population could be missed 
or classed as rare from a small survey of random individuals. 
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Web-based resource 
NCBIFntrez Gene 
UCSC Genome Bioinformatics 
Ensemb] 
Gene, Aindow 
GeneSNPs 
ESEFinder 
Poll, 'Phen 
SNPetTect 
IlapMap 
Noncoding SNPs 
ressive Periodontitis and IL-lA Pol 11 Cl 
World Wide Web URL 
JLI,: Iý I cl; l 'di, -, -mw 
hapl/ge-nor edu, ' 
hap. /Amwensembl. ort: 
http: //geneýýindow. nci. nili gov/Welcomc 
http Pwww. genome utah. edu/2enesni2s/ 
http //rulai. cshl edu/tools/ESE 
http //www. bork 
httpý//snMffect. vib be/ 
http //", A, " hapmap ý)i, -Vcgi-pgr 
Imp //ecrbroAser dcode o_r,, ' 
Table 4.2 Examples of web-based resources available for assessment ot'SNI's 
Therefore, the aims of this chapter were: 
moriDhisms 
1. To identify the common IL-IA gene promoter polymorphisms present inpatients with 
aggressive periodontitis 
2. To test the detected polymorphisms to ascertain if there was a significant difference 
between patients with aggressive periodontitis and unrelated healthy individuals in 
terms of allele frequencies or genotype frequencies. 
In this thesis two strategies were used for detecting all polymorphisms including direct 
sequencing using BigDye Q and TaqMan analysis. The first strategy was to directly 
sequence the 2.1 kb genomic sequence upstream of the transcriptional start site as well as 
first exon and intron by surveying the frequency and occurrence of all variation within 
this region including SNPs. insert ion/de letions and VNTRs (variable number of tandem 
repeats) within a Caucasian population of diseased individuals. Secondly, after 
identifying the existence and abundance of different polymorphisms in the promoter 
region of the IL-1A gene, TaqMan analysis was performed to provide information 
regarding the abundance of polymorphisms in the IL- IA gene in a range of ethnic groups 
including both diseased and control individuals. 
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SNPs can be numbered relative to their locations to the ATG start site. Reported studies 
have used either rs ID numbers in the database or previously reported positions (Table 
4.3). There are several transcriptional start sites in the human IL-IA promoter but Ets 
data confirms that the most common start site is what has been considered here (see in 
Appendix IV). To avoid unnecessary confusion, throughout this thesis these 
polymorphisrns are referred to by their rs SNP ID numbers in the NCBIEntrez SNP 
database, instead of the base locations reported in the original publications. Furthermore. 
for the sake of clarity these SNPs have been referred to IN in the thesis text. 
SNP ID 
rs i SM, 87 
rs3783521 
rs 1800794 
rs3783571 
rs3783570 
Position Sequence 
Rare Allele frequency (%) ID 
Allele Euromn Asian /Afri n-Amencs 
(-990) 
or ATAATAGTAACCAGGCAACACCATTGAAG 
(-899) TCATATGTAA 
C/T 33% 39% 12% 
(4607) CTGTGTTGCCTAAAGAGGAACCAAGGTAA, 
C/T 27% loo/. 67% AGAAATGTAG 
(-1303) TATCCAACTCACACAACiCTGC'I-TTCCTCCC 
ATCCA'FGCT C/T 
33% 2% 12% III 
(-1287) 
(-2037) 
TATTATTTTTTAGAGATGGGGGCTrCACTA 
TTGlCCCACA A/G Non no data 2% IV 
TTGAAAAATTCAACAACCACCTTTGGGIGA, crr Non non 2% v TATTTACAAC 
Table 4.3 SNPs in the RAA gene promoter. Position column indicates base positions with respect to the 
translation initiation site. Theý are allocated to the positions -990. -1303, -1607, -1287 and -2037 upstream 
of the translational initiation codon. SNP ID column refers to their rs. SNP 11) numbers in the N('1311. ', ntrez 
SNP database. Rare allele frequencies were taken from N('BlEntrez SNP database. No- it does not exist. 
no data= there is no data available in database. Furthermore. for the sake ofclaritý these SNI's hake been 
referred to I-V in the thesis text. 
4.2 MATERIAL & METHODS 
4.2.1 Patient Cohort 
The study was approved by the Local Research Ethics Committee (P/00/021 East London 
and The City Health Authority) and by the Local Research Ethics Committees in the 
Faculty of Medicine, Queens University, Belfast. Informed consent was obtained from all 
patients involved in the study. 
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The patients for this study were a cohort of 150 subjects with generalized aggressive 
periodontitis (GAP). One hundred and ten subjects with GAP were collected during an 
MRC-funded clinical study of risk and prognostic factors at the Royal London Hospital. 
Subjects were recruited from among new patients attending the Periodontal Consultant 
Assessment clinic and criteria for their inclusion are indicated in Table 4.4. All 
participants were interviewed with respect to systemic health history and current 
medication. and smoking habits were recorded according to a simplified protocol: 
0=subjects who had never smoked; I=former smokers 2=current smokers. This group 
was ethnically diverse with an approximate breakdown of 74% white Caucasian, 11% 
Asian and 15% Afro-Caribbean. 117 healthy controls were recruited from both staff 
within Barts and the London School of Medicine and Dentistry and within Institute of 
Cell and Molecular Science. The age and gender distribution was reasonably well 
balanced, with cases being on average 33.7 years old (16-42, SD 5.3) and controls 33.7 
years old (18-53, SD 7.6). Forty subjects with GAP (24 females and 16 males with the 
mean age of 30 ±5 years ranging from 16 to 37 years). were identified from referrals to 
the Periodontal Department. School of Dentistry, Queen's University, Belfast 
(collaboration with Prof Gerry Linden). 
Age 16-40 years 
No systemic conditions 
6 teeth CAL > 6mm 
No medication in the last 6 months 
No periodontal treatment in the last 6 months 
Table 4.4 Patient Selection Criteria. Subjects were recruited from among nc%% patients attending the 
Periodontal Consultant Assessment clinic and criteria for their inclusion arc indicated. 
4.2.2 Sample collection and preparation 
A5 ml venous blood sample was taken from each patient using a standard vacutainer 
containing sodium citrate and stored at -200C prior to extraction of DNA. 
4.2.3 DNA extraction 
Genomic DNA was extracted from 2 ml of blood using a salt precipitation technique as 
described previously (Miller et al., 1988) and outlined in the Appendix 111. DNA yields 
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were quantified using Nanodrop, ND-1000 (NanoDrop Technologies. LISA) and the 
concentration was expressed as ng/ýd (Appendix Ill. Table 1-2). The purity of' the 
extracts , %as determined from the ratio of the absorbanc\, values at 260 nm and at 280 
nm, to assess for protein contamination. The samples were stored at 4'C until Further 
analysis. 
4.2.4 Direct DNA sequencing and allele genotyping 
Polymerase chain reaction (PCR) 
The strategy to identify polymorphisms was based on PCR amplification of putative 
promoter. the first exon and first intron which directly sequenced using BigDye Q. The 
sequence for the human IL- IA gene was obtained using the Ensemble genorne browser. 
The accession number is AF536338 (Appendix IV). PCR primers were designed with 
assistance of the online PCR primer design programme, Primer3 
(http:, ' 1rodo. \ýi. init. edLi,, 'cý,, i-biil, 'pi-iiner3/Pi-imcr3 -cgi) and all primers were checked 
on the BLAST online sequence search engine to ensure they had low similarity with 
other known human cDNA sequences (http: //ww\, v. ncbi. nim. nih. aov/Bi-AST). All 
primers \vere synthesized by Invitrogen, UK (Table 4.5). 
PCR is a commonly used method for amplifying defined target DNA sequences of 
interest. Two oligonucleotide primers (15-25 nucleotides) which are specific for the 
target sequence are used. After the primers are added to denatured template DNA, they 
bind specifically to complementary DNA sequences at the target site. In the presence of a 
suitably heat-stable DNA polymerase and DNA precursors (the four deoxynucleoside 
triphosphates, dATP, dCTP, dGTP and dTTP), they initiate the synthesis of new DNA 
strands which are complementary to the individual DNA strands of the target DNA 
segment (Figure 4.1). The PCR is a chain reaction because newly synthesized DNA 
strands will act as templates for further DNA synthesis in subsequent cycles. After about 
25 cycles of DNA synthesis, the products of the PCR will include, in addition to the 
starting DNA, about 105 copies of the specific target sequence, an amount which is easily 
visualized as a discrete band of a specific size when submitted to agarose gel 
electrophoresis. 
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Figure 4.1 A schematic representation of Polymerase Chain Reaction (PCR). PCR is an in viiro method 
for amplifying DNA sequences using defined oligonucleotide primers. Oligonucleotide primers A and B 
are complementary to DNA sequences located on opposite DNA strands and flanking the region to be 
amplified. Adapted from Human Molecular Genetics 2 (Strachan, 1999). 
Genomic polymerase chain reaction (PCR) was carried out on a Thermal Cycler 
(Hybaid) in a l0x PCR buffer containing 10 mM Tris-HCI (pH 8.3), 200 ng of genomic 
DNA, 50 ng/pI mix of forward and reverse primer, I OmM dNTPs (Sigma), 50mM MgCl' 
and 4U Bio-X-Act Polymerase (Table 4.6). Each primer set was optimised for MgCl' and 
temperature using four MgCl, concentrations (1,1.5,2, and 2.5 mM) and four 
temperatures (50'C, 55C, 60'C, 65'C). Optimized annealing temperature was 60'C and 
the MgCl, concentration for primers was 2.5 mM. 10 pl of the PCR reaction was loaded 
onto aI% agarose gel using loading buffer and run for 40 min at I OOV. I kb DNA Ladder 
(New England Biolabs, Hitchin, UK) was used as marker to estimate size of product. The 
samples were then stored at 4'C until further analysis. 
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Primer F-Primer (forward) 3'-Primer (reverse) 
Promoter I'ACG'FTCCACTGTCCCI"FCC A('('(i('('AA'I'CiAAA'I'GA("I'CC 
First exon TCAATAACTTCTGGAATATCT CAAAATGAGAGAATCATT 
First intron AATTACAGTCAGATITCAGAA TGTAACAG Il ("I IVAGG R"I'T 
Table 4.5 The PCR primer sequences. The primers were designed using IIrimer3 veb programme and 
synthesized by Invitrogen, UK. The 5'-*3' sequences of the sense (S) and the 3'->5' antisense (AS) primer 
pairs are shovvn. 
Stock concentration Concentration required Volume used 
IOX OptiBuffer IX5 pI 
50 mM MgCl Solution 1-2.5 mM 1-2.5 ýLl 
100 mM dNTPs 2mM I ý11 
Genomic DNA (25 ng/pl) 50 ng 2 pl 
Primer mix 100 pM 2 ýM 2 pI 
BIO-X-ACT Long (4 u/pl) 4uI PI 
Water (ddli, O) x 37.5-39 pl 
Total 50 pl 50 g) 
Table 4.6 Components ofthe PCR mix. Polýmerase chain reaction (11CR) was carried out on athermal 
C)cler(Hybaid. UK) in aI Ox PCR buffer containing 10 mM Tris-I I CI (p] 1 8.3), 200 ng ot'genomic DNA. 
50 ng/ýd mix of forward and reverse primer, I OmM dN'FPs (Sigma). 50mM MgC12 and AJ Bio-X-Act long 
polymerase. 
Sequencing of PCR products 
Seven primer pairs were used to sequence directly the 2.1 kb genornic sequence upstream 
of the transcriptional start site as well as the first exon and intron (Table 4.7). The 
strategy is outlined in Figure 4.2. 
A) 
-2100 +1 +678 +734 
I No 
+58 
m 
4- 2.1 kb promoter 
Exon I Intron I Exon2 
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Figure 4.2 A) Schematic diagram of the IL-1A gene. Boxed white regions depict the DNA sequences 
corresponding to the 2.1 kb genomic sequence upstream of the transcriptional start site as well as first exon 
and intron. The numbers are distance in base pairs from the transcriptional initiation site (black arrow). B) 
Schematic diagram of the sequencing primers. Arrows indicate the position of all 5 currently reported 
polýmorphisms in the 2.1 kb genomic sequence upstream of the transcriptional start site ( 
ýý 
-500bp). 
Primer 5'-Primer (forward) 3'-Primer (reverse) 
I AGAAGAGGTGACTGTTGTTCA ATAACATTTTCAGGTGAAGGC 
2 AAATATCTTCAGGCTTTCAAT TGGTGCTATAATAGTTATAAC 
3 TTACATCCAAGTGTGGTTATT TTTATAATTCCTGTGGCCAGC 
4 TCAT'17GCTAAGAGTCTGGTG TAAGGCATAAATCACCTCAGA 
5 ATTCAGAAGAGTAAGAGGATC ATAGTGAAAGATGGCATAGCT 
6 TCAATAACTrCTGGAATATCT CAAAATGAGAGAATCAT-F 
7 TCAATAACTTCTGGAATATCT CAAAATGAGAGAATCATT 
Table 4.7 The primers used for direct sequencing of the IL IA gene to detect polymorphisms. The primers 
were designed using Primer3 programme and synthesized by Invitrogen, UK. The 5'--)-3' sequences of the 
sense (S) and the Y-O'antisense (AS) primer pairs are shown. 
PCR products were prepared for sequencing using the ABI BigDye Terminator 
sequencing kit (Applied Biosystems, Warrington, Cheshire, UK) in accordance with the 
manufacturer's instructions. Firstly, PCR primers and dNTPs were removed before 
sequencing. 3,5 gL of PCR product was incubated with 1.5 gi of ExoSaplT (Amersham, 
UK) for 37 min at 37C followed by 20 min at 80'C to inactivate the enzymes (Appendix 
V-14). This method employs shrimp alkaline phosphatase (SAP) and exonuclease I 
(Exol) to degrade nucleotides and single stranded DNA (primers) remaining after PCR 
(Werle et al., 1994). PCR products are sequenced by controlled termination of their 
replication and the assay is based around the Sanger method of DNA sequencing (Sanger 
et al.. 1977). With either the forward or the reverse primer used for the PCR in the 
117 
Chapter 4: Aggressive Periodontitis and IL-lA Polymorphisms 
sequencing reaction, AmpliTaq DNA polymerase catalyses complemantary DNA strand 
synthesis using dNTPs in the reaction mix. Four separate fluorescent dyes are labelled 
onto a base-specific dNTPs. The order of the nucleotides is determined using argon ion 
laser, which scans the fragments on the gel measuring their emission spectrum and 
determining the order which dNTPs where incorparated (Figure 4.3A). This produces an 
emission plot along the gel, called electropherogram, which reveals the sequence of the 
DNA (Figure 4.313). The infori-nation is recorded and data is stored in a computer 
database. 
A) 
2 -3 4 -5 .6 C L! Jl±JL! J1iVL! fl±I 
iiiiiý 
G 
B) 
Law 
Output 
--_j 
Datecor 
, AAA C-^- ITT A AAA GC -A GTACCCAGTACCT -I CTAGTTCCAAAGCCCAATGT TGTTCACT AT GGTT CA 150 160 .0 200 21 Igo 
A A 
A 9 
Figure 4.3 A) Principles of automated DNA sequencing. Four separate fluorescent dyes are used as labels 
for the base-specific reactions (the label can be incorporated by being attached to a base-specific dNTP). 
During the electrophoresis run. a laser beam is focused at a specific constant position on the gel. As the 
individual DNA fragments migrate past this position, the laser causes the dyes to fluoresce. Maximum 
fluorescence occurs at different wavelengths for the four dyes, and the information is recorded 
electronically and the interpreted sequence is stored in a computer database. Adapted from Human 
Molecular Genetics 2 (Strachan. 1999). B) Example of DNA sequence output (an electropherogram). This 
figure shows a typical output of sequence data from an ABI 3700 DNA analyzer automated DNA 
sequencer as a succession of dye-specific (and therefore base-specific) intensity profiles. 
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Each 10-Itl sequencing reaction contained 50 ng of purified PCR product, 1.5 pmol of 
sequencing primer, I gl of BigDye Terminator mix, 1.5 gl of 5x sequencing dilution 
buffer (400 mM Tris, pH 9.0,10 MM MgCl2), and water to volume. Cycling conditions 
were 94*C for I min and 25 cycles of 94"C for 30 s, 50*C for 30 s, and 60'C for 4 min, 
finishing with a single 720C extension step for 5 min. Sequencing products were ethanol 
precipitated, air-dried, resuspended in 25 Id ddH20, and analyzed on an ABI 3700 DNA 
analyzer (See detailed method in Appendix V. 14). 
Sequence analysis 
The sequence analysis was carried out using the GAN analysis software by Staden 
(Bonfield and Staden, 2002). The forward and reverse sequences for each patient were 
aligned for comparison with a reference sequence imported from Ensembl. Because no 
sequence reading is 100% reliable, the search for mutations is not quite as simple as 
comparing a suspected polymorphic sequence against a wild type. Differences between 
two sequences can be due to mutations or to base calling errors. Thus the problem is 
recognising the real mutations within a background of base calling errors. The program 
TRACE_DIFF was used which normalizes and subtracts the pairs of reference and 
patient traces to produce a new set of traces which represent their differences. The 
difference traces are effectively flat except where a difference occurs and this provides a 
much simpler visual method of searching for mutations (Figure 4.4). While sequence 
alignment was performed and polymorphic ranking scores were identified using 
software, genotypes were read by eye. 
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Figure 4.4 The traces as displayed by the GAN contig editor. This illustrates the features of the trace 
differences as analysed b,, TRACE-DIFF. The top trace is the reference trace. the middle one is a patients 
reading ad the bottom one the difference between the other two. The differences trace contains very few 
features: in this case three base changes are shown with their associated peaks in the differences plot. 
4.2.5 TaqMan analysis 
SNPs for TaqMan analysis were selected on the basis of having relatively high minor 
allele frequencies (>10%). In addition to direct sequencing results, the 3 SNPs were also 
checked on public databases including the National Center for Biotechonology 
Information SNP database (http: //", wA. ncbi. nim. nih., Qov/SNP) and the SNP Consortium 
database (http: //snp. cshl. orp, ). TaqMan analysis were performed to provide infon-nation 
regarding the abundance of polymorphisms in the IL- IA gene in a range of ethnic groups 
including both disease and control individuals. Further analyses were done if there was a 
significant difference between patients and unrelated healthy individuals, in terms of 
allele frequencies or genotype frequencies. Genotyping was carried out by Pre-made 
TaqMan Genotyping assays (Applied Biosystems, Warrington, UK). TaqMan assay IDs 
and the context sequence (the nucleotide sequence surrounding the SNP site provided in 
the (+) genome strand orientation relative to NCBI reference genome is shown in Table 
4.8. The TaqMan SNP Genotyping Assay exploits the 5'-exonuclease activity of 
AmpliTaq Gold DNA polymerase to cleave a doubly labeled probe hybridized to the 
SNP-containing sequence of DNA (Livak et al., 1995). Cleavage separates a 5'- 
fluorophore from a Y-quencher leading to detectable fluorescent signal (Kutyavin et al., 
2000). The use of two probes, one specific to each allele of the SNP and labeled with two 
fluorophores, allows detection of both alleles in a single tube. Fluorogenic probes with a 
minor groove binder (MGB) produce enhanced allelic discrimination, because the MGB 
stabilizes the double-stranded probe template structure. This provides enhanced 
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mismatch discrimination between these shorter probes, resulting in improved allele 
specificity (Figure 4-5). 
SNP ID Assay ID Forward primer Reporter dyes 
rs3783521 (CiT) C-1839900-10 ACTGGCTACATTTCTGCTTACCTTG[A/G] Allele Iý VIC 
TTCCTCTTTAGGCAACACAGAAATG 
Allele2 - FAM 
rs 1800794) (Cfr) C-9546482-30 CAGGAACAGAGGGAATACTTTATCCAA Allele I =VIC 
Allclc2 = FAM 
(rs 1800587) (CT) C-9546481-20 ACTGGCTACATTTCTCjCTTACCTTG[A/G] Allele I= VIC 
TTCCTCTTTAGGCAACACAGAAATG 
Allcle2 = FAM 
Table 4.8. 'FaqMan genotý ping probe and primer sequences. TaqMan assaý I Ds and the context sequence 
(the nucleotide sequence surrounding the SNP site provided in the (+) genome strand orientation relative to 
NCBI ref , erence genome) are shown. 
5 
Forwaid 
Prow 
3'---- 
5' 
(A) 
Probe 
4 
B) 
ý 5' 
Reverse 
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3' 
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L-ýnd 
Vic 
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I cipoi hAnor Grove 8014W 
OA 
-P& I aq 
G. Id DNA 
P04~ame 
Figure 4.5 A diagram of the TaqMan SNP Genotyping Assay A) Probe binding and primer extension in a 
'I-aq%, Ian SNP Genot,, ping Assay. (B) Allelic discrimination is achieved by the selective annealing of 
matching probe and template sequences. which generates an allele-specific (fluorescent d-Ne-specific) 
signal. BrieflN. during PCR. each TaqMan MGB probe anneals specifically to its complementary sequence 
between the forward and re, erse primer sites. AmpliTaq Gold DNA polymerase cleaves only probes that 
are h)bridized to the target and cleaý age separates the reporter dye from the quencher dye. which results in 
increased fluorescence b-, the reporter. Adapted from Applied Biosystems. UK. 
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The amount of genomic DNA in samples was quantified before using TaqMan SNP 
Genotyping Assays as recommended by Applied Biosystems (Appendix 111). DNA 
samples were diluted with DNase-free water (Sigma. UK) to deliver a final DNA 
concentration in the range of I to 20 ng per \, Nell. 2ýtl of diluted genomic DNA was 
delivered to the bottom surface of a MicroAmp Optical 384-Well Reaction Plate by 
pipeting and the DNA samples were dried down completely by evaporation at room 
temperature. The plate was covered with a lint-free tissue while drying. 10 samples were 
randomly selected and included as replicates for each genotype tested. 
PCR amplification 
AmpliTaq Gold DNA polymerase from the TaqMan Universal PCR Master Mix 
amplifies target DNA using sequence-specific primers and TaqMan MGB probes from 
the SNP Genotyping Assay. The reaction mix was prepared for each assay. 5 PI of the 
reaction mix was added to the prepared DNA reaction plate. The plate was sealed with 
the cover (MicroAmp Optical Adhesive Film). Applied Biosystems 7900HT Fast Real- 
Time PCR System was used for PCR amplification. The thermal cycling conditions for 
PCR are shown in Table 4.9. 
Amplitaq Enzyme activation 95*C 10 min 
Denaturation 92 CI Ssec 
Anneal ing/Extension 60T I min 
Table 4.9 The thermal c)cling conditions f'or PC'R. Applied llios,, stems 790011 V Fast Real-Timc PCR 
System xas used for PCR amplification 
Allelic Discrimination Plate Read and Analysis 
After PCR amplification, an endpoint plate read was performed using an Applied 
Biosystems Real-Time PCR System. The Sequence Detection System (SDS) Software 
uses the fluorescence measurements made during the plate read to plot fluorescence 
values based on the signals from each well. Genotype calls for individual samples were 
made by plotting the normalized intensity of the reporter dyes in each sample well on a 
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cluster plot. A clustering algorithm in the data analysis software assigns individual 
sample data to a particular genotype cluster (Figure 4.6). 
-ýj cm. 
AgeNc DiscrImUmion Pkpt 
Pt- eInIm. I ok I 
L. g.. d 
x . -. 
0 Meft y 
0 NTC 
------------------------- -- - ------ Io20 40 60 60 70 
AN. I. X (2) 
Figure 4.6 Cluster plot of DNA samples generated from TaqMan assay for rs3783521 SNP. DNA samples 
were genot)ped simultaneously on 384-well plate. Genotype calls for individual samples were made by 
plotting the normalized intensity of the reporter dyes in each sample well on a cluster plot. A clustering 
algorithm in the data anal) sis software assigns individual sample data to a particular genotype cluster. Data 
points Blue= Allele 1/1 homozygous, Green= Allele 1/2 heterozygous, Red= Allele 2/2 homozygous. 
Circuled area shows failed samples. 
4.3 Statistical analysis 
Two-group comparisons for demographic values were assessed with Mann-Whitney U- 
tests and P<0.05 was considered to be statistically significant. The association of allele 
and genotype frequencies in cases and controls was analysed by the chi-square test. The 
genotype frequencies in the control population were in Hardy-Weinberg equilibrium. The 
Hardy-Weinberg principle dictates that the genotype frequencies in the population are 
determined solely by the allele frequencies in the population (Balding, 2006). The 
computation is staright forward: if p and q are the allele frequencies in the population, 
where p+q=l. then the genotype frequencies will be p2 (for homozygous of type one), 
2pq (for heterozygous), q2 (for homozygotes of the other type). In initial analysis, 
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genotype and allele frequencies between cases and controls were compared without 
categorizing subjects by ethnicity or smoking. In a separate analysis, genotype and allcle 
frequencies were compared between smoker and non-si-noker cases and controls. 
Furthermore, genotype and allele frequencies were compared between Caucasian cases 
and controls. Since Afro-Caribbeans and Asians were only in small numbers, no further 
statistical analysis was done on these groups. 
The population genetics program Haplovie\, \ was utilized to estimate haplotype 
frequencies based on the EM algorithm (Barrett et al., 2005). Pair-wise linkage 
disequilibriurn (LD) between SNPs was evaluated using two statistical measures, (D") 
and r2 which are respectively useful for modelling recornbination rates and association 
power. Haplotype frequencies of three SNPs were derived from genotype data using the 
Phase and Harlequin software programmes (Stephens and Donnelly. 2003). 
4.4 RESULTS 
4.4.1 Identification of genetic polymorphisms in the IL-IA gene 
DNA samples were amplified by PCR using primers corresponding to the promoter and 
the region including intron and exon. The PCR product generated a 2,1 00bp or 500bp 
fragment which was run on ethidium-bromide stained agarose gel and viewed under 
ultraviolet (UV) illumination as illustrated in Figure 4.7 and Figure 4.8. respectively. One 
sample (lane 4) failed to amplify on this run and was repeated on the next run. 
Ladder 1234567 
10 kb 
3 kb-00- 
2 kb -I' 
1,5 kb 
Figure 4.7 Lthidiuni-broinidc stained aprose ý,, cl shmýing i-csults (if IICR 1111plil-Ication ()I 1)', "\ 
A 2.100bp fragment -, %as generated by amplification with DNA polýmerasc. The DNA "as analý zed on 1% 
agarose gel containing ethidium bromide. Lanes: lane 1. Ne\, \, Fngland Biolabs*s I kb DNA Ladder. lanes 
2-8, amplified genomic DNA for 7 patients. 
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12345678 Ladder 
500hp 
Figure 4.8 Lthidium-bromide stained agarose gel shoý\ing results of' PCR arnplification of' rcgion 
including both Exon I and Intron 1. A 500 bp Fragment was generated bý amplification \6th DNA 
poINmcrase (arrový indicates expected size of' PCR product). The DNA ý%as analwed on 1% agarose gel 
containing ethidium bromide. Lanes: lane 9 indicates 100 bp Gene ruler DNA Ladder (Fermentas. UK). 
lanes 1-8. amplified genomic DNA tor se,, en patients. 
Screening of the first intron and the first exon ofthe ILIA gene in 15 patients revealed no 
genetic variation related to aggressive periodontitis. Three polymorphic PCR fragments 
SNP I C>T (rsI800587), SNP 11 C>T (rs')783521) and SNP III C>T (rs1800794) were 
detected in the IL-IA putative promoter region of Caucasion patients with GAP. Three 
SNPs already had a database SNP ID number (http: //, A\\\N. ncbi. nii-n. nih. i,, ov/entrez). 
The base substitutions in all PCR fragments were confirmed by direct sequencing by both 
the forward and reverse strand. Figures 4.9-4.10 show DNA sequence outputs 
(electropherograms) for two patients. The single blue peaks show the sample does not 
contain the SNP; they are in the homozygous forms CC. The double peaks (red and blue) 
show the sample contains the SNP C>T in heterozygous form. 
The genotype data and allele frequencies for all SNPs are shown in Table 4.10. Minor 
allele (Allele 2 or T) frequencies for SNP 1, SNP 11, SNP III were 36.25%. 32.5% and 
33.75%, respectively. None of the patients carried previously reported SNP IV C>T 
(rs3783571) and SNP V G>A (rs3783570). All patients had C or G at these positions, 
respectively. 
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A) rs1800794 CC 
170 
, A:;. 
CA AG 
B) rs1800587 CC 
70 80 
AA, AC CAT :G AAGGCTCATA' 
ow"m 
C) rs3783521 CT 
280 . 190 
AGAGGA A': CAAGG-AAGC 
Figure 4.9 1.1 ectropherograms showing different genot)pes (Patient I ). I -J cctropherograms N. %crc produced 
bý fluorescence-based sequencing using an ABI 3700 showing the genomic DNA from an individual. 
These electropherograms sho\% d,, e-specific (base-specitic) intensity profiles. The single blue peaks in the 
left (A) and middle traces (B) shows the sample does not contain the SNP. they are in the homozygous 
forms CC. The double peak (red and blue) in the right trace with N letter (C) shows the sample contains 
the SNP C>T in heterozýgous form. The change "as also confirmed by sequencing the reverse strand. 
A) rs 1800794 CT 
1 'O 180 
7T CC 7 
B) rs1800587CT 
70 80 
GG 
-- AA, A ': 
CA GAAGG 
-- -7 ]-A 
AA A 
IVA 
C) rs3783521 CC 
280 290 
AGAGGA AC CA AGG- AA G I- AG 
Figure 4.10 Flectropherogram showing different genotypes (Patient 2). Electropherograms vvere produced 
b) fluorescence-based sequencing using an ABI 3700 showing the genomic DNA from an individual. 
These electropherograms sho\\ d,. e-specific (base-specific) intensity profiles. The double peak (arrow) in 
the left trace (A) and middle trace with letter N (B) shows the sample contains the SNP C>T in 
heteroz)gous form. Single blue peak in the right trace (C) shows the sample does not contain the SNP. it is 
in the homozy gous form CC. The change was also confirmed by sequencing the re\ erse strand. 
GAP (n=40) 
rs1800587 rs3783521 rs1800794 
SNP I SNPII SNPIII 
Genotype (nýQ) n (%) n (%) n (%) 
CT 23(57.5) 18(45) 25(62.5) 
TT 3(7.5) 4(10) 1(2.5) 
cc 14(35) 18(45) 14(35) 
Allele frequency (2n=80) n (%) n (%) n (%) 
Allele I (C) 51 (63.75) 54(67.5) 53(66.25) 
Allele 2 (T) 29(36.25) 26(32.5) 27(33.75) 
Table 4.10 GenotNpe and allele frequencies of the identified IL-1A SNPs in Caucasion patients with GAP. 
I he base substitutions in all PCR fragments were confirmed by direct sequencing. 
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4.4.2 The LD analysis and haplotype profiles of the IL-IA gene promoter 
Using the haploview program, it was possible to examine measures of LID (Figure 4.11). 
Pair-wise LID between SNPs was evaluated using two statistical measures, (D') and r' 
which respectively help modelling recombination rates and association power (Table 
4.11). Using an r2 value of over 0.3 as a threshold to represent useful LD for association 
studies (Pritchard and Przeworski, 2001), only SNP 1 (rs1800587) & SNP 111 (rs1800794) 
gave r' =0.74. The similar LD linkage of the IL-1 A gene closely resembled those seen in 
the Caucasion data from the International HapMap project (http: //www. hapmap. org/cgi- 
perl/gbrov, se). 
Measures Haploview 
of LD output 
Ll L2 D' LOD r^2 Cllow Clhi T-int 
rs3783521 rs1800794 0.74 1.76 0.148 0.29 0.91 4.04 
rs3783521 rsI800587 0.765 2.28 0.158 0.36 0.92 - 
rs 1800794 rs 18005 87 0.877 12.29 0.741 0.75 0.95 14.57 
Table4.11 Measures of linkage disequilibrium (LD) for three studied SNPs in the IL-IA gene promoter 
region. Pairwise LD in the IL- IA gene was evaluated by Dand r2 in GAP. 
2-3 
74 87 ip 
76 
Figure 4.11 LD plot showing linkage disequilibrium between studied SNPs in the IL-IA gene promoter. 
The haploview program was used. The SNPs were numerated as follows rs3783521= 1 rs1800587=2 
rs 1 800794=3 
Haplotype frequencies of three SNPs were derived from genotype data using the Phase 
and Harlequin software programmes (Stephens and Donnelly, 2003). A summary of 
haplotype probabilities is presented in Table 4.12. Most common haplotypes were (C T 
T), (C CQ and (T CQ occurring at > 25% frequency in the studied population. 
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Harlequin Output Phase Output 
haplotype frequency frequency 
CFT0.29804 0.280811 
CCC 0.29743 0.343748 
TCC0.28653 0.277871 
CCT 0.01852 0.030921 
TTT 0.01473 0.029542 
CTC0.01314 0.016679 
TTC 0.01308 0.013137 
Table 4.12 Frequenc,, of IlAA promoter region haplotýpes. HaplotNpes ýNere estimated from three SNPs 
using both Harlequin and Phase programmes. Se,. en different haplotypes occurred in the studied 
population. 01' the 7 possible haplotý pes. three represented greater than 25% of' haplotypes in the studied 
population 
4.4.3 TaqMan Analysis 
Since DNA concentration is a critical variable in PCR reactions, this was optimized using 
patient samples (1-2). as well as control DNA (human genomic DNA, Promega, LJK). 
DNA amount used was diluted to 0.625,1.25,2.5,5,10.20 ng/lil. 2 pi of DNA was added 
to each well and dried overnight and then a 5pl reaction ran using primers for SNP III 
(rs 1800794) and 60 cycles to make detection as sensitive as possible. 
Results are shown in Figure 4.12. Graphs represent the cycle threshold plotted against 
DNA concentration for each sample. Amplification of samplel appeared to be inhibited 
at 20 ng/ýd. reaching the cycle threshold of 60. Sample 2 gave amplification for all 
concentrations used. As the concentration of DNA independently was also assayed by 
nano-drop methodology it is possible to be confident of the amount of the concentration 
used. The most likely explanation for differences is the presence of different levels of salt 
in the samples. Since all of the samples tested had a CT value around 18-20 at Ing per 
well, further analysis was carried out using DNA at Ing per well. 
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Figure 4.12 Real-time PCR cycle threshold plotted against DNA concentration (ng/pl). (A) Control 
human DNA. Promega. UK. (B-C) Patient DNA samples. DNA amount used was diluted to 0.625.1.25. 
2.5.5 ng/pl. 2 pl of DNA was added in each well and dried overnight and then ran a5 PI reaction using 
primers for SNP 111 (rs1800794) and 60 cycles to make detection as sensitive as possible. 
It 
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4.4.5 Study Groups and Genotype Distributions 
For each assay, 10 samples were randomly selected and included as replicates for each 
genotype tested. All replicates gave the same genotype. Relatively few samples between 
3 and 8 failed to react for each SNP (96.1-98.5% completion rate). 
Patient demographics 
The study included a total of 267 subjects, 150 cases and 117 controls. The GAP group 
consisted of 88 females and 61 males between the ages of 16 and 42 years (mean 
33.77±5.36 of years). The healthy group consisted of 65 females and 48 males ranging in 
age from 18 to 53 years with a mean age of 33.76 ± 7.6 years. No significant differences 
were detected between cases and controls groups regarding the mean age (P>0.05). The 
frequency of female and males were similar between cases (F: M, 55.6%: 41% and 
controls (F: M, 58.7%: 40.7%). GAP group consisted of 73% of Caucasian, 15% of Afro- 
Caribbean and 12% of Asian. Control group included 85% of Caucasian, 12% of Asian 
and 3% of Afro-Caribbean. Smoking status was divided in to three categories (none: 
smoker: previous smoker). The frequency of smokers was higher in cases (43% P<0.05) 
than in controls (16%). The frequency of previous smokers in cases and controls was 6%, 
3%, respectively. 
4.4.6 Genotype Distributions and Allele Frequencies 
Only three SNPs in the 2.1 kb promoter of the IL-IA gene were polymorphic in the 
Western European population (Northern Ireland). In this section, these three SNPs 
including SNP 1,11 and III were analysed in a mixed population including Caucasians, 
Asians and Afro-Caribbeans. Further analyses were done if there was a significant 
difference between patients and unrelated healthy individuals, in terms of allele 
frequencies or genotype frequencies. 
The frequencies of the genotypes and alleles in GAP patients and controls are presented 
in Tables 4.13. Allele 2 (1) frequencies for SNP 1, SNP 11, SNP III were 34.2%, 26.7%, 
34.2% in cases, 29.8%, 29.6%, and 30.6% in controls, respectively. No statistically 
significant differences were found between patients and controls for any of the genotype 
or allele frequencies investigated (SNPI, SNPII, SNP III). 
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(Chi-squared (for genotypes) =0.22,0.23,0.37, respectively. Chi-squared (for allele 
frequencies) = 0.64.0.56,0.36, respectively). 
Genotypes frequencies /Allele frequencies(2N) 
SNPs Genotypes Alleles Control N M) GAP. N M) 
rs1800587, SNPI CT Mick I (C) 44 (38.5) / 160 (70.2) 68 (45.94) / 198 (65.7) 
TT Allele 2 (T) 12 (10.5) 168 (29.8) 15 (10.14) / 98 (34.2) 
cc 58(50.8) 65(43.92) 
Chi-squared anal) sis =0.22 / 0.64 (Genotype / allele frequency) (aggressive vs. control) 
rs378352 1, SNPII CT Allele I (C) 50 (43.4) / 162 (70.4) 59 (39.4) / 210 (73.4) 
TT Allele 2 (T) 9 (7.8) / 68 (29.6) 13 (8.8)/ 76 (26.57) 
cc 56(48.6) 76(51.7) 
Chi-squared anaksis =0 23 / 0.56 (GenotN pe , allele frequency) (aggressive vs. control) 
rs1800794, SNPIII CT Allele I (C) 53 (45.6) / 161(69.3) 64 (42.93) / 214 (71.8) 
TT Allele 2 (T) 9 (7.75) / 71(30.6) 10 (6.7) / 84 (28.2) 
cc 54(46.65) 75(50.3) 
Chi-squared analysis= 0 37 / 0.36 (Genotype / allele frequency) (aggressive vs. control) 
Table 4.13 Genot)pe and allele frequencies for the 3 SNPs examined in patients with generalized 
aggresske periodontitis (GAP. n=150) and healthý controls (n=l 17) ]'here were no significant differences 
(P >0.05) in allele frequencies between the unstratified cases and the controls for any ofthe 3 SNPs. For 
significance at the 0.05 level. chi-square should be greater than or equal to 3.84. 
4.4.7 Genotype Distributions and Allele Frequencies and ethnic background 
The three SNPs were examined in three different populations, namely Caucasians, Afro- 
Caribbeans and Asians. Allele frequency distribution differed among the different 
populations (Table 4.14). Only two of controls were Afro-Caribbeans and carried allele I 
(C) for all SNPs studied. SNPs 11 and III may be a population specific SNP since the SNP 
11 and III T allele accounts for 4% of Afro-Caribbeans allele frequencies in the diseased 
group. SNP frequencies were not significantly different between control and cases for all 
populations. Minor allele frequencies for Caucasians were 30%, 28%, 31% in controls 
and 28%, 31%. and 30% in cases, respectively (Table 4.14). There was no significant 
difference in the prevalence of the carriage of rare alleles (allele 2) in the three studied 
SNPs observed between a group of generalized aggressive periodontitis patients 
(Caucasians) and a control group (Table 4.14). 
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Allele frequencies (2n) 
Control (2n=234) n (%) CAP (2n=300), n (%) 
Caucasian A-Caribbean Asians Caucasian A-Caribbean Asians 
rsl800587, SNPI Allele 1 (C) 136(69) 4(100) 18(75) 140(67) 29(63) 26(77) 
Allele 2 (T) 60(31) (0) 6(25) 70(33) 17(37) 8(23) 
Chi-squared Aggrcssi,. e Ns control (Caucas ion: A-Caribbean: Asian) 0.34: 2,23: 0.01 
rs3783521, SNP[I Allele I (C) 135(70) 4(100) 16(67) 143(69) 44(96) 21 (62) 
Allele 2 (T) 59(30) (0) 8(33) 65(31) 2(4) 13 (38) 
Chi-squared Aggressive vs control (Caucas ion: A-Caribbean. Asian) 0.03: 0.18: 0.14 
rsIS00794, SNP]II Allele I (C) 134(68) 4(100) 19(79) 140(66) 45(96) 26(77) 
Allele 2 (T) 62(32) (0) 5(21) 72(34) 2(4) 8(23) 
Chi-squared Aggressive vs control (Caucasion: A-Caribbean: Asian) 0.25: 0,17: 0.05 
Table 4.14 Allele frequencies for the 3 SNPs in different populations. There were no significant 
differences (P >0.05) in allele frequencies between the stratified cases (GAP) and the controls (according 
to ethnic background) for anN of the 3 SNPs. For significance at the 0.05 level. chi-square should be greater 
than or equal to 3.84. 
4.4.8 Genotype Distributions and Allele Frequencies and smoking status 
Table 4.15 shows the genotype frequencies in smokers and non-smokers. The frequency 
of smokers was 65% in cases, but only 19% controls were smokers. No statistically 
significant differences were found between smoker GAP and non-smoker GAP for any of 
the genotype (CC versus CT/TT) investigated (SNPI, SNPIL and SNP 111). Chi-squared 
for genotypes =1.02,0.39,0.23, respectively. No statistically significant differences were 
found between smoker controls and non-smoker controls for any of the genotlype (CC 
versus CT/TT) investigated (SNPI, SNPII, and SNP 111). Chi-squared for genotypes =3.1, 
3.7,1.2, respectively. 
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Control N (%) 
SNPs Genotypes Smoker N-smoker 
GAP. N (%) 
Smoker N-smok-e 
rs1860587, SNTI CT 9(50) 31 (33) 32(50) 28(39) 
TT 3 (17) 9(10) 6(9) 8(11) 
cc 6(33) 5](57) 26(41) 35 (50) 
rs3783521, SNPII CT 5(26) 42(47) 23(36) 31 (43) 
TT 1 (5) 8(10) 6(9) 5(8) 
cc 13(69) 39(43) 35(55) 35(49) 
rs 1800794, SN PI II CT 9(47) 38(42) 29(45) 27(36) 
TT 3 (15) 6(7) 3(4) 6(11) 
cc 7(38) 46(51) 32(51) 39(53) 
Table 4.15 Genotype and allele frequencies for the 3 SNPs according to smoking status in patients with 
generalized aggressi%e periodontitis (GAP, n=150) and healthy controls (n=l 17) There were no significant 
dift'crences (P >0.05) in allele frequencies between the stratified cases and the controls (according to 
smoking status) for aný of the 3 SNPs. For significance at the 0.05 IeN cl. chi-square should be greater than 
or equal to 3.84. 
4.5 DISCUSSION 
This study screened the upstream region of the IL-IA gene including first intron, first 
exon and promoter region (2.1 kb of the genomic sequence upstream of the 
transcriptional startsite). Direct sequencing ofexon I and intron I ofthe ILIAgene from 
patients with aggressive periodontitis revealed no genetic variation. Previous studies of 
IL-I A transcription suggested that inclusion of the first intron sequence in reporter 
constructs did not affect transcriptional activity (Huang et al., 1999). Therefore, further 
investigations were focused on the promoter region upstream of the IL-IA gene. Three 
previously described polymorphisms were observed in Caucasians with generalized 
aggressive periodontitis: a) SNP I C->T substitution, b) SNP 11 C->T substitution and c) 
SNP III C->T substitution (http: //ý\\, %". iicbi. nlt-n. nihj4ov/entrez). No additional 
unreported polymorphisms were detected. No individuals were identified carrying the 
previously reported SNP IV C->T or SNP V G-> A polymorphisms 
(http:, '/\\\\\\. ncbi. nlrn. nih. goventrez). All patients had C or 6 at these positions, 
respectively. Interestingly, the SNP database showed a very low frequency of these 
polymorphisms, with 2.7±1.3% only being carried in African/ Sub-Saharan Africans. It is 
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likely that these polymorphisms are restricted to certain ethnic groups. Therefore, no 
further studies were conducted in relation to the SNP IV and SNP V polymorphisms. 
In the present study, 40 West European subjects with generalized aggressive periodontitis 
were screened for three polymorphisms and 55% of them carried allele 2 (T) either as a 
heterozygote or homozygous for SNP 11. This was a similar frequency to that in the 
public database as shown in Table 4.3. The frequency of heterozygotes varied between 
different ethnic populations the lowest being in Sub-Saharan Africans (1%). A high 
proportion of the patients (65%) carried allele 2 (T), either as heterozygotes or 
homozygotes for SNP Ill. This frequency was higher than in the public database where 
an average frequency of 24 ± 25% for heterozygotes is reported. The frequency of 
heterozygotes in the database varies between different ethnic populations, the highest in 
European (48-571/o) and absent within Sub-Saharan Africans. However, in all cases 
periodontal status was unknown. There is no public data available for either the SNP 11 or 
SNP Ill polymorphisms relating to periodontal disease. To our knowledge, this is first 
identification of the SNP II or SNP Ill polymorphisms in patients with generalized 
aggressive periodontitis. 
Of the three identified SNPs, only SNP I (referred to -889) has been previously 
associated with periodontal diseases (Shirodaria et al., 2000) as a part of genetic 
susceptibility test for periodontal disease (Komman et al., 1997a). A high proportion of 
Caucasian patients (65%) carried allele 2 (T), either heterozygote or homozygous status 
for the SNP 1. However, according to published reports and the SNP database, carriage 
rates of SNP I alleles differ across populations. The frequency of carriage of allele 2 (T) 
varies with the highest being in Caucasians (35%) and lowest in Chinese and Japanese 
(6%, 9%, respectively). 
The association of the SNP Il and the SNP III polymorphisms with periodontal disease 
has not been studied previously. No studies have addressed the relationship of these 
SNPs to the risk of developing aggressive periodontitis. These polymorphisms has been 
reported in the SNP database (http: //www. ncbi. nim. nih. gov/entrezE). However, in all 
cases periodontal status was unknown. In the present study, the SNP 11 genotype 
frequency (number of individuals with either CT or TT genotypes) for the case and the 
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control population was 48.2%, 51.2%, respectively. This was a similar frequency to a 
public database, where SNP genotyping data is available from European, African 
American, Asian and Sub-Saharan African populations with an average heterozygote 
frequency of 44±15% (bttr): //www. ncbi. nlm. nih. ggv/entrez). However, there was no 
statistical difference regardless of smoking or ethnic background. In the previous chapter, 
when only Western European subjects with generalized aggressive periodontitis were 
screened, this heterozygote frequency was 55%. The SNP III allele 2 carriage rate 
(number of individuals with either CT or TT genotypes) for the case and the control 
population was 49.7%, 53.4%, respectively. These frequencies are higher than those 
reported in the public database where allele frequency is available from European, 
African American, Asian, and Sub-Saharan African populations with average frequency 
of 24 ± 25% at heterozygote status. However, there was no significant association 
between SNP III genotypes and aggressive periodontitis. 
The SNP I genotyping frequency (number of individuals with either CT or TT genotypes) 
for the control population was 49%. This was somewhat different than other reports 
where carriage rates vary considerably; 57.1% in European Caucasians (Hodge et al., 
2001), 41.5% in Brazilians (Moreira et al., 2007), of 45% in Caucasians (Rogers et al., 
2002), 32.5% in Italians (Scapoli et al., 2005). This may be due to variation between 
different populations. Indeed, when the data was stratified based on ethnic background, 
allele 2 was absent in Afro-Caribbeans while the frequency of the same allele in the 
control Caucasians was 31% and only 25% in Asians. 
The results presented here are in accordance with other reported studies that have 
observed no significant differences in the frequencies of the SNP 1 (-889) alleles or 
genotypes between a population of individuals with aggressive periodontitis and controls 
in Caucasians, African-Americans, Thai ethnic group, Central Americans, Brazilians 
(Anusaksathien et al., 2003; Brett et al., 2005; Gonzales et al., 2003; Hodge et al., 2001; 
Moreira et al., 2007; Rogers et al., 2002; Walker et al., 2000). Since there is strong 
linkage disequilibrium between IL-IA -889 SNP and IL-IA+4845 SNP in exon 5 (G to C 
transition), some of the studies have chosen to test the latter (Gore et al., 1998; McGuire 
and Nunn, 1999). Tai et al., (2002) examined the IL-IA+4845 SNP in a Japanese 
population with generalized aggressive periodontitis and found no significant difference 
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between patients and controls, although there was a significant association with the IL- 
IRN intron 2 variable numbers of tandem repeat genotype (Tai et al., 2002). However, 
there was no similar association with IL-IRN intron 2 variable numbers of tandem repeat 
genotype in a UK population (Parkhill et al., 2000). In addition, Liu et al., (2004) 
investigated the IL-IA+4845 SNP in a Chinese population with generalized aggressive 
periodontitis and found significant differences between patients and controls (Li et al., 
2004a). The contradictory results found in several studies may also be explained by 
differences in the diagnostic criteria used to define populations, the low number of 
subjects studied, and the characteristic of the controls such as age, unknown periodontal 
status. 
Several studies have used control subjects of unknown periodontal status (Brett et al., 
2005; Walker et al., 2000) and therefore likely to fail to find associations. The use of 
subjects of unknown periodontal status as controls involves the possibility of chance 
deviations, especially if there is no data available of the prevalence of studied 
polymorphisms. To avoid these problems, the control subjects included in the present 
study were periodontally healthy, ethnically mixed population with mean age of 33.7. In 
the study presented here the control subjects were matched for age. Control subjects not 
only belonged to dental hospital staff often used as control populations, since it is also 
possible that the high level of oral hygiene of the control population used in the previous 
studies may have masked any genetic predisposition to periodontitis. A relatively small 
sample size is one of the major reasons for the lack of reproducibility of case--control 
association studies and is a key limiting factor (Kinane et al., 2005). Current evidence 
from complex diseases (with large heritable components) indicates that the predicted 
odds ratios for many genes may be 1.5 or less (Cardon and Bell, 2001) and to identify 
such associations, as a general rule at least 100 cases and controls should be genetically 
characterized. In the present study, 150 cases and 117 controls were included and the 
sample size was adequate to be reasonably confident of concluding that there was no 
association with the IL-IA promoter polymorphisms and generalized aggressive 
periodontitis. 
it has been widely recognized that the two most important environmental risk factors for 
periodontal disease are smoking and the presence of specific bacteria (Barbour et al., 
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1997; Grossi et al., 1994). When smoking status was included in this thesis analysis as a 
covariate there was still no significant difference between the patient and control groups. 
Unfortunately, the control subjects were not well matched for smoking status. The low 
numbers of smokers (65% versus 19%) in the control group complicates interpretation of 
the data. In particular, smoking may affect both disease prevalence and severity. 
Therefore, due to the uneven distribution of smokers in present case and control 
populations, it may be reasonably assumed that part of the difference in the clinical 
condition between generalized aggressive periodontitis patients and periodontally healthy 
controls might be attributed to the detrimental impact of smoking on periodontal tissues. 
It should also be considered that a gene-environmental interaction between smoking and 
the IL-I polymorphisms has been recently reported (Meisel et al., 2004; Meisel et al., 
2002). Contrary to previous reports, in agreement with the data presented here smoking 
status was not found to influence the results (Hodge et al., 2001). Further studies are, 
therefore, needed to determine whether and to what extent differences in IL-IA 
polymorphisms may affect the onset and severity of the periodontal lesions in 
generalized aggressive patients with different smoking exposure. 
Given the complex biology of IL-I regulation and the extensive polymorphisms in the 
IL-I gene cluster, it is very likely that if IL-I genes influence disease, then a combination 
of specific alleles will be important rather than individual alleles. In the present study, 
between tested SNPs, only SNP III & SNP I gave strong LD with rý =0.74. A correlation 
between physical distance and the degree of LD in the IL-I cluster has been described 
(El-Omar et al., 2000). Since these two SNPs are -300bp away from each other, it is 
likely that they will be in a strong LD. In addition, the possibility of other polymorphisms 
that linked to the studied three polymorphisms may not be excluded. There is linkage 
disequilibrium across the IL-I cluster (Cox et al., 1998; Danis et al., 1995; Diehl et al., 
1999; Scapoli et al., 2005), and it is likely that combinations of specific alleles are more 
important rather than individual alleles (Chen et al., 2006). Therefore further studies will 
be required to make dense SNP typing within the IL-I gene cluster to fully determine an 
extended informative haplotype structure and its possible associations with aggressive 
periodontitis. 
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In contrast to aggressive periodontitis, several reports on chronic periodontitis indicate 
that the IL-IA genotype is significantly associated with this form of periodontal disease 
(Laine et al., 2001; McDevitt et al., 2000; Papapanou et al., 2001; Shirodaria et al., 
2000). However, other studies have failed to find an association between the IL-IA 
genotype and chronic periodontitis (Armitage et al., 2000; Lopez et al., 2005). In an 
interesting study, Socransky and co-workers have reported that IL-1 (allele 2) genotype 
appears to be associated with the levels of specific bacterial complexes with an increase 
in those containing periodontal pathogens (Socransky et al., 2000). Another study 
reported an interaction between IL-I genotype, P. gingivalis, smoking and age and stated 
that IL-1 genotype is a contributory but not essential risk factor for periodontal disease 
progression (Cullinan et al., 2001). Previously published reports, as well as the data 
presented here suggest that the nature of the underlying genetic susceptibilities may 
differ between aggressive and chronic periodontal disease. 
The main findings of the present study can be summarized as follows: a) no signiflcant 
difference in the prevalence of the carriage of either allele I or allele 2 in the three 
studied SNPs was observed between an ethnically mixed group of generalized aggressive 
periodontitis patients and a control group of periodontally healthy subjects; (b) No 
statistical difference was observed when comparing SNPs between the control and 
aggressive periodontitis groups, when only a Caucasian population was included in the 
analysis (c) When smoking status was included in the analysis as a covariate, the 
distribution of genotypes for three SNPs in smokers and non-smokers showed no 
statistical significance either in controls or in cases. d) Using the haploview program, it 
was possible to examine measures of linkage disequilibriurn (LD) and haplotype 
frequencies for those three SNPs. The analysis showed that SNP III & SNP I had the 
strongest linkage disequilibrium (12 =0.74), whereas SNP 11 & SNP III has the weakest 
LD. Nevertheless, these results in this chapter do not exclude a role for the identified 
SNPs in periodontal disease. Periodontal disease is a complex disease in which many 
interacting gene variants will act synergistically with confounding environmental factors 
such as smoking or bacterial flora could interact with the genotype. Therefore further 
studies will be required to make wide SNP typing within the IL-I gene cluster to fully 
determine an extended informative haplotype structure and its possible associations with 
aggressive periodontitis. 
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5.1 INTRODUCTION 
Whilst there is evidence for transcriptional regulation of IL-la gene expression (Alheim 
et al., 1996; Bailly et al., 1996a; Kawaguchi et al., 2003; Mori and Prager, 1996), 
polymorphisms in the promoter region of the IL-IA gene may be important for IL-la 
gene expression and protein production. There are four reports describing the functional 
importance of IL-IA gene polymorphisms. There is evidence that the C/T single base 
variation in the ILIA promoter (SNP I or previously called -889) was associated with 
fourfold increase of GCF IL-la protein levels in chronic periodontitis patients 
(Shirodaria et al., 2000). Furthermore, periodontitis patients carrying the IL-IA-889 T 
allele has been associated with significantly increased serum interleukin-6 or C-reactive 
protein levels (D'Aiuto et al., 2004). There is also evidence that the TT genotype of the 
-889 polymorphism significantly increased plasma levels of IL-lP (Hulkkonen et al., 
2000). However, it is not clear whether these promoter polymorphisms are of functional 
relevance in the regulation of IL-la transcription. A single in vitro study has tested the 
effect of SNP 1 (-889) C->T substitution on transcriptional activity (Dominici et al., 
2002) and reported that the SNP IT allele was associated with a 1.8-fold increase at basal 
transcription rate compared with a construct containing the allele C in PC IJ cel Is. 
There are a number of possible genetic associations between polymorphisms in the IL- 
IA gene and periodontal disease; however there is as yet no consensus on their functional 
importance. Therefore, the objective of the present study was to investigate if different 
bacteria interact with specific IL-IA promoter polymorphisms. Reporter gene assays 
were used to assess the relative importance of polymorphic variation in the proximal 
promoter region on IL-IA gene expression. Since more than 55% of patients carried 
studied SNPs, it is possible that presence of those polymorphisms may lead to altered IL- 
la expression levels and so contribute to aberrant or inappropriate immune function. 
Therefore, we investigated the effects of these alleles in a reporter assay perforined in 
LPS or periodontopathogen stimulated cell lines. Further examination of the SNPs was 
performed using the web-based transcription factor binding site identification program 
TFSEARCH. Analysis for transcriptional binding sites revealed that these SNPs were 
located in putative regulatory element sequences. Therefore they were chosen for 
replication in reporter constructs. 
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5.2 MATERIAL & METHODS 
5.2.1 Cloning strategy of the IL-IA promoter construct 
The 5'-flanking region of the human IL- IA gene was amplified by using a standard PCR 
protocol. The obtained PCR fragment was initially cloned into the plasmid vector 
pCR2.1-TOPO (TOPO Cloning Kit; Invitrogen). The amplified DNA fragments were 
cloned in a Kpnl- and BgIll-digested pGL3 basic plasmid vector (Promega) using Quick 
stick DNA ligase (Bioline, UK) to generate pGL3-IL-IA reporter constructs. The 
polymorphisms of interest were introduced into pGL3-IL-IA reporter construct by 
oligonucleotide-directed PCR mutagenesis (QuickChange Site-Directed Mutagenesis Kit, 
Stratagene. UK). Nucleotide sequences of the cloned DNA fragments were confirmed in 
each case by sequencing. 
5.2.2 Construction of IL-1 A Promote r/Luciferase Reporter Gene Plasmids 
The IL-1A promoter sequence was amplified by PCR using Bio-X-Act Polymerase 
(Bioline. London. UK). Commercially available genomic DNA (Human genomic DNA, 
Promega) with the homozygous genotype (C/C) was used as the template. To facilitate 
directional cloning of the PCR fragment into the pGL3-basic plasmid, a Kpnl site was 
introduced to the 3' end of the forward primer, and a BgIl I site to the 5' end of the reverse 
primer (Table 5.1). 
5'-Primer (forward) Y-Primer (reverse) 
TACGTTCCACTGTCCCTTCC ACCGCCAATGAAATGACTCC 
Annealing 
60 T 
G_AAGATCTTCTTAAGCCTGAGTCAGTCTTC GGGGTACCCCAAAACAATGCAAGGACCC 58C 
Table 5.1 The 5'-4 3' sequences ofthe sense (S) and antisense (AS) primer pairs are listed. Sites for KpnI 
and Bg1ll in the primers used for IL-1.4 cloning are underlined. 
5.2.3 Cloning into TOPO vector 
The PCR fragment was initially cloned into the plasmid vector pCR2.1-TOPO (TOPO 
Cloning Kit: Invitrogen) to make sub-cloning easier. After 5 minutes at room 
temperature, the ligation reaction was placed on ice prior to transforming competent 
cells. Detailed information about cloning protocol isprovided in the Appendix V-1. 
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The pCR TOPO vectors are ideal for general subcIoning. These vectors are ready for 
direct ligation of unpurified PCR products. The key to TOPO Cloning is the enzyme 
DNA topoisomerase 1, which functions as both a restriction enzyme and a ligase. Its 
biological role is to cleave and rejoin DNA during replication (Figure 5.1). 
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Figure 5.1 TOPO TA Cloning of PCR product (Invitrogen, UK) 
5.2.4 Cloning into pGL3 Vector System 
Lipfim complele 
Topowmerase I 
isreleased 
The promoterless pGL3-basic vector (Promega, Southampton, UK) containing a 
luciferase reporter gene was used for promoter constructs. The pGL3-Basic Vector lacks 
eukaryotic promoter and enhancer sequences, allowing maximum flexibility in cloning 
putative regulatory sequences. The pGL3 Vectors contain a modified coding region for 
firefly (Photinus pyralis) luciferase that has been optimized for monitoring 
transcriptional activity in transfected eukaryotic cells (Gould and Subramani, 1988) 
(Figure 5.2). 
The amplified fragments in TOPO were cleaved with Kpnl and Bg1ll (Appendix V-9). 
The products were run on I %agarose (w/v) gel in IX TAE, with I gg/ml ethidium 
bromide, in IX TAE running buffer. Gencruierlkb DNA Ladder (Fermentas, UK) was 
also run on the gel to determine the size of bands. Under a UV illuminator bands were 
cut out of the gel and transferred into sterile microfuge tubes and DNA bands were 
purified using a MinElute Gel Extraction Kit (Qiagene, Crawley, UK) according to 
manufacturer's intructions (Appendix IV-4) and ligated into the multiple cloning site of 
pGL3 basic vector which was cut with the same two enzymes. Ligation was perfon-ned 
using Quick stick DNA ligase (3U/pl, Bioline, UK) following a standard protocol 
(Appendix V-5). Following ligation, the vector was transformed into JM109 (Promega) 
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competent cells. Plasmid DNA was purified from bacterial cells using Qiagen chemistry 
and procedures (Qiagen, UK) as detailed in Appendix V-8. 
The plasmid DNA was sequenced using Big Dye Terminator chemistry (Applied 
Biosystems) in both directions using primers specific for the pGL3-basic luciferase 
expression vector (RV primer 3 and GL primer 2, Promega Corp, UK) (Table 5.2) to 
confirm that the haplotypes present in genomic DNA were faithfully represented. The 
chromatographs were recorded at a wavelength of 260nm. The sequencing results were 
compared with known human genomic DNA sequences using BLAST online search 
engine (http: //w%N, \N. ncbi. nim. nih. gov/BLAST) to confirm amplification and sequencing 
of the correct region (Appendix V- 16). 
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Figure 5.2 Schematic representation of generation of IL- IA reporter construct. The PCR fragment was 
initial 1ý cloned into the plasmid vector pCR2.1-TOPO and the amplified fragments were cleaved with KpnI 
and BgIll ligated into the multiple cloning site of pGL3 basic vector which was cut with the same two 
enzymes. pGL3-Basic vector circle map adapted from Promega, UK. 
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Primer name Primer Sequence 
RVprimer4 GACGATAGTCATGCCCCGCG 
GLprimer2 CTTTATGTTTTTGGCGTCTTCCA 
Table 5.2 Primers for the pGL3 basic vector sequence. 
5.2.5 Site-Directed Mutagenesis 
The polymorphisms of interest were introduced into ILIA construct plasmid by 
oligonucleotide-directed PCR mutagenesis (QuickChange Site-Directed Mutagenesis Kit, 
Stratagene, UK). This method is based on the capability of DNA polymerases (Pfu 
polymerase) to be used for the synthesis of entire plasmids, using a pair of completely 
complementary primers. The second key element of the procedure is the use of the 
restriction enzyme Dpnl. This enzyme only cuts DNA that is methylated or hemi- 
methylated (G m6 ATC) by the dam methylase of E coli. Thus, non-mutated parent DNA 
or mutants-wild-type heteroduplexes are inactivated by DpnI (Appendix V. 11). 
Mutagenic primers were designed using web-based Primer Design Program available 
online at http: //bioinformatics. org/12rimerx. Primers should be between 25 and 45 bases in 
length, the desired mutation should be in the middle of the primer with -10 -15 bases of 
correct sequence on both sides. The bases in red are the point mutation to be introduced 
(Table 5.3). 
5'- 3'Primer (Forward) Mutation and position 
GTTGCCTAAAGAGGAA I CAAGGTAAGCAGAAATG SNP 11 (RS3783521) C>T 
CAACTCACACAAGCTGTTTTCCTCCCAGATCC SNP III (RS1800794) C>T 
GTAACCAGGCAACATCATTGAAGCjCTCATATG SNP I (RS1800587)9 C>T 
Table 5.3 The primers for Site-Directed Mutagenesis. *The red bold letters indicate the introduced 
mutation. Numbers in column two refer to mutation and ID number. 
Briefly, two primers were prepared and simultaneously annealed and were extended 
using parental vector as template with Pfu polymerase using PCR as outlined in Table 5.4 
and 5.5.1 ýLl of Dpnl-treated DNA was transformed into DH5cc cells by a standard 
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transformation procedure (Appendix V. 11.3). The bacteria (I /10) were plated onto LB 
plates with arnpicillin. Plasmid DNA was isolated by miniprep and once mutagenesis was 
confirmed by sequencing, a large scale preparation was made. Mutated plasmid DNA 
was prepared with an Endo-free Maxiprep plasmid DNA isolation kit (Qiagen, UK). 
PCR Mix component Volume per 50 pL 
Plasmid DNA, 200 ng/pI I PI 
Polymerase buffer, lOx 50 
dNTPs. 12,5 mM I PI 
Mutant sense primer (1.25 ng) 2,50 
Mutant antisense primer (1.25 ng) 2,5 gl 
Sterile distilled water 370 
, ýfu pol ý merase, 2.5 U /gl I gi 
Table 5.4 Mutant Strand Sýnthesis Reaction 
Segment Cycles 
Step II 
Step 2 12 
Temperature 'rime 
95 C 30 seconds 
95 *C 30 seconds 
55 'C I minute 
68'C 7 minutes 
Table 5.5 RI -PUR cý cling parameters lor the Quick('hangc Site-Directed Mutagcnesis 
5.2.6 Transient Transfections and Reporter Gene Assays 
The process of introducing nucleic acids into eukaryotic cells by nonviral methods is 
defined as -transfection-. Using various chemical, lipid or physical methods i. e. 
electroporation. this gene transfer technology is a powerful tool for studying gene 
function in the context of a cell. Chemicals like calcium phosphate (Loytner et al. 1982) 
and DEAE-dextran (Vaheri and Pagano, 1965; McCutchan and Pagano, 1968) or cationic 
lipid-based reagents (Feigner et al. 1987) coat the DNA, neutralizing or even creating an 
overall positive charge to the molecule. Physical methods like microinjjection or 
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electroporation simply punch through the membrane and introduce the DNA directly into 
the cytoplasm. 
Firefly luciferase is widely used as a reporter gene for studying gene regulation. It is a 
very sensitive genetic reporter due to the lack of any endogenous luciferase activity in 
mammalian cells or tissues and the functional enzyme is created immediately upon 
translation (de Wet et al., 1987). Firefly luciferase is a 62,000 dalton protein, catalyzes 
ATP-dependent D-luciferin oxidation by oxygen into oxyluciferin with emission of light 
centered on 560 nm. 
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Figure 5.3 Schematic representation of reporter systems (adapted from Promega, UK). 
5.2.7 P-Galactosidase Assay 
The pSV-0-Galactosidase Control Vector is a positive control vector for monitoring 
transfection efficiencies of mammalian cells (Hall et al., 1983). The SV40 early promoter 
and enhancer drive transcription of the lacZ gene, which encodes the P-Galactosidase 
enzyme. The pSV-P-Galactosidase Control Vector can be co-transfected with DNA of 
interest and it provides cell extracts that can be assayed for both luciferase and 0- 
galactosidase activities. In this manner, we used the pSV-0-Galactosidase Vector 
(Promega. UK) as an internal control for transient expression assays. 
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5.2.8 Transient transfection into Monomac-6 cells 
Transient transfection of cultured cell lines with reporter plasmids is commonly used to 
determine the transcriptional activity of promoter sequences. Gene transfection is known 
to be cell type-dependent. However, gene transfection in monocytes has proven difficult. 
A number of non-viral gene transfer methods have been used to improve monocyte 
transfection, including calcium-phosphate precipitation (Thompson et al., 1999), DEAE- 
dextran (Mack et al., 1998) and electroporation (Klan and Steinhilber, 2003) and 
nucleofection (Martinet et al., 2003). Although the reasons underlying the resistance of 
monocytic cells to DNA transfection is not known precisely, it has been proposed that 
much of the exogenous DNA enters the cell via endocytosis, resulting in degradation of 
the DNA by abundant lysosomal nucleases. 
In this study, a range of gene transfection systems for Monomac-6 cells including a 
variety of liposomal agents (Fugene-Roche, Lipofectamine 2000, Invitrogen, UK), 
diethylaminoethyl (DEAE)-dextran (CellPhect Transfection Kit, Amersham Biosciences, 
UK) and nucleofection (Amaxa, UK) were used. Transfection efficiency of these systems 
was optimized and compared several methods for DNA-mediated cell transfection to 
determine which would be optimally applicable to Monomac-6 cells. 
pEGFP-N3 vector (BD Bioscineces Clontech, Oxford, UK) was used to express EGFP, 
the red-shifted, humanized Aequorea protein in the cell line as a transfection marker 
(Chalfle et al., 1994). pEGFP-N3 expresses green fluorescent protein under the control of 
a CMV promoter. The cell populations were photographed using a fluorescent 
microscope. 
Monomac-6 cells were refractory to transfection by liposomal agents or DEAE-dextran. 
Despite many attempts transfection rates were below 3% and the construct was not able 
to drive detectable levels of luciferase. The Nucleofector technology, a new 
electroporation-based gene transfer technique yielded higher transfection efficiency (-20- 
30%). However, this method was associated with higher cell death (70-80%). 
Monomac-6 cells were difficult to transfect. Thus, to substantiate this point, various cell 
lines from different origins including THP-1 monocytes, human primary fibroblasts, 
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HeLa and embryonic kidney cell line 293T were transfected with the IL-1 A-luciferase 
reporter plasmid or pEGFPN3 vector. 
5.2.9 Transient transfection into THP-1 cells 
A variety of established cell lines exist that exhibit monocytc-like characteristics 
including THP-1. Preliminary experiments (see in Chapter2) showed that the more 
mature monocytic cell line, Monomac-6 (Ziegler-Heitbrock et al., 1994) is more 
susceptible to bacterial stimulation than untreated THP-1 or U-937 cell lines (Schwende 
et al., 1996). However, the Monomac-6 cell line was difficult to transfect. Therefore, 
THP-1 cells were tested and transfected according to the published method (Warny et al., 
2000). 
Human monocytic THP-1 cells (American Type Culture Collection) were grown in 
RPMI-Glutamax supplemented with 10% FCS, in a humid atmosphere containing 5% 
C02. THP-1 cells were transiently transfected using the DEAE-dextran procedure. 
Briefly, 2X 107 THP-1 cells were suspended in I ml prewarmed Tris-buffered saline and 
incubated for 10 minutes at 37*C with 80 ILg DEAE-dextran (Pharmacia). For 
transfection, THP-1 cells were transfected with 5 gg DNA of the luciferase IL-IA 
reporter plasmid and co-tranfected with 2 gg of pSV-beta-galactosidase vector as internal 
control. Transfection was stopped by adding 25 ml Tris-buffered saline. After washing, 
cells were cultured for 48 hours before stimulation. After stimulation, for 6 hours with a 
range of periodontopathogens or LPS, THP-1 cells (2 x 106 cells per stimulus) were 
washed in PBS. Cell lysis and luciferase assay were performed using the Luciferase 
Assay System from Promega Corp. following the instructions of the manufacturer 
(Appendix V. 12). Luciferase activity was normalized for pSV-beta-galactosidase activity 
measured with P-galactosidase enzyme assay as detailed in Appendix V. 13. All 
transfection experiments were performed in triplicate. 
5.2.10 Transient Transfection into Human fibroblasts, HeLa and HEK 293T 
Human primary skin fibroblasts were kindly provided by Dr. Baki Akgul, Cancer 
Research UK, Institute of Cell and Molecular Science, Queen Mary, University of 
London. Fibroblasts derived from the normal skin of the healthy controls and the human 
derived epithelial-like cell line HeLa (ATCC, CCL-2) were chosen as much of the 
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previous analysis of the ILIA gene promoter had been performed in these cells 
(McDowell et al., 2005). In addition, the human embryonic kidney cell line HEK 293T 
was included for comparison since it is known to be easy to transfect. Cells were cultured 
in Dulbecco's modified Eagle's medium (DMEM, Gibco, UK) plus 10% fetal calf serum 
(FCS, Sigma, UK). 
Plasmids were transfected into cultured cells by using the FuGene 6 transfection reagent 
(Roche) per the manufacturees instructions. Before transfection, 2 x. 105 cells in 2 ml of 
medium were plated in a six-well plate overnight. On the day of the experiment all 
transfections were performed on 6 well plates with sub-confluent (60%) cells by the non- 
liposomal formulation method. Cells were transfected with 1.5 pg of reporter plasmid and 
0.5 pg pSV-beta-galactosidase internal control vector using FuGENE 6 reagent (Roche 
Molecular Biochemicals, Germany) at a 3: 1 ratio in a polystyrene tube, incubated at 
room temperature for 15 min and 100gi of complex were added to cells. Control 
transfections were performed using the equivalent amount of pGL3 empty vector 
(Promega). Cells were harvested at 48 hours post-transfection. Cells to be assayed for 
luciferase activity were lysed in reporter lysis buffer and cellular debris was removed by 
centrifugation. Cell lysates were assayed using the Luciferase Reporter Assay System 
(Promega) on a luminometer. Luciferase activity was normalized to P-galactosidase to 
standardize transfection efficiency. 
5.3 Statistical analysis 
The nonparametric Kruskal-Wallis test and Dunnett's multiple comparisons test were 
used to compare luciferase levels under the various experimental conditions, using 
GraphPad software. AP value less than 0.05 was considered statistically significant. 
5.4 RESULTS 
5.4.1 Cloning of pGL3-IL-IA reporter construct 
A fragment of the promoter region of the human IL-A gene was amplified by PCR using 
human genomic DNA as template and the forward primer with Kpn I site and the reverse 
primer with BgI 11 site (Figure 5.4A). The PCR fragment was initially cloned into the 
plasmid vector pCR2.1-TOPO (TOPO Cloning Kit; Invitrogen). Figure 5.413 shows an 
agarose gel picture for DNA of 15 colonies containing the IL-IA gene promoter 
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fragment. Five positive colonies (lanes 1-3-4-5-6) were selected for preparation of 
Minipreps and Maxipreps (Appendix V. 8). They were subjected to endonuclease 
digestion , kith Kpn I and Bgl 11. Following digestion, the DNA product was run on an 
agarose gel and the DNA band was excised as indicated by the red arrow (Figure 5.5A). 
Following digestion of the pGL3 basic luciferase with Kpn I and Bgl 11 and purification, 
these fragments were inserted into the pGL3 basic luciferase reporter as previously 
described in Materials and Methods (Figure 5.513). To analyse recombinants obtained 
after cloning of the IL-1A gene promoter fragment into the pGL3 basic vector, the 
plasmid DNA was then digested with Kpn I and Bgl 11 to release the insert from the 
vector (Figure 5.6). 
A) R"I'-P('R of-IL- IA gene promoter B) Screening after TOPO cloning 
1 11 
MEM 
H 1= 
2 kh 
ý'igure 5.4 X) RI -PCR ofa 2.1 kb promoter fragment of' I L- IA gcne. B) PCR products %%cre subcloned 
i nto the TOPO cloning N ector as detailed in Material & Methods. InN itrogen's I kb DNA ladder was used to 
estimate size of PCR products. 
A) TOPO Cloning 
( L11 I ficul I idder 
o kh 
I kh 
-4kh 
I iuure 5.5 1 he ucnornic 1ragnicin cI ca\ aue h,, restriction enz,, mes A) I hc 2.1 kh -, c no rnic 
fraLnicnt %ýaý', 
released bN Kpn I and BgI 11 digestion and separated from the vector backbone (2.7 kb). Since TOPO 
vector has also Bgl 11 cut site. 1.3 kb fragment (the lo%Nest band) was released from the vector backbone. 
GeneRuler lkb DNA Ladder (Fermentas. UK) B) Kpn I and Bgl II digestion of analysis of pGL3 vector 
(4.8kb). The DNA ýkas analyzed on 1% agarose gel containing ethidium bromide. Lanes: Lane 1. 
In% itrop-cn's I kb DNA Ladder: Lanes 3-5 are digested recombinant plasmid DNA. 
X76ý4321 Ladder 
B) pGL3 vector digestion analysis 
/ýizl II(; C kpll IýVI Ada 
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Figure 5.6 Analýsis of' rccornhinants obtained after cloning of' ll, -lA promoter fragment into the p0l.., 
Basic Vector. A 2. lkb fragment was generated by amplification with DNA polNmerase. 2 VI was then 
ligated into the pGL3 Basic Vector. The ligation reaction was transformed into JIM 109 Competent Cells. 
Plasmid DNA was isolated usingthe QlA Spin Miniprep Kit DNA (Qiagen. UK). To anahýse the generated 
construct. the plasmid DNA , %as then digested with Kpn I ad BgI 11 to release the insert trom the vector 
backbone (4-8 kb). The DNA was analyzed on 1% agarose gel containing ethiclium bromide. Lanes: lane 1. 
In\trogen's lkb DNA Ladder. lanes 2-9. -digested recombinant plasmid DNA. 
5.4.2 Identification of the mutated constructs 
The polymorphisms of interest were introduced into the ILIA gene reporter construct 
plasmid b-N oligonucleotide-directed PCR mutagenesis as detailed in Materials & I 
Methods. Direct sequencing of the mutated constructs showed that the bases at the SNP 1. 
SNP 11 and SNP III were all T (Figure 5.7A). The other sequences were exactly the same 
as the IL-IA gene sequence registered in Genebank (AF536338) indicating successful 
construction (Figure 5.713). 
. 
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Figure 5.7 D\ A sequence output sho, ýNing mutated all eles. A) Sequence ofthe mutated AI lele 2 (T) I L- IA 
constructs B) Sequence of the AI lele I (C) I L-I A construct 
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5.4.3 Allele-Specific Transcriptional Activity in THP-1 cells 
Since transfection efficiency in Monomac-6 cells was less than 3% and the construct was 
not able to drive luciferase activity, further studies were performed in THP- I monocytes. 
Figure 5.8 shows images of THP- I cells transfected with control pEGFPN3 vector which 
is CMV-driven green fluorescent protein. The enhanced green fluorescent protein 
(EGFP) was monitored by fluorescence microscope (blue light, 20 X objectives). 
Transfection efficiency was around 50%. 
- 
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Figure 5.8 RcprcNcnidti\ c im ag coCII IP- i cc I Is transfected \% ith contro I pl'(11'1'-, 3 \ ector. pl, ( iI- P-V 
ýector was used to express EGFP. the red-shifted. humanized Aequorea protein in the cell line as a 
transfection marker. The cell populations were photographed using a fluorescent microscope (X20 
objjectke. blue light). 
Basal IL- IA promoter activity (non-induced) 
The rates of transcription of the wild-type construct where all SNPs were set to the more 
common allele (allele 1, Q were compared with those containing allele2 (T). There were 
statistically significant differences in mean basal values of luciferase activity among the 
four reporter constructs tested. The non-parametric test showed F-value of 4.4. P<0.05, 
for overall variation among the basal levels of IL-IA CC and IL-IA TT construct 
luciferase activity. ANOVA with Dunnett's multiple comparisons test was then used to 
compare the results of each of the variant constructs with that of the CC. Only the SNP 1 
(-889) showed statistically significant differences (P<0.05) compared to IL-IA CC. 
Conversion of SNP 11 and SNP III from allele I (C) nucleotide to allele 2 (T) had no 
significant effect on transcription at the basal level (p=0.7516, p=0.1155. respectively) 
(Figure 5-9). Conversion of SNP I from allele I (C) nucleotide to aliele 2 (T) resulted in a 
significant decrease (34.01 ± 15.23% p=0.0045) in basal transcriptional activity. 
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Figure 5.9 Allele-specific transcriptional activity in THP-1 cells. Luciferase activities of constructs 
harbouring 2.1 k'b fragments with either the Allele I(C) or the Allele 2 (T) site (three independent 
experiments in duplicate) were compared in transfection studies using THP-1 cells. Luciferase levels are 
expressed as a percentage of control (Allele I(Q) after standardization for [beta]-galactosidase activity. 
Bars indicate mean values with standard error of mean. The statistical significance of differences was 
determined bý the non-parametric Kruskal-Wallis test and Dunnett's multiple comparisons. AP value less 
than 0.05 %\as considered statistically significant. 
Bacteria- induced IL- ]A promoter activity 
Since only SNP I allele 2 (T) had a significant effect on basal transcriptional activity, 
further investigations were done to test if bacterial stimulation could influence 
transcription of the construct carrying T allele of this SNP. All bacterial stimulants 
significantl) increased (-42%) transcriptional activity compared to the unstimulated one 
(P<0.05). Nevertheless. there were no significant differences between Ecoli LPS and 
tested periodontopathogens including A. actinomycetenicomilans, C. reclus, P. gingivalis 
and P. intermedia. SNP I allele 2 (T) showed significant decrease in transcriptional 
activity when compared with allele I (C) with or without bacterial stimulant (Figure 
5.10). Table 5.6 summarizes mean data (% decrease) from three independent 
experiments. 
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Figure 5.10 Allele-specific transcriptional activity in the presence of' bacteria in THII-I cells. A. 
actinonij, cetemcomilans (A. a). C. rectus (Cr), P. gingivalis Wg) and P. interniedia (PJ) and E. coli ITS 
(Ec) N%ere used as stimulant. Luciferase actiN ities of the constructs harbouring 2.1 kb fragments vvith either 
the Allele I(C) (IL-IWT) or the Allele 2 (T) (SNP I or rsI800587-889) site (one out ofthrce independent 
experiments ýOich \Nas performed in triplicates (Mean ± SD) ) were compared in transfection studies using 
THP- I cells. Fireflý luciferase activity was normalized to co-transfiected P-gal activity. **P<0.05 
Stimulant NS E. coh LPS A. a Cr Rg P. i 
% decrea: e in the activitv 41.51: f-15.04* 60.4±21.3* 46.8: 1: 16.6* 41.09±14.77* 45.43±28.6* 51.02 ± 12.1* 
Table 5.6 Allele-specific transcriptional activity in the presence or absence of bacteria in THP- I cells. A. 
actinontycetemcomilans (Aa). C reclus (C. r). P. gingivalis (P. g) and P. intei-media (N) and k,. coli LPS 
(E. c) ý%ere used as stimulant. Reduction in lucitlerase activity of the HAA gene reporter construct carrying 
SNP I ýNith either the allele I(C) or the allele 2 (T) site v,, as calculated from three independent experiments 
in triplicates. P<0.05. 
5.4.4 Allele-Specific Transcriptional Activity in Different Cell Lines 
Transcriptional activity of the IL-JA promoter constructs was compared in different cell 
lines of different origin to investigate potential cell type-specific control of gene 
expression. The transient transfection studies \vere conducted in embryonic kidney cell 
line 293T. human primary skin fibroblasts and HeLa cell line to explore whether the 
studied polymorphisms influence the basal rate of transcription of the I L- IA gene. 
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The human embryonic kidney cell line HEK 293T 
sis of IL-lA SNP 
Transfection efficiency was - 80% in the human embryonic kidney cell line HEK 293T 
when transfected with control pEGFPN3 vector (Figure 5.11). 
w 
m 
r 
Figure 5.11 Representative image of human HEK 293T transfected with pEGFP-N3 ýcctor. pl-. (Jl-'I'-N3 
Nector was used to express EGFP. the red-shifted. humanized Aequorea protein in the cell line as a 
transfection marker. The cell populations were photographed using a fluorescent microscope (X40 
objective. blue light). 
The rates of transcription of the wild-type construct where all SNPs were set to the more 
common allele (allele 1, C) were compared with those containing allele2 (T). As shown 
in Figure 5.12, conversion of SNP 11 and SNP III from allele I (C) nucleotide to allele 2 
(T) had no significant effect on transcription at the basal level (P>0.05). Conversion of 
SNP I from allele I (C) nucleotide to allele 2 (T) resulted in a significant decrease of 
basal transcriptional activity (a 14% decrease, p=0.03). The pilot data indicate that the 
C>T substitution at the SNP I of the IL-IA gene promoter decreases the basal 
transcriptional rate of IL-IA gene in the human embryonic kidney cell line HEK 293T 
(Figure 5.12). 
155 
Chapter 5: Functional Analvsis of IL-lA SNP 
8000 
7000 
.6 6000 
5000 
4000 
3000 
0 2000 
luuu 
0 
Allelel(C) 
* 
II I 
RS3783521(T) RS 1 800587(T) RS 1 800794(T) 
Figure 5.12 Allele-specific transcriptional activity in HEK 293T cells. Luciferase actk itics of' constructs 
harbouring 2.1 kb fragments with either the Allele I(C) or the Allele 2 (T) site (one experiment which was 
performed in triplicates ) were compared in transfection studies using in the human embr-, onic kidney cell 
line HEK 293T. Firefly luciferase activity was normalized to co-transfected [beta 1-galactosidase acti% ity. 
Bars indicate mean values with standard deviations. The statistical significance of ditTerences was 
determined bý the non-parametric Kruskal-Wallis test and Dunnett's multiple comparisons. APN alue less 
than 0.05 %N as considered statistically significant. *p<0.05 
HeLa Cell Line 
The transient transfection studies were also conducted in the HeLa cells. The transfection 
efficiency was more than 70% when transfected with control pEGFPN3 vector (Figure 
5.13). 
Figure 5.13 Rcprcscntati\c image of llcl, a cells transtected ), Nith pEGI: I"-N3 \cctor, PLGl: l'-N3 \ector 
\ýas used to express EGFP, the red-shifted. humanized Aequorea protein in the cell line as a transfection 
marker. The cell populations were photographed using a fluorescent microscope (X40 objective. blue 
light). 
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Any of the studied SNPs did not show significant transcription differences at the basal 
level by allele (P>0.05) in HeLa cells (Figure 5.14). The pilot data suggest that the C>T 
substitution at the position of all identified SNPs in the IL-IA gene promoter did not 
change the basal rate of transcription of IL-IA gene in the HeLa cells. 
1800 -1 
Allelel(C) 
1600 
1400 
1200- 
1000 - 
800 - 
600 - 
400 1 
200 
0 
R53783521(T) RS1800687(T) Rs I 800794(T) 
Figure 5.14 Allele-specific transcriptional activity in HeLa cells. Luciferase activities of constructs 
harbouring 2.1 kb fragments with either the Allele I(C) or the Allele 2 (T) site (one experiment which was 
performed in triplicates) were compared in transfection. studies using in HeLa cells. Firefly luciferase 
activity was normalized to co-transfected [beta]-galactosidase activity. Bars indicate mean values with 
standard deviations. The statistical significance of differences was determined by the non-parametric 
Kruskal-Wallis test and Dunnetfs multiple comparisons. AP value less than 0.05 was considered 
statistically significant. 
Human skinfibroblasts 
The studies were also carried out in human primary skin fibroblasts. Transfcction 
cff icicncy was - 40% when transfected with control pEGFPN3 vector (Figure 5.15). 
Conversion of SNP 11 and SNP III from allele I (C) nucleotide to allele 2 (T) had no 
significant effect on transcription at the basal level (P>0.05) (Figure 5.16). Conversion of 
SNP I from allele I (C) nucleotide to allele 2 (1) resulted in a significant decrease of 
basal transcriptional activity (42% decrease, p<0.05) (Figure 5.16). The pilot data 
indicate that the C>T substitution for SNP I of the IL-lA gene promoter decreased the 
basal rate of transcription of IL-IA gene in human primary skin fibroblasts. 
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Figure 5.15 Represcntatike ima,; c ol- hunian prirnarý skin tibroblasts transtectcd %kith pl-'(jlA'-N3 C. 3\ ector. 
pEGFP-N3 \ector \\as used to express EGFP. the red-shifted, humanized Aequorea protein in the cell line 
as a transfection marker. The cell populations were photographed using a fluorescent microscope (X20 
objecti\e. blue light). 
Boo * 
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Figure 5.16 Allele-specific transcriptional activity in human skin fibroblasts. Pilot results are presented 
from one experiment %Nhich was performed in triplicates (Mean ± SD). Firefly luciferase acti%it) was 
normalized to co-transfected, 6-ga/ activity to control for transfection efficiency. The statistical significance 
of differences %kas determined by the non-parametric Kruskal-Wallis test and Dunnett's multiple 
comparisons. AP %alue less than 0.05 -, vas considered statistically significant. 
5.5 TRANSFAC analysis for transcriptional binding sites for identified SNPs 
In the absence of experimental or epiderniologic evidence, the potential functional 
consequences of a SNP can be predicted using various bioinformatics tools to query large 
online databases and algorithms, namely "in silico" referring to modeling research 
conducted with computers only (Zhu et al., 2004). 
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Putative transcription factor binding sites were identified by the programme the 
TFSEARCH. The effect of different SNPalleles inthe IL-1A promoter may alter affinity 
of the DNA for trans-acting factors. Therefore using the TFSEARCH site which uses a 
transcription factor binding site profile database in the TRANSFAC databases 
(http:, ', /ýNvý". cbrc. ip, 'research), it is possible to make an assessment in silico of possible 
changes to promoter binding sites (Wingender et al., 2001). For each SNP within an 
aligned region, two allelic versions of a 20-bp alignment slice centred the SNP were 
searched for putative transcriptional binding sites using the TRANSFAC databases. 
Transcriptional binding sites with a relative matrix score exceeding 70% were selected. 
5.5.1 TRANSFAC analysis for transcriptional binding sites for SNP I 
Analysis of the database indicated that the presence of T creates a consensus binding site 
for the transcription factors Nkx-2, GATA-1-2-3, Pbx-1, CDP CR, CdxA. The C allele 
abolishes most of the consensus binding sites with the exception of CDP CR, CdxA. In 
addition, the presence of T in position -899 abolishes the consensus binding site for v- 
Myb and c-Rel (Figure 5.17). 
rs 1800587 (SNP 1) 
C 
I CCAGGCkACA CCAT7GAAGG C 
---------- > 
> 
< 
< ---------- 
entry ! score 
M00106 CDP CR 79.0 
X00100 CdxA 78.2 
M00227 v-Nyb 76.5 
M00053 a-Rel 76.0 
T 
1 CCAGGCLACA TCATTGAAGG C 
< 
-------- > 
---------- 
---------- > 
> 
------ > 
< ---------- 
< 
entry score 
M00101 CdxA 87.1 
M002ql Nkx-2.82.4 
M00075 GATA-1 61.6 
M00106 CDP CR 79.0 
M00096 Pbx-1 78.4 
M00100 Cdxk '78.2 
M00076 GATA-2 77.9 
M00096 Pbx-1 77.5 
M00077 GATA-3 75.3 
Figure 5.17 TRANSFAC analysis for transcriptional binding sites for SNP 1. Two allelic versions of a 20- 
bp alignment slice centred around the SNP were searched for putative transcriptional binding sites using 
the TRANSFAC databases. Transcriptional binding sites with a relative matrix score exceeding 70% were 
selected. 
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5.5.2 TRANSFAC analysis for transcriptional binding sites for SNP 11 
Analysis of the database indicated that the presence of T creates a consensus binding site 
for the transcription factors Pbx-1, GATA-1-2, Nkx-2, Tst-1, CDP CR, HSF2. The C 
allele abolishes most of the consensus binding sites (Figure 5.18) 
rs3783521 (SNP 11) 
C 
T 
1 TAAAGIGGLA CCkAGGTAAG C entry score 
< ----------- M00073 delt&E 79.1 
------------- > M00074 C-Ets- 78.7 
-------- > MOOOII Evi-i 76.8 
------------- > M00156 RORalp 76.4 
------- > MOO148 SRY ? 6.4 
< ------------ M00131 HNF-3b ? 5.1 
1 TAAAGAGGAA TCAAGGTAIG C entry score 
--------- > M00096 Pbx-1 86.3 
< ---------- M00075 GATA-1 83.? 
------------- > M00156 ROR&lp 82.9 
------- > M00148 SRY 81.8 
--------------- > M00133 Tst-1 81.2 
< ----------- M00073 deltaE 80.9 
< ---------- E00106 CDP CR '79.5 
< -------- E00241 Nkx-2.79.4 
------------- > H00074 C-Ets- 78.3 
-------- > ROO011 Evi-1 76.8 
---------- > M00147 HST2 7S. 6 
< ---------- M00076 GATA-2 75.5 
< ------------ M00131 HNF-3b 7S. 1 
< ---------- P100147 HST2 75.0 
Figure 5.18 TRANSFAC anal)sis for transcriptional binding sites for SNP 11. Two allelic versions of a 
20-bp alignment slice centered around the SNP 11 were searched for putative transcriptional binding sites 
using the TRANSFAC databases. Transcriptional binding sites with a relative matrix score exceeding 70% 
were selected. 
5.5.3 TRANSFAC analysis for transcriptional binding sites for SNP III 
Analysis of the database indicated that the presence of T creates a consensus binding site 
for the transcription factors HNF-3b, c-Ets, Tst-I, v-Myb, E217. In addition, the presence 
of T abolishes the consensus binding site for GATA-2 (Figure 5.19). 
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C 
T 
I ICACkIGCTG CTTTCCTCCC A 
< -------- 
< -------------- 
< ------------ 
---------- > 
< ---------- 
< ------- 
< ---------- 
> 
> 
-------------- 
1 ACACAAGCTG TTTTCCTCCC A 
< ------- 
< -------------- 
< ------------ 
< 
------------ > 
---------- > 
< -------------- 
< --------------- 
rs 1800794 (SN PI 11) 
entry 5core 
M00083 MZFI 77.4 
M00127 GATA-1 74.7 
MOOO01 MyoD 74.4 
M00053 c-Rel 74.4 
M00076 GkTA-2 73.5 
M00148 SRY 72.7 
M00075 GATA-1 71.0 
M00148 SRY 70.9 
M00217 USF 70.4 
M00159 C/EBP 70.0 
entry score 
M00148 SRY 86.4 
M00127 GATA-1 80.7 
MOOO01 XyoD 79.1 
M00083 MZF1 77.4 
M00131 HNF-3b 75.1 
M00053 c-Rel 72.7 
M00074 c-Ets- 72.7 
M00148 SRY 70.9 
M00133 Tst-I 70.8 
M00217 USF 70.4 
M00050 E2F 70.1 
M00227 v-Kyb 70.1 
Figure 5.19 TRANSFAC analysis for transcriptional binding sites for SNP 111. Two allelic versions of a 
20-bp alignment slice centered around the SNP III were searched for putative transcriptional binding sites 
using the TRANSFAC databases. Transcriptional binding sites with a relative matrix score exceeding 70% 
were selected. 
5.6 DISCUSSION 
The objective of the present study was to test the hypothesis that the IL- IA gene contains 
physiologically relevant polymorphisms that influence IL-IA gene regulation. There is 
evidence for transcriptional regulation of IL-IA gene expression (Alheim et al., 1996; 
Bailly et al.. 1996a; Kawaguchi et al., 2003; Mori and Prager, 1996). In order to 
investigate whether the I L- IA promoter SNPs were associated with functional regulation 
of IL-IA expression, firefly luciferase reporter constructs were madeand studied in vitro. 
Studies described in this thesis show that Monomac-6 cells are difficult to transfect. This 
is consistent with previous reports (Martinet et al., 2003). To confin-n that this construct 
was not intrinsically problematic, various cell lines including THP-1 monocytes, human 
skin fibroblasts, HeLa cells and 293T embryonic kidney cell line were transfected with 
the IL-IA-luciferase reporter plasmids. High efficiency (>60%) transfection was possible 
in all these cell lines. The cell lines were chosen to represent a variety of human tissues 
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types and represent a balance between choosing cell lines with different tissue origins and 
robustness of the assay conditions. The activity of promoters varied widely between cell 
lines. This in part is likely to represent quantitative differences in the transfection 
efficiencies of different cell lines. There were also qualitative differences in the responses 
of the cell lines to individual promoter haplotypes. Although one can question the 
specific choice of cell lines used, this observation supports the importance of using 
multiple cell lines in this analysis. 
Using the other cell lines it was possible to compare the reporter constructs carrying 
different polymorphisms. Firstly, only SNP I allele 2 (previously reported as -889) 
showed functional activity compared with allele I (see Figure 5.10). These transfection 
studies provided evidence that the SNP I allele 2 (T) is associated with a decreased basal 
transcription rate compared with constructs harbouring the allele I (C). Secondly, 
TRANSFAC databases analysis indicated that the presence of T in position -899 
abolishes the consensus binding site for v-Myb and c-Rel transcription factors. The 
previous studies show that c-Rel proteins act as transcription factors and share extensive 
homology with the p50 and p65 subunits of the NF-O complex (Ghosh et al., 1990; 
Hansen et al., 1994). NF-KB regulates a wide variety of inflammatory and 
immunoregulatory genes, and together with other factors has been reported that it is a 
positive trans-acting factor in controlling IL-2 gene transcription (Tan et al., 1992). 
Transactivation of the IL-Ia promoter in T cells by the HTLV-1 Tax protein has been 
described suggesting that NF-iffl may be involved in the transcriptional regulation of IL- 
Ia (Mori and Prager, 1996). The NF-kappa B/rel family of transcription factors has also 
been shown to regulate IL-IP promoter activity (Hiscott et al., 1993). NF-kappaB/Rel 
transcription factors have also been implicated in the differentiation of monocytes to 
macrophages or dendritic cells (Baltathakis et al., 2001). Differences in the binding 
affinity of c-Rel transcription factors may be the basis for the observed differences in 
transcriptional activity of the two alleles. However, the effects of SNPs in the binding 
site are unlikely to be simple. While some binding sequence alterations made by SNPs 
may totally interrupt gene expression, others may only influence the level of expression. 
Considering that gene transcription is a complex process involving many transcription 
factors, a single position change may not influence all of them. Therefore, the fact that 
more SNPs are located in the transcription factor binding sites may demonstrate a 
differential requirement for gene expression under a given condition. 
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Since only SNPI allele 2 (T) had a significant effect on basal transcriptional activity, 
further investigations were done to test if bacterial stimulation could influence 
transcription of the construct carrying T allele of this SNP. Exposing transfectants to 
bacterial stimuli elevated basal luciferase activity, nevertheless, there were no significant 
differences between E. coli LPS and tested periodontopathogens including A. 
actinomycetemcomitans, C rectus, P. gingivalis and P. intermedia. The presence of SNP 
rsI 800587 allele 2 (T) decreased significantly luciferase expression driven by the IL-IA 
promoter in both un-stimulated and stimulated THP-I cells suggesting a role for IL-IA 
rs1800587 polymorphism in the complex regulation of IL-lA gene transcription. The 
relationship between IL-IA genotype and specific bacteria is unknown. While it is 
conceivable that cytokine polymorphisms may result in a non-protective immune 
response, thus allowing specific pathogens to persist, the results of the present study 
demonstrate that the presence of the IL-IA polymorphic allele is associated with a 
decreased stimulated transcription rate. Socransky and co-workers have reported that IL- 
I (allele 2) genotype influences the levels of specific bacterial complexes with an 
increase in those containing periodontal pathogens (Socransky et al., 2000). Another 
study has also shown an interaction between IL-I genotype, P. gingivalis, smoking and 
age (Cullinan et al., 2001). In these studies, the IL-1 genotypes were defined by either 
presence of either IL-IA (-899) or IL-lB (+3953) and no genotyping data was given for 
each gene, therefore it is difficult to compare these results with IL-IA SNP 1 (-889) 
alone. 
As mentioned in Chapter 1, a few studies have suggested a functional effect of the 
polymorphism SNP 1 (-899). Notably, carriage of allele 2 (T) in the (-889) locus resulted 
in an almost three fold increase of interleukin-la protein levels in a small group of 
chronic periodontitis patients (Shirodaria et al., 2000). Interestingly, differences in IL-la 
in patients according to IL-lA genotype were higher in non-smokers (four fold) than in 
heavy smokers (2-8 fold), emphasizing the possible role of confounding factors in 
cytokine regulation. Furthermore, periodontitis patients carrying the SNP IT allele had 
significantly higher serum levels of interleukin-6 or C-reactive protein concentrations 
than subjects carrying C allele (D'Aiuto et al., 2004). There is also evidence that the Tr 
genotype of the SNP I polymorphisin significantly increased plasma levels of IL-lP 
(Hulkkonen et al., 2000). 
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A single in vitro study has tested the effect of SNP 1 (rsl800587) C->T substitution on 
transcriptional activity in reporter gene assays (Dominici et al., 2002). In this study, the 
SNP I (T) allele was associated with a 1.8-fold increase at basal transcription rate 
compared with a construct containing the allele C in PCIJ cells (human pancreatic cell 
line). The same TT genotype was also associated with significantly higher (five fold) 
levels of secreted IL-la in compared with the CC genotype when PMBC cells were 
stimulated with LPS for 3 hours. Interestingly, no differences were observed after 6 hours 
of cell stimulation between the two genotypes. However, the effect on IL-la mRNA 
level was small, showing only a 5% difference between the two genotypes in 
nonstimulated cells. It was concluded that the substantial difference in the protein level 
might be due to differences in the instability of the mRNA as a consequence of the 
polymorphism irrespective of the promoter activity. 
These results are in contrast to the findings of this thesis in that the SNP I (T) allele is 
associated with a significant decrease in the basal or stimulated rate of IL-la 
transcription in vitro in THNI cells. The differences between the previous study and the 
present findings may reflect the different cell lines employed. PCIJ is a transformed cell 
line whilst monocytic cells are more likely to be involved in the inflammatory processes. 
Cell-type specific differences may be the results of differential expression of essential 
transcription factors or underlying differences in transcriptional control. Since different 
cell types use different receptors, signalling pathways and transcription factors, it is 
possible that the same SNIs may show tissue-specific differences in function (Knight, 
2005). Indeed, the pilot data in the present study suggest that the SNP I C>T substitution 
has no effect on the basal rate of transcription of the IL-IA gene in HeLa cells. In 
addition, it is also important to consider the other possible reasons for the differential 
expression including the effect of construct size. The previous study (Dominici et al., 
2002) cloned a 1.4 kb promoter region of the IL- IA gene compared to 2.1 kb used in this 
thesis. Expression levels may differ between long and short constructs (McDowell et al., 
2005). The present results suggest that the regulation of ILIA gene transcription may be 
cell type-specific, which may be physiologically relevant when considering different 
disease processes localised to different tissues or organs. 
The functional significance of the SNP Il C->T and the SNP III C->T are unknown. The 
physiological significance of those polymorphisms has not been directly investigated. A 
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recent study investigating the relationship of polymorphisms in the IL- Ia gene to the risk 
of osteoporosis found no association between fracture risk or bone turnover and carriage 
of the alleles of the SNP III polymorphism (Knudsen et al., 2007). There have been no 
published studies of the effect of these polymorphisms on transcriptional activity using 
reporter gene assays. TRANSFAC data suggests that the polymorphisms could alter 
transcription factor binding sites. However, in the present study, no effect of the 
polymorphic sites was seen in assays of transcription of the IL-IA promoter when tested 
in vitro in THP-1, human skin fibroblasts or HeLa cells. The effects of polymorphisms in 
the binding site are unlikely to be simple. Considering that gene transcription is a 
complex process involving many transcription factors, a single position change may have 
little effect. Use of the TRANSFAC database is limited by considering only a subset of 
transcription factors and analysis suggest the role possible candidate factors play to 
explain observed functional differences. It seems better to test whether polymorphisms 
are functional or non-functional on the basis of standardised reporter gene assays. To 
understand further differential transcriptional activity of individual alleles in the reporter 
assays, an electrophoresis mobility shift assay using specific antibodies for these 
transcription factors would be a logical method. Overall, the data presented in the present 
study indicates that the SNP I polymorphism affects the transcriptional levels of IL-IA 
gene at least in the reporter system. 
It should be emphasized that whereas the data presented in this thesis are compatible with 
the above interpretation, not all components of this hypothesis have been tested 
experimentally. Firstly, I have not tested the effects of the identified polymorphisms on 
IL-la mRNA or protein levels in response to bacterial stimulants in human monocytes 
derived from subjects genotyped for the identified polyrnorphisms. This could answer 
functional effects of the identified polymorphisms at the translational level. Periodontal 
disease is considered as a complex disease in which many interacting gene variants act 
synergistically with environmental factors, as noted earlier, confounding factors such as 
smoking, a pathogenic flora contribute could exert an influence in addition to the 
genotype. Secondly, it is likely, that polymorphisms would interact with environmental 
factors in order to confer susceptibility to disease. It can not be formally excluded that 
other polymorphisms, linked to the SNP I polymorphism might influence the expression 
of IL-la. There is linkage disequilibriurn across the IL-1 cluster (Cox et al., 1998; Danis 
et al., 1995; Diehl et al., 1999; Scapoli et al., 2005), and it is likely that a combination of 
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specific alleles is more important rather than individual alleles (Chen et al., 2006). 
Further studies are needed to understand haplotype structure between identified 
polymorphisms and also test the influence of haplotype context on the molecular function 
of a polymorphism in a gene promoter. 
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CHAPTER6 
Modulation of IL-1ct in Periodontal Diseases by 
Doxycycline 
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6.1 INTRODUCTION 
IL-Ia plays a critical role in stimulating the innate host response and this capacity 
prepares the host to defend itself against bacteria (Glaccum et al., 1997). However, the 
resulting inflammation, while effective in protecting the host from being overrun by 
bacteria, can cause collateral damage. If IL-la has a pivotal role in the progression of 
periodontitis then pharmacological inhibition of IL-la activity may be of therapeutic 
benefit to patients with periodontitis. There are several potential targeting strategies 
which could be employed for reducing activity at the stage of transcription, during 
translation or synthesis. Conceptually, this can be accomplished with use of 
natural inhibitors such as IL-I receptor antagonists, soluble receptors to IL-I 
or monoclonal antibodies (Carteron, 2000). 
drugs that can inhibit the synthesis and/or release of IL-la or increase the 
synthesis of endogenous inhibitors of IL-la 
IL-la is regulated in vivo by soluble IL-I receptor antagonist (IL-IRa), a 22kD 
glycosylated protein (Dower et al., 1992; Harrison et al., 1990). However, IL-111a is not 
the only endogenous inhibitor of IL-la. The IL-I family receptors also include IL-IsR-I 
and IL- I sRlI generated by proteolytic cleavage of their membrane-anchored counterparts 
(Colotta et al., 1994; McMahan et al., 1991). Soluble cytokine receptors have been used 
in several inflammatory diseases to antagonize IL-I responses (Opal and DePalo, 2000). 
Treatment of periodontal disease in a model of Macaca fascicularis with soluble 
receptors including IL-I receptor type I plus soluble TNF-a receptor was shown to 
inhibit progression of inflammation in the alveolar bone and limit the destructive effects 
of periodontal pathogens as well as osteoclast activity (Assuma et al., 1998; Dclima et 
al., 2001; Graves et al., 1998). Compared with control animals, intrapapillary injection of 
soluble receptor antagonist of IL-I and TNF-a reduced 80% of the inflammatory cell 
numbers and alveolar bone loss by 50% as measured by computer-assisted densitometric 
image analysis (Assuma et al., 1998). Since these studies used a combination of IL-I and 
TNF inhibitors, the precise role of IL- I was not defined. Moreover, a recent study showed 
that treatment of periodontal disease using human soluble IL-I receptor type I as a 
specific inhibitor (slL-IRI) alone is also highly effective in reducing progression of 
inflammation (by 50-70%), loss of attachment (by 30-70%) and alveolar bone (by 60- 
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65%) in a Macacafascicularis primate model (Delima et al., 2002). Those studies not 
only further support the pivotal role of IL-I in periodontal disease progression but also 
suggest that reduction in IL-1 activity by specific inhibition could reduce disease 
progression. However, the modulation of IL-I(x by soluble receptors is still limited to in 
vitro or preclinical animal periodontitis models and it remains to be tested in a clinical 
environment. 
A second possible approach is the pharmaceutical inhibition of IL-Ia as adjunctive or 
alternative therapy for periodontal disease. Several anti-inflammatory drugs and 
antibiotics have been investigated as adjuncts to mechanical non-surgical periodontal 
therapy. The only systemic host modulatory agent currently approved for adjunctive use 
with nonsurgical periodontal procedures, however, is Periostat (20mg doxycycline 
hyclate) (Caton, 1999). Doxycycline, a member of the tetracycline family, is a broad- 
spectrum antibiotic effective against a wide range of gram-positive and gram-negative 
organisms. Doxycycline has been studied extensively in several diseases including 
osteoarthritis, rheumatoid arthritis, adult periodontitis that are characterized by high 
levels of pro-inflammatory mediators and protease activities (Brown et al., 2004; 
Lamparter et al., 2002; Lee et al., 2004; Preshaw et al., 2004b). In each of these 
disorders, the beneficial effects of doxycycline are not due to their antimicrobial effects 
but rather their efficacy in inhibiting pro-inflammatory and protease activities. 
6.2 Cytokine modulation by Tetracyclines 
Since cytokines are involved in the destruction of both periodontal tissue and alveolar 
bone and they can stimulate increased production of MMPs (MacNaul et al., 1990), 
another non-antimicrobial mechanism by which the Tetracyclines may inhibit tissue 
breakdown could be through inhibition of cytokines. There is evidence to support 
inhibition of extracellular matrix breakdown by Tetracyclines through inhibition of 
cytokines (D'Agostino et al., 2001; Kirkwood et al., 1999; Krakauer and Buckley, 2003; 
Milano et al., 1997; Sandier et al., 2005; Shapira et al., 1997; Shapira et al., 1996). In 
addition, processing of cytokines such as TNF-a can be mediated by matrix 
metalloproteinase enzymes (Gearing et al., 1994). A recent study reported that 
antagonists of IL-1 or TNF-a alone or in combination down regulated MMP-1, MMP-3 
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and MMP-13) expression in cultures of cartilage from osteoarthritic patients (Kobayashi 
et al.. 2005). 
In addition to in vitro and animal studies, there are also studies which have monitored 
GCF levels of proteolytic enzymes or cytokines in clinical trials of non-surgical 
periodontal therapy with adjunctive subantimicrobial dose doxycycline (SDD) (Choi et 
al.. 2004. Erningil et al.. 2004; Golub et al., 2001; Gurkan et al., 2005). The findings of 
these studies suggest that a combination of SIDD with non-surgical therapy improves 
clinical parameters of periodontal disease and decreases GCF inflammatory mediator 
levels. 
6.3 IL-Ict Modulation by Tetracyclines 
6.3.1 In v, itro and animal evidence of modulation of IL-Ia by Tetracyclines 
Tetracyclines, especially doxycycline are able to exert a range of biological activities 
including differential inhibition of the activity of members of the matrix 
metal loproteinase (MMP) family, inhibition of MMP synthesis, inhibition of cytokine 
synthesis, inhibition of activated B cell function, inhibition of nitrous oxide synthesis by 
lipopolysaccharide activated macrophage. However, data on modulation of IL-Ict 
production by doxycycline is limited. 
INFLAMMATION 
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(Bone formation, osteoclast function) 
Figure 6.1 A schematic representation of non-antimicrobial activity of tetracyclines and their chemically 
modified counterparts 
it is generally considered that metal chelation is key to their non-bactericidal properties 
(Golub et al., 1987; Golub et al., 1995; Greenwald et al., 1987). However, some evidence 
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has suggested that inhibition of proteases by doxycycline is an indirect result of 
inhibiting the secretion of IL-I (Rawdanowicz et al., 1994; Shlopov et al., 2001; 
Solomon et al., 2000). A recent study investigated the effects of doxycycline in an 
experimental murine dry eye model and showed that doxycycline decreased mRNA 
levels of IL-la as well as IL-10 and TNF-a in the corneal epithelium (De Paiva et al., 
2006). 
6.4 Doxycycline as direct catalytic inhibitor of MMPs 
Doxycycline has been shown to inhibit MMP activity and alter pro-collagenase and 
collagenase conformation by binding to their Ca? + (Golub et al., 1995; Smith et al., 1996). 
This was the first mechanism proposed for the ability of tetracyclines to inhibit activity 
of metalloproteinases. This mechanism is supported by elimination of the ability of 
tetracyclines to inhibit collagenase activity in vitro when excess Ca2+ or excess Zn 2+ is 
present (Golub et al., 1983; Yu et al., 199 1). 
Although tetracyclines could directly inhibit protease activity by binding diavalent 
cations, there is reason to believe that other mechanisms may also be involved. The 
interaction kinetics of MMP-8 with doxycycline suggest that doxycycline acts as a non- 
competitive inhibitor of collagenase in vitro (Sorsa et al., 1994). In addition, the 
chemically modified tetracycline (CMT-5) which lacks a Ca2' or Zný' binding site can 
inhibit the oxidative activation of pro-MMP (Sorsa et al., 1998). Tetracyclines can also 
inhibit activation of MMPs by scavenging reactive oxygen intermediates such as HOCI 
generated by peripheral blood neutrophils (Gabler and Creamer, 1991). This property of 
tetracyclines appears not to be dependent on their metal-ion binding properties. 
Moreover, inhibition of the proinflarnmatory secretory enzyme phospholipase A2 
(sPLA2) by Tetracyclines cannot be blocked by addition of excess calcium (Pruzanski et 
al., 1992; Pruzanski et al., 1998). A recent study showed that cysteine proteinase 
inhibition by doxycycline was not affected by the presence of calcium (Imarnura et al., 
2001). These findings suggest that the inhibitory activity of tetracyclines cannot be 
completely accounted for by the ability to bind metal-like ions. Their exact mechanisms 
of action independent of chelation are still unclear. 
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The use of tetracyclines and their analogues in the treatment of periodontal diseases has 
been reviewed in several articles (Golub et al., 1998; Preshaw et al., 2004a; Rifkin et al., 
1993; Vernillo et al., 1994). Tetracyclines, mainly doxycycline, tend to be highly 
concentrated in the gingival crevicular fluid at levels 5-10 times greater than those found 
in serum (Pascale et al., 1986). In addition, the gradual release of doxycycline from teeth 
in active form also may contribute to increased exposure, and maintain effectiveness 
during the post-treatment period (Baker et al., 1983). Doxycycline has a long half-life, 
which makes convenient twice-a-day dosing possible. Subantimicrobial doses of 
doxycycline have no antimicrobial activity and therefore do not produce any microbial 
resistance after prolonged use (Kornman and Karl, 1982; Thomas et al., 1998). 
The concentrations required to achieve the direct inhibition of MMP activity by 
doxycycline are higher than clinically achievable levels (Gilbertson-Beadling et al., 
1995). This may imply that subantimicrobial doses of doxycycline may decrease MMP 
activities due to indirect mechanisms such as cytokine inhibition. Little work has been 
carried out on the effect of doxycycline on monocytes which are involved in cell 
mediated immune responses, including IL-la production. Therefore, the aims of this 
study were to identify the mechanism by which doxycycline modulates cytokine 
production, including IL- I a. More specifically these studies aimed to test; 
" the regulation of IL- Ia production in monocytes by doxycyc line 
" the effect of metal ions on IL-la production and if doxycycline regulates cytokine 
response via the chelation of metal ions 
" the specificity of the response to doxycycline in IL-la and other cytokines 
6.5 MATERIALS & METHODS 
6.5.1 Bacterial stimuli and materials 
Bacterial supernatant was obtained from cultures of A. actinomycetemcomitans Y4. 
Cultures were grown in appropriate growth medium (see Table 2.1) in an anaerobic 
chamber containing an atmosphere of 80% N2,10% H2, and 10% C02. Cultures were 
grown to approximately 5xI 07 colony forming units/nil and harvested by centrifugation 
at 100OOg for 15 min at 4*C. The culture supernatants were collected, filter-sterilized and 
stored at -80"C until used. The supernatant of bacterium was directly diluted in culture 
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medium to final dilutions of 1: 250, a concentration that has been shown to induce 
cytokine production in the absence of cell toxicity (Bostanci et al., 2006). LPS from the 
non-oral bacterium Escherichia coli 026: B6 (Sigma-Aldrich, UK) was used as a positive 
control. Doxycycline was dissolved in distilled water (stock of 50 mg/ml) and filter- 
sterilized and stored at -80T. Doxycycline, when used, was added simultaneously with 
bacterial stimuli. Other chemicals including ammonium tetrathiomolybdate and copper II 
sulphate were also purchased from Sigma-Aldrich, UK 
6.5.2 Cell culture 
Peripheral blood was obtained from healthy individuals by venous puncture and collected 
in EDTA vacutainers (Becton Dickinson). All participants signed a written consent form. 
Protocols for the study were approved by the East London and City Health Authority 
London Research Ethnics Committee. Human peripheral blood mononuclear cells 
(PBMQ were separated by density gradient centrifugation using Ficoll-Paque Plus 
(Amersharn Biosciences, UK) according to the manufacturer's instructions. The cells 
were washed twice with PBS containing EDTA (2mM) and bovine serum albumin (2%), 
pH 7.3. Cell viability was determined by Trypan blue exclusion. PBMC count was 
performed with a haernocytometer and processed for magnetic labelling. 
The Monocyte Isolation Kit 11 (Miltenyibiotec, Germany) was used to isolate 
unstimulated monocytes from human peripheral blood mononuclear cells (PBMC) using 
an indirect magnetic labelling system. The purity of isolated monocytes was evaluated by 
flow cytometry on a FACScan flow cytometer (Becton Dickonson) using a CD14 FITC- 
conjugated antibody. Purified monocytes were re-suspended in RPMI-Glutamax (Gibco 
BRL Life Technologies, UK) supplemented with 10% heat-inactivated fetal bovine 
serum (Bio-Whittaker, Maryland). The myelomonocytic cell lines, Monomac-6 and 
THP-I were obtained from the German Collection of Microorganisms and Cell Cultures 
(Braunschweig, Germany). MonoMac-6 cells were cultured in RPMI-Glutamax (Gibco 
BRL Life Technologies, UK) supplemented with 10% fetal bovine serum, 1% non- 
essential amino acids (Gibco BRL), 1% sodium pyruvate (Gibco BRQ and 9Ag/ml 
bovine insulin (Sigma-Aldrich, UK). THP-1 cells were cultured in RPMI-Glutamax 
(Gibco BRL Life Technologies, UK) supplemented with 10% fetal bovine serum. The 
assays were perforined with cells at a density Of IX106 cells per ml. 
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6.5.3 ELISAs for cytokine production 
The cells were seeded in 96-well microtitre plates at density Of IX106 cells/ml and 
incubated in the presence of either 10 ng of LPS or bacterial supernatant from A. 
actinomycetemcomitans Y4 (A. a) with or without doxycycline at various concentrations 
(2.5 pg/ml to 50 jig/ml) for 6 hours at 37'C in a 5% C02 atmosphere. In some 
experiments, cells were preincubated with doxycycline for I hour and before exposure to 
bacterial challenge. To assay cytokine production, the cell free culture supernatants were 
collected by centrifuging at 1000 rpm for 5 minutes and stored at -80'C until the cytokine 
assays were performed. The concentrations of TNF-a, IL-1a, IL-10 and IL-6, IL-8 were 
determined by an enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer's protocols. The absorbance at 
450 nm was read using a microplate reader (Model 680, Bio-Rad Laboratories) with a 
wavelength correction set at 570nm. A standard curve was generated using a four 
parameter logistic (4-PL) curve-fit (Microsoft Office Excel) for each set of samples 
assayed. The values of the samples were assigned according to the standard curve. 
For further analysis, levels of a number of cytokines were assessed in the culture 
supernatants using multiplex immunoassays. The Proteoplex 16 well Human Cytokine 
Array Kit, Merck Biosciences, UK) was used forthe assessmentof TNF-a, IL-la, IL-1p, 
IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IFN-y and GM-CSF. The minimum detectable 
concentration in this assay was 5 pg/ml for each analyte. 
6.5.4 Transfection and luciferase reporter gene assays 
Since Monomac-6 cells were resistant to transfection, THP-1 cells were used. 2x 107 
THP-1 cells were suspended in I ml prewarmed Tris-buffered saline and incubated for 10 
minutes at 37*C with 80 pg DEAE-dextran (Pharmacia). For transfection, THP-1 cells 
were transfected with 5 pg DNA of the luciferase IL-1A reporter plasmid or 1.5 Pg of a 
luciferase reporter pIasmid containing five sequential NF-O binding sites upstream of a 
minimum promoter element, NF-rB-Luc (PathDetect NF-1cB Cis-Reporting System, 
Stratagene, UK). 2 pg of pSV-beta-galactosidase vector (Promega, UK) was transfected 
as an internal control. Transfection was stopped by adding 25 ml Tris-buffered saline. 
After washing, cells were cultured for 24 hours before stimulation. THP-1 cells (2 x 106 
cells per stimulus) were stimulated with culture supernatant of A. actinomycetemcomitans 
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or E. coli LPS for 6 hours. After stimulation, luciferase assay was performed using the 
Luciferase Assay System (Promega, UK) following the instructions of the manufacturer 
(Appendix V. 12). Luciferase activity was normalized for pSV-beta-galactosidase activity 
measured with P-galactosidase enzyme assay as detailed in Appendix V. 13. All 
transfection experiments were performed in triplicate. 
6.5.5 Cell viability assays 
LDH assay 
Cell viability was determined by measurement of lactate dehydrogenase (LDH) release 
using the CytoTox96 non-radioactive cytotoxicity assay (Promega, UK). In brief, 
Monomac-6 cells or primary human monocytes were exposed to bacterial supernatants 
and then incubated for 6 hours at 37"C. 50 gl/well supernatant was carefully removed 
and transferred into an optically clear 96-well plate. Reaction solution was added to each 
well and incubated for 30 min in darkness. The enzyme reaction was then stopped by the 
addition of IN HCI. The absorbance at 490m'n was measured using an ELISA reader 
(Model 680, Bio-Rad Laboratories). The activity of the enzyme released from damaged 
cells into the supernatant was measured, and the activity was expressed as a percentage of 
the total LDH activity released from cells lysed by exposure to 0.1% Triton X- 100 for 45 
min. Values shown represent the mean ± standard deviation of three wells. 
AflTAssay 
Cytotoxicity of copper sulfate (CUS04). tetrathiomolybdate (TTM), Iron (111) chloride 
(FeC13) or Ferrichrome in Monomac-6 cells was determined by the use of the MTT assay 
(Mosmann, 1983). The MTT system is a means of measuring the activity of living cells 
via mitochondrial dehydrogenase activity. The key component is 3-[4,5-dimethylthiazol. 
2-yl]-2,5- diphenyl tetrazoliurn bromide. Solutions of MTT solubilized in tissue culture 
media or balanced salt solutions, without phenol red, are yellowish in color. 
Mitochondrial dehydrogenases of viable cells cleave the tetrazoliurn ring, yielding purple 
MTT formazan crystals which are insoluble in aqueous solutions. The crystals can be 
dissolved in acidified isopropanol. The resulting purple solution is 
spectrophotometrically measured. 
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In brief, Monomac-6 cells (I X106) were plated into each well of a 96-well plate in the 
presence or absence Of CUS04 (250 pM), TTM (400nM), FeC13 (25uM) and Ferrichrome 
(25 pg/ml) incubated at 371C for 6 hours. After 6 hour incubation, the medium was then 
removed and 100 gI of MTT reagent (0.5 mg/ml) was added to all wells. After a3 hours 
additional incubation, 100 jil of acidified isopropanol was added to all wells and 
incubated I hour at 37'C; then, the absorbance of solution was determined with ELISA 
plate reader (Model 680, Bio-Rad Laboratories) using a test wavelength of 570 nm. The 
net absorbance taken from the wells with cells cultured with control medium was taken as 
the 100% viability value. The percentage of viability of the treated cells was calculated 
from the net absorbance of the sample divided by net absorbance of the control times 
100. 
6.6 Statistical analysis 
The results were statistically analysed using Student's mest with P values <0.05 
considered significant. 
6.7 RESULTS 
6.7.1 The effect of doxycycline on cytokine production by human monocytes 
Several pro-inflammatory cytokines are considered to participate in the inflammatory 
process associated with tissue destruction in periodontal disease. The effect of 
doxycycline on the production of several key pro-inflammatory cytokines using freshly 
isolated human monocYtes was investigated. To determine the effects of doxycycline on 
the production of proinflammatory cytokines, either E. coli LPS or culture supernatant 
from A. actinomycelemcomitans was added to the cells together with or without 
doxycycline (from 5 gg/ml to 25 gg/ml). Exposure of freshly isolated human monocytes 
to 10 ng/ml E. coli LPS or culture supernatant from A. actinomycetemcomitans for 6h 
induced a marked increase in the levels of IL-la, IL-1p, IL-6 and IL-8 production (Figure 
6.2 A, B, C, D). Doxycycline at concentrations of 5-25 gg/ml caused a dose-dependent 
inhibition of IL-la, IL-1p, IL-6 and IL-8 by 21-70%, 31-74%, 18-84% and 24-85%, 
respectively. 
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Figure 6.2 The levels of IL-la, IL-10, IL-6 and IL-8 in human monocytes regulated on activation by A. 
actinomycetemcomilans or Ecoli LPS in the presence or absence of doxycycline (Figures A-D). Freshly 
isolated CD14+ monocytes were plated at a density of IX 106 cells/ml in 96-well dishes. Cells were 
exposed to culture supernatants from Aa or Ec LPS (10 ng/ml) in the presence or absence of doxycycline 
(5 to 25 pg/ml). After 6h incubation, cell-frce supernatants were collected to assess cytokine release by 
ELISA. The data are means ± SD (n=3) representative of one of three separate experiments. *Doxycycline 
treated cells are statistically different as compared with untreated controls. *P < 0.05 
6.7.2 The effect of doxycycline on cytokine, production by Monomac- 6 cells 
To eliminate problems of variation associated with use of the primary cells Monomac-6 
cells were used for most of the following experiments. The cffect of doxycycline on the 
production of several key pro-inflammatory cytokines using Monomac-6 cells was 
investigated. Previous studies have shown that these cells provide a good model of 
cytokine production in response to bacterial stimulation (Bostanci et al., 2006). 
As shown in Figure 6.3 Monomac-6 cells produced variable levels of IL-la (A), TNF-a 
(B), IL- IP (C), IL-6 (D), IL-8 (E). The levels of these cytokines significantly increased in 
response to either E. coli LPS or culture supernatant from A. actinomycelemcomitans as 
compared with untreated controls. Doxycycline (10-25 pg/ml) significantly inhibited the 
stimulated or un-treated control levels of IL-la, TNF-a, IL-lP, IL-6 and IL-8 by 39 to 
63%, 55 to 73%, 79 to 86%, 97 to 98%, and 87 to 98%, respectively. 
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Figure 6.3 The levels of IL-la, IL-1p, TNF-a, IL-6 and IL-8 in Monomac-6 cells in response to culture 
supernatant from A. actinomycetemcomitans in the presence or absence of doxycycline (Figures A-E). 
Monomac-6 cells wcre exposed to culture supernatants from A. a (1: 250) in the presence or absence of 
doxycycline (10-25 pg/ml). After 6 hours incubation, cell-free supernatants were collected to assess 
cytokine release by ELISA. The data are the mcan: L-standard deviations (S. D. ) n=3. 
*Doxycycline treated 
cells are statistically different as compared with untreated controls. .P<0.05 
The toxicity testing demonstrated that the ability of doxycycline to inhibit a significant 
cytokine response was not related to its toxicity to the Monomac-6 cells or isolated 
human monocytcs. It should be noted that even the highest concentration of doxycycline 
used did not appear to be toxic as determined by levels of LDH release (Figures 6.4A-B). 
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Figure 6.4 Effects of doxycycline on cell viability. Monomac-6 (A) and freshly isolated human monocytes 
(B) were incubated with the indicated concentrations of doxycycline for 6 hours. Cytotoxicity was 
determined by the release of the cytosol enzyme lactate dehydrogenase (LDH). The activity was expressed 
as a percentage of the total LDH activity released from cells lysed by exposure to 0.1% Triton X- 100 for 45 
min. The data are the mean±standard deviations (S. D. ) n=3. 
Monomac-6 cells were also pre-incubated with doxycycline for Ihour prior to challenge 
with either 10 ng/mI E. coli LPS, or culture supernatant from A. actinomycetemcomitans 
for 6 hours. Pre-incubation effectively suppressed IL- Ia production induced by these two 
bacterial stimuli by 57% to 65% at 5 [ig/ml to 50 jig/ml (Figure 6.5), indicating that 
doxycycline suppresses pathways through which E. coli LPS or other bacterial signals are 
transmitted into the cell and thus suppresses pro-inflammatory cytokine production by 
monocytes and Monomac-6 cells. Since doxycycline is removed before exposure to 
bacterial stimuli it must induce a lasting change in the cell rather than act by interfering 
in the interaction of the bacterial components and the cell. 
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Figure 6.5 The effect of pre-incubation with doxycycline prior to challenge. Monomac-6 cells were plated 
at a density of IX 106 cells/ml in 96-well dishes. Cells were exposed to culture supernatants from A. a 
(1; 250). Doxycycline (5 to 25 pg/ml) was added Ih prior to activation. After 6h incubation, cell-free 
supernatants were collected to assess cytokine release by ELISA. The data are the mean I standard 
deviations (S. D. ) n=3. 'Doxycycline treated cells are statistically different as compared with untreated 
controls. .P<0.05 
6.7.3 Doxycycline does not affect expression of IL-Ia promoter in THP-1 cells 
If doxycycline suppresses IL-la production one obvious mechanism is via the inhibition 
of transcription. To investigate the effect of doxycycline on transcriptional regulation of 
IL-la gene, a luciferase reporter construct pGL3-IL-la was transfected into THP-1 
monocytic cells. After transfection, cells were allowed to recover for 24 hours then 
treated with culture supernatant from A. actinomycetemcomilans or E. coli LPS in the 
presence or absence of doxycycline for 6 hours. Background activity of the construct was 
low but significantly increased over 60% in the presence of bacterial stimulants (Figure 
6.6). In the presence of doxycycline there was no evidence of reduced transcriptional 
activity. 
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Figure 6.6 Effect of doxycycline on the IL-IA gene promoter activity. THP-1 cells were transfected with 
5 pg DNA of the luciferase IL-IA reporter plasmid and 2 pg of pSV-beta-galactosidase vector as internal 
control. After 24 hours incubation, cells were exposed to Aa supernatant with or without doxycycline for 6 
hours. Luciferase levels are expressed after standardization for [beta]-galactosidase activity. Bars show the 
mean and SD of triplicate assays. 
6.7.4 Effect of Doxycycline on E. coli LPS induced NF-KB activation 
LPS-induced production of several cytokines, including IL-la and TNF-a, is dependent 
on the activation and translocation into the nucleus of NF-KB. Since doxycycline inhibits 
secretion of multiple cytokines, the potential inhibition of NF-KB activation by 
doxycycline was examined. To study the effects of doxycycline on the transcription 
factor NF-KB, a luciferase reporter plasmid containing five sequential NF-KB binding 
sites upstream of a minimum promoter clement, NF-KB-Luc (PathDetect NF-KB Cis- 
Reporting System, Stratagene) was used. NF-KB-Luc was transiently transfected into 
Monomac-6 cells and after 24 hours, cells were treated with doxycycline and LPS for 6 
hours. After a further 6 hours, activity of the NF-KB promoter construct was measured. 
Addition of LPS induced a 2-fold increase compared to control cells (Figure 6.7). 
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Figure 6.7. Effect of doxycycline on the NF-icB promoter construct activity upon transient transfections. 
THP-1 monocytic cells were transfected with 1.5 pg of reporter plasmid and 0.5 jag pSV-beta-galactosidase 
internal control vector using Dextran. Cells were exposed to F-coll LPS with or without doxycycline for 6 
h. Luciferase activity was measured in the extracts using a luciferase assay system that was normalized for 
P-galactosidase activity. Bars show the mean and SD of triplicate assays. *p<0.05 
However the presence of doxycycline failed to reduce transcriptional activation of the 
NF-O reported in LPS-stimulated cells. These results suggest that doxycycline did not 
interfere with the LPS induced activation of NF-KB and that the inhibitory effect of 
doxycycline on the production of cytokines might act elsewhere in the pathway from 
signal to cytokine. 
6.7.5 The ion-chelation properties of doxycycline 
Since doxycycline, like other tetracyclines can act as a chelating agent the inhibitory 
effect of doxycycline on cytokine production in Monomac-6 cells could result from 
changes in levels of specific ions. In addition, secretion of IL-1a is believed to involve a 
copper containing complex (Mandinova et al., 2003). An attractive hypothesis is that 
reduced IL-lu production in the presence of doxycycline could result from depletion of 
copper levels. Therefore, the ability of Cu2+ to regulate cytokine secretion at secreted and 
cell- associated level was assessed. 250 gM copper increased secretion of IL-I a by 88% 
(Figure 6.8). There was a slight increase in the cell associated level (12%). Under the 
same conditions, TTM (4OOnM), a specific copper chelator, inhibited secretion of IL-la 
by 31%. In addition, the effect of iron was tested under same conditions. Fe +3 had a slight 
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effect on IL-Ia by reducing both secreted and cell associated levels. In contrast, 
Ferrichrome, a specific iron chelator had no effect on the total levels of IL-la. The 
inhibiting effect of doxycycline on IL-la was not abolished when excess amounts of 
either copper were added (Figure 6.8A) or iron (Figure 6.813). The MTT assay testing 
demonstrated that the ability of ions or their chelators to regulate IL-la production was 
not related to their toxicity to the Monomac-6 cells (Figure 6.9). 
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Figure 6.8 The ion-chelation properties of doxycycline. Monomac-6 cells were plated at a density of Ix 
106 celWml in 96-well dishes. Cells were exposed to culture supernatants from A. a (1: 250) with or without 
doxycycline (10 Pg/Ml), CUS04 (250 IN), TTM (400nM), FeC13 (25uM), Ferrichrome (25 pgIml). After 6 
h incubation, cell-free supernatants were collected to assess cytokine production by ELISA. The data are 
the mean: k standard deviations (S. D. ) n=3. 
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Figure 6.9 Cytotoxicity of ions or ion chelators in Monomac-6 cells. Monomac-6 cells (I X106) were 
plated into each well of a 96-well plate in the presence or absence of copper, tetrathiomolybdate (TTM), 
iron (FeC13) or Ferrichrome and incubated at 37"C for 6 hours. Cytotoxicity was measured with the MIT 
assay as described in Material and Methods. The net absorbance taken from the wells with cells cultured 
with control medium was taken as the 100% viability value. The percentage of viability of the treated cells 
was calculated from the net absorbance of the sample divided by net absorbance of the control times 100. 
Each data point represents the mean ± SD from three individual wells. 
6.7.6 Kinetics of, cytokine release in the presence of doxycycline 
A cytokine array analysis was further employed to demonstrate the kinetics of cytokine 
inhibition in Monomac-6 cells by doxycycline. Using multiplex cytokine analysis 
doxycycline activity was tested on the production of several key pro- or anti- 
inflammatory cytokines. The Monomac-6 cells produced various levels of cytokines in 
response to culture supernatant from A. actinomycetemcomitans, including I L- I a, IL- I P, 
IL-6, IL-8, IL-10, IL-12, GM-CSF and TNF-a. The cells produced low- (<5 pg/ml) to- 
undetectable levels of IL-2, IL4, IL-7 and IFN-y. 
A reduction in pro-inflammatory cytokine levels was demonstrated over 4h with the 
administration of 10 Itg/ml doxycycline to the cells. The cytokine inhibition was 
observed already at 2h in IL- Ia and IL- 10, IL-6, IL-8, whereas a change in TNF-a levels 
was observed at 4 h. TNF-a, IL-la , IL-1p, IL-6 and IL-8 production were inhibited by 
23 to 27%, 55 to 67%, 40 to 43%, 46 to 97%, and 87 to 98%, respectively (Figure 6.10 
A-E). In contrast, the production of IL-10 and IL-12 increased by 46% to % 100 in the 
presence of doxycycline (Figure 6.10 F-G). 
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Figure 6.10 Kinetics of cytokine release in the presence of doxycycline. Monomac-6 cells were plated at a 
density of IX 106 cells/ml in 96-well dishes. Cells were exposed to culture supernatants from A. 
actinomycetemcomilans (A. a) (1: 250) in the presence or absence of Doxycycline (DOX) (10 pg/ml). Cell- 
free supernatants were collected at indicated time points (0.5 h-Ih-2h-4h) to assess cytokine release by 
cytokine array. The data are means ± SEM from three separate experiments. 
6.8 DISCUSSION 
Doxycycline has been studied at sub-antimicrobial concentrations in human and animal 
diseases that are characterized by high levels of pro-inflammatory mediators and protease 
activities, the diseases such as rheumatoid arthritis and periodontitis (Brown et al., 2004; 
Madan et al., 2007; O'Dell et al., 2006; Preshaw et al., 2004a; Salvi and Lang, 2005). 
The present study demonstrated that doxycycline inhibits the production of several 
cytokines by human monocytes and the Monomac-6 monocytic cell line, when 
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stimulated by E. coli LPS and culture supernatant from A. actinomycetemcomitans. 
Inhibition of bacteria-induced cytokine secretion by doxycycline occurred in a dose- 
dependent manner within a concentration of 5-25 gg/ml. In subsequent studies a 
concentration of 10 gg/ml doxycycline was used as it did not affect cell viability. 
Doxycycline concentrations of 2 ttg/mI tolO pg/ml have been reported in GCF, gingival 
tissue or plasma after oral administration of this drug (Lavda et al., 2004; Sakellari et al., 
2000). Thus, the concentrations used in the present study are approximately in the range 
of those found in patients after the administration of a subantimicrobial dose. The 
kinetics of cytokine production in Monomac-6 cells showed that doxycycline is more 
effective in modulating pro- inflammatory cytokine production rather than anti- 
inflammatory ones. Doxycycline displayed an early (at 2 h) inhibitory action towards IL- 
Ia and IL-10, IL-6, IL-8, whereas a change in TNF-a level was observed at 4 h. Under 
the culture conditions of the study, cells produced low- (<5 pg/ml) to-undetectable levels 
of IL-3, IL4, IL-7 and IFN-y during 4h of incubation. These findings are in agreement 
with previous reports showing that doxycycline inhibits the release of TNF-a, IL- 10, IL-6 
by human monocytes (Krakauer and Buckley, 2003; Shapira et al., 1997). It therefore 
appears that doxycycline has an inhibitory effect on the production of a number of 
cytokines as a putative mechanism of action not specifically restricted to IL- Ia. 
Most of the studies that have addressed gene regulation by doxycycline have found that 
its effects occur via a post-transcriptional or translational mechanism (Kirkwood et al., 
1999; Shapira et al., 1996; Uitto et al., 1994). Therefore, in the present study using 
reporter assays as an in vitro model, the hypothesis that doxycycline suppresses IL- 
la production via the inhibition of transcription was tested. Based on the regulation of 
the IL-IA gene promoter activity in monocytes, the results suggest that doxycycline 
decreases IL-la protein levels due to the inhibition of protein translation rather than 
transcription at the promoter level. This result is supported by a previous study 
demonstrating that doxycycline inhibits LPS-induced TNF-a and IL-1 secretion by 
monocytes but not accumulation of cytokine mRNA (Shapira et al., 1996). 
The transcription factor NF-icB is an important regulator of genes encoding 
proinflammatory cytokines, including IL-1, IL-6, IL-8, and TNF-alpha (Karin and 
Delhase, 2000; May and Ghosh, 1998). It is of interest that the results of the present 
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study revealed that although treatment with LPS induced activation of NF-KB, treatment 
with doxycycline did not inhibit this activation. In the present study, analysis of the NF- 
KB transcription pathway suggested that it may not play a significant role in attenuating 
production of cytokines after exposure to doxycycline. This concept is supported by a 
recent study demonstrating that doxycycline-modulated inhibition of NO production in 
murine LA4 cells is independent of the NF-icB pathway (Hoyt et al., 2006). 
Doxycycline, like other tetracyclines is known to bind divalent cations such as calcium, 
copper, and zinc (Golub et al., 1983; Yu et al., 1991). Recent studies have indicated that 
cytokine release may depend upon metal ions (Bar-Or et al., 2003; Lewis et al., 2003; 
Mandinova et al., 2003). Indeed, a copper-dependent release of IL-la from the U937 
human monocytic cell line has been documented (Brewer, 2003; Mandinova et al., 2003). 
Earlier studies have also shown a linear relationship between the concentration of iron in 
GCF (26 to 170 pM) and severity of periodontal disease (Wang et al., 1990). Analysis of 
the effect of copper in the present study suggested that intracellular transport of this ion is 
involved in the regulation of IL-la release. This effect was also verified by the use of 
TTM, a specific copper chelator (Miller and Engel, 1960) and since TTM reduced both 
intra-cellular and secreted IL-la levels by Monomac-6 cells. The effects of TIM on 
TNF-a production have also been recently demonstrated (Brewer et al., 2004). A 
potential hypothesis could be that reduced IL-la production in the presence of 
doxycycline could result from the depletion of copper levels. However, in the present 
study, when excess amounts of copper were added to the culture media, there was no 
change in the inhibitory effect of doxycycline on bacterial stimulation. In addition, the 
presence of excess biological concentrations of iron did not change the activity of 
doxycycline. Whilst a strong iron chelating activity for doxycycline has been 
demonstrated, this was only at a concentration 250 jig/ml, which is higher than the 
clinically achievable levels at sub-antimicrobial doses (Grenier et al., 2000). Taken 
together, these findings suggest that the inhibitory activity of tetracyclines can not be 
fully accounted by their ability to bind metal-like ions, and therefore it seems unlikely 
that these actions are mainly dependent on ion chelation. 
Previous studies have shown that the addition of excess Ca2+ (mM concentrations) or 
excess Zn 2+ (ItM concentrations) can eliminate the inhibition of collagenase activity by 
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tetracyclines (Golub et al., 1983; Yu et al., 1991). However, the concentrations of 
doxycycline (250 pg/ml) required to achieve the direct inhibition of MMPs activity are 
very high (Gilbertson-Beadling et al., 1995). The chemically modified tetracycline 5 
(CMT-5) which lacks Ca2+ and Zn2+ binding sites is also able to inhibit the oxidative 
activation of pro-MMP (Sorsa et al., 1998). These results are also supported by other 
studies showing that proinflammatory secretory enzyme phospholipase A2 (sPLA2) 
inhibition by doxycyline can not be eliminated by the addition of excess calcium up to 50 
mM (Pruzanski et al., 1992; Pruzanski et al., 1998) and cysteine proteinase inhibition by 
doxycycline is not affected in the presence of calcium (Imamura et al., 2001). Taken 
together, these results suggest that subantimicrobial doses of doxycycline may decrease 
MMP activities via indirect mechanisms including cytokine inhibition. 
In summary, the results of this study indicate that doxycycline is an inhibitor of secretion 
of cytokines by human monocytes stimulated with Ecoli LPS or A. 
actinomyretemcomitans supernatant. This inhibitory effect does not appear to involve 
regulation of NF-O activity or the suppression of transcription of IL-la. The inhibitory 
effects are also independent of the ability of doxycycline to chelate metal ions. The data 
presented here suggest that low doses of doxycycline below the threshold for 
antimicrobial actions may be useful for treatment of periodontal diseases due to anti- 
inflammatory activity. 
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7.1 GENERAL DISCUSSION 
Periodontal diseases are multifactorial infectious diseases that manifest clinically by 
destruction of the supporting tissues of the teeth. The host immune and inflammatory 
response to peridontopathogenic bacteria is a critical determinant of susceptibility to 
develop the destructive periodontal disease, under the influence of multiple behavioral, 
environmental, and genetic factors (Cohen, 2002; Jenner and Young, 2005; Schumann, 
2004). 
The observation that severe periodontitis affects only 7-15% of individuals means that 
not all individuals are at equal risk of developing the disease. Genetic factors are 
important determinants of periodontitis susceptibility and progression (Kinane et al., 
2005). SNPs are the most common source of human genetic variation (Suh and Vijg, 
2005), their association with human disease phenotypes has the potential to be used as 
diagnostic and prognostic markers and potentially lead to the development of novel 
therapeutic targets. Since large scale screening for SNPs is still very complex (Cantor 
and Nelson, 2005), alternative approaches which can be used for identification of disease 
associated SNPs include selection of candidate genes coding for particular features of a 
disease (Goldstein et al., 2003). 
This thesis included a candidate gene approach using the IL- IA gene. IL- Ia was selected 
on the basis of available information from both human and transgenic animal studies for 
the potential function of the lL-lA gene involved in the pathogenesis of periodontal 
disease (see Chapter 1.8). This approach was based on the hypothesis that increased or 
unregulated production of IL-la in response to periodontopathogens may occur in 
subjects carrying functional polymorphisms of this gene. Firstly, studies were conducted 
to investigate how different periodontopathogens may regulate IL-la production by 
monocytes. This was followed by screening of exon, intron and promoter regions of IL. 
IA for polymorphisms and then an examination of the identified polymorphisms to 
determine if there was a significant difference between patients and unrelated healthy 
individuals, in terms of allele frequencies or genotype frequencies. Moreover, the 
functional impact of identified polymorphisms on transcriptional activity and their 
interactions with periodontopathogens was assessed using in vitro reporter gene assays 
and in silico analysis. 
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The stimulation of IL-la production by bacterial products has been previously studied. 
However, there has not been a systematic comparison of a full range of periodontal 
pathogenic bacterial species (Henderson et al., 2002; Sugano et al., 2004). Studies in 
Chapter 2 aimed to determine the optimal culture conditions for bactcrial-stimulated 
production of IL-Ia in monocytes and included a systematic comparison of a full range 
of periodontal pathogenic bacterial species. The amount of IL-Ia production was highly 
dependent upon monocyte culture conditions and under the experimental conditions 
assayed, maximum IL-Ia production by Monomac-6 was obtained once these cells were 
stimulated in the presence of 10% FCS for 6 hours at density of IxIO6/mI (Pradines- 
Figueres and Raetz, 1992; Schwende et al., 1996; Ziegler-Heitbrock et al., 1994). The 
results indicated that a range of periodontal pathogens have the capacity to induce IL-la 
production in Monomac-6 cells; nevertheless the nature of the component responsible for 
this effect may vary between them. This activity was due to either LPS or to the 
proteinaceous components of the bacteria depending upon the specific species tested. 
The studies in Chapter 2 demonstrated that most periodontopathogens induced a 
significant level of IL-la release from Monomac-6, while P. gingivalis induced IL-la to 
only a minimal level. It was surprising that P. gingivalis is strongly associated with 
periodontal disease but did not induce IL-la production. In addition, the stimulation of 
IL-la at the site of infection by other periodontopathogens could be antagonised by 
P. gingivalis. Therefore, the studies in Chapter 3 compared IL-Ict production by 
monocytic cells when treated with single bacterial supernatants to those treated with 
combination of P. gingivalis. P. gingivalis supernatants inhibited the capacity of most 
pathogens studied to stimulate IL-1a production by monocytes. The most pronounced 
inhibition was seen in combination with C. rectus, where the overall level of IL-la 
production was reduced by approximately 72% in the presence of P. gingivalis. Further 
studies investigated the mechanism of antagonistic activity and showed that P. gingivalis 
LPS appeared to be the crucial component for this antagonistic activity. This study 
suggests that P. gingivalis appears to play a role in the short term inhibition of innate 
immune responses. Although P. gingivalis LPS exhibited a weak cytokine stimulating 
capacity, it may cause an early inactivation of immune cell responses to other bacteria. in 
this situation other periodontal bacterial species may be more likely to persist, therefore 
favouring the establishment of a chronic inflammatory lesion typical of periodontitis. 
195 
Chapter 7: General Discussion 
Genetic polymorphisms within the IL-1 gene cluster, including IL-la, may identify 
individuals who are susceptible to periodontitis, although there is disagreement about 
which variant of the IL-1 gene confers susceptibility. The NCBIEntrez SNP database 
(http: //www. ncbi. nlm. nih. gov/entrez currently lists 15 polymorphisms in 5' upstream 
region of the gene of which five are located in the putative promoter (2.1 kb of the 
genomic sequence upstream of the transcriptional start site ) (Table 4.1). Many of the 
reported polymorphisms are based on studies of relatively small numbers of individuals 
(often only 46) and in all cases periodontal status is unknown. Surveys of the abundance 
of polymorphisms generally aim to identify those polymorphisms with a frequency above 
about 4%. However, since severe periodontitis has an incidence of about 8% in the 
general population, it is possible that any given polymorphism abundant in this sub- 
population could be missed or classed as rare from a small survey of random individuals. 
Therefore, in Chapter 4 two strategies were used to identify the common IL-1A gene 
promoter polymorphisms including direct sequencing and TaqMan analysis. The first 
strategy used was to sequence directly the 2.1 kb genomic sequence upstream of the 
transcriptional start site as well as the first exon and intron by surveying the frequency 
and occurrence of all variation within this region including SNPs, insertion/deletions and 
VNTRs within a Caucasian population of subjects with generalized aggressive 
periodontitis. Three previously described polymorphisms in the public database were 
observed in patients with generalized aggressive periodontitis, designated here as SNP 1, 
SNP 11 and SNP 111. No additional novel polymorphisms were detected. SNPs for further 
analysis were selected on the basis of having relatively high minor allele frequencies 
(>10%). 
After identifying the existence and abundance of different polymorphisms in the 
promoter region of the IL-IA gene, TaqMan analysis was performed to provide 
information regarding the abundance of polymorphisms in the IL-IA gene in a range of 
ethnic groups including both disease and control individuals. Further analyses were done 
if there was a significant difference between patients and unrelated healthy individuals, in 
terms of allele frequencies or genotype frequencies. Of the three identified SNPs, only 
SNP I (referred to as -889) has been previously associated with periodontitis (Kornman et 
al., 1997a; Shirodaria et al., 2000). The association of the SNP 11 and the SNP III 
polymorphisms with periodontal disease has not been studied previously. The results 
presented in Chapter 4 showed no significant differences in the prevalence of the carriage 
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of either allele of the three studied SNPs between an ethnically mixed group of 
generalized aggressive periodontitis patients and a group of periodontally healthy 
subjects. In addition, no statistical difference was observed when comparing SNPs 
between the control and aggressive periodontitis groups, when only the Caucasian 
population was included in the analysis. When smoking status was included in the 
analysis as a covariate, the distribution of genotypes for three SNPs in smokers and non- 
smokers showed no statistical significance between controls and cases. Within the 
limitations of the study, results suggested that there was no association with the IL-IA 
gene promoter polymorphisms and generalized aggressive periodontitis. The results are 
in agreement with other studies that have reported no significant differences in the 
frequencies of the SNP I (referred to as -889) alleles in populations of individuals with 
aggressive periodontitis and healthy subjects (Anusaksathien et al., 2003; Brett et al., 
2005; Gonzales et al., 2003; Hodge et al., 2001; Moreira et al., 2007; Rogers et al., 2002; 
Walker et al., 2000). 
Nevertheless, these results in Chapter 4 do not exclude a role for the identified SNPs in 
periodontal disease. Periodontal disease is a complex disease in which many interacting 
gene variants will act synergistically with confounding environmental factors such as 
smoking or bacterial flora could interact with the genotype. In addition, an important 
feature of the complex disease is that most susceptible individuals are at elevated risk due 
to the combined effects of several susceptibility alleles (Bertram et al., 2007). If the 
complex disorder is influenced by multiple rare variants in a gene, each of minor or 
modest effect, each risk-increasing variant may be too rare to achieve a level of 
significance in association studies. Given the complex biology of IL- I regulation and the 
extensive polymorphisms in the IL-1 gene cluster, it is very likely that if IL-I genes 
influence disease, then a combination of specific alleles will be important rather than 
individual alleles. There is linkage disequilibrium across the IL-I cluster (Chen et al., 
2006; Cox et al., 1998; Danis et al., 1995; Diehl et al., 1999; Scapoli et al., 2005). 
Therefore further studies will be required to make wide SNP typing within the IL-I gene 
cluster to fully determine an extended informative haplotype structure and its possible 
associations with aggressive periodontitis. Moreover, further studies are needed to 
determine whether and to what extent differences in IL-IA polymorphisms may affect 
the onset and severity of the periodontal lesions in generalized aggressive patients with 
different environmental exposures. 
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There are a number of possible genetic associations between polymorphisms in the IL- 
IA gene and periodontal disease (Shirodaria et al., 2000), but as yet there is no consensus 
on their functional importance. Whilst there is evidence for transcriptional regulation of 
IL-la gene expression (Alhcim ct al., 1996; Bailly et al., 1996a; Kawaguchi et al., 2003; 
Mori and Prager, 1996), polymorphisms in the promoter region of the IL-IA gene may 
be important for IL-la gene expression and protein production. Studies in Chapter 5 
aimed to investigate the functional impact of the polymorphisms identified on 
transcriptional activity and their interactions with periodontopathogens using in vitro 
reporter gene assays and in silico analysis 
In silico investigation for transcriptional binding sites using TFSEARCH revealed that 
these SNPs are located in putative regulatory element sequences. However, the effects of 
polymorphisms in the binding site are unlikely to be simple and use of the TRANSFAC 
database is limited by considering only a subset of transcription factors. Therefore it was 
decided to test whether these polymorphisms have functional significance on the basis of 
standardised reporter gene assays. 
Reporter gene assay studies in THP-1 monocytes showed that the SNP I allele 2 (T) 
resulted in decreased basal and stimulated levels of IL-1A transcription compared with 
constructs containing the allele I (C). This is a novel finding since a single previous in 
vitro study testing the effect of SNP 1 (rs1800587) C->T substitution on transcriptional 
activity in reporter gene assays (Dominici et al., 2002) showed that the SNP IT allele 
was associated with a 1.8-fold increase at basal transcription rate compared with a 
construct containing the allele C in PCH cells (human pancreatic cell line). The 
differences between the previous study and the present findings may reflect the different 
cell lines employed. PCH is a transformed cell line whilst monocytic cells are more 
likely to be involved in the inflammatory processes. Cell-type specific differences may be 
the results of differential expression of essential transcription factors or underlying 
differences in transcriptional control. Since different cell types use different receptors, 
signalling pathways and transcription factors, it is possible that the same SNPs may show 
tissue-specific differences in function (Knightý 2005). Indeed, the pilot data in the present 
study suggest that the SNP I C>T substitution has no effect on the basal rate of 
transcription of the IL-1A gene in HeLa cells. In addition, it is also important to consider 
the other possible reasons for the differential expression including the effect of construct 
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size. The previous study (Dominici et al., 2002) cloned a 1.4 kb promoter region of the 
IL-IA gene compared to 2.1 kb used in this thesis. Expression levels may differ between 
long and short constructs (McDowell et al., 2005). The present results suggest that 
regulation of ILIA gene transcription may be cell type-specific, which may be of 
physiological relevance when considering different disease processes localised to 
different tissues or organs. 
The functional significance of the SNP II C->T and the SNP III C->T are unknown. The 
physiological significance of those polymorphisms has not been directly investigated. 
TRANSFAC data suggests that the polymorphisms could alter transcription factor 
binding sites. However, in this thesis, no effect of the polymorphic sites was seen in 
assays of transcription of the IL-lA promoter when tested in vitro in THP-1, human skin 
fibroblasts or HeLa cells. However, these results do not completely exclude the role of 
SNP 11 and SNP III since there is a strong linkage between SNP III & SNP 1 (-899). In 
addition, the possibility of other polymorphisms that are linked to the studied three 
polymorphisms may not be excluded. Using the three SNPs, the distribution of IL-lA 
promoter haplotypes in Caucasians with aggressive periodontitis were also estimated in 
the present study. However, the influence of haplotype context on the transcriptional 
activity of the IL-1A gene has not been investigated. Further experiments should define 
the major haplotype combinations that might influence the regulation of IL-1A promoter 
activity in response to periodontopathogens. 
The central role played by IL- Ia in the pathogenesis of periodontal disease suggests that 
immunomodulation may offer a suitable therapeutic target for investigation. In Chapter 6, 
the present studies have confirmed the previous findings by showing that doxycycline 
inhibits the production of several cytokines, including IL-la, by human monocytes. This 
inhibitory effect did not appear to involve regulation of NF-KB activity or the suppression 
of transcription of IL-la. The inhibitory effects are also independent of the ability of 
doxycycline to chelate metal ions. The data presented suggest that low doses of 
doxycycline below the threshold for antimicrobial actions may be useful for treatment of 
periodontal diseases due to anti-inflammatory activity. 
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7.2 FUTURE STUDIES 
It is evident from data obtained from this thesis that bacteria can induce IL- Ia production 
by a range of mechanisms. Different bacterial virulence factors may act through a range 
of distinct signalling mechanisms to stimulate the production and release of cytokines 
(Darveau et al., 2002; Saklatvala, 1995). Toll-like receptors (TLRs) 2 and 4 have recently 
been identified as possible signal transducers for various bacterial ligands (Bainbridge 
and Darveau, 2001; Yoshimura et al., 2002). To further clarify the mechanisms involved, 
the ability of different bacterial virulence factors to interact with different TLRs to 
stimulate IL- Ia production could be investigated further. 
In addition, this thesis also demonstrates an antagonism between P. gingivalis and C 
reclus in terms of IL-I a production that appears to rely on the integration of positive and 
negative signals through cell signalling rather than any direct interaction between 
components in the supernatants. One possible explanation for the observed antagonistic 
effect is that although P. gingivalis LPS is a weak stimulus for proinflammatory 
cytokines it is a potent inducer of IL-IReceptor antagonist (IL-IRA) (Ogawa et al., 
1994). Regulation of IL-IRA in the present system could be studied. Alternatively, the 
antagonistic effect could be attributed to competition of the two species for common 
signalling receptors, such as CD14 and TLRs (Darveau et al., 2004; Hajishengallis et al., 
2002; Yoshimura et al., 2002; Zhou et al., 2005). It would be interesting to investigate if 
P. gingivalis and C rectus possess any components such as LPS that initiate common 
signalling pathways involved in this antagonism. 
Recent periodontitis infection models suggest that a consortium of bacteria rather than a 
single species is associated with more severe periodontal tissue destruction (Lakshmyya 
et al., 2007). In vitro studies using mixed bacteria in a macrophage-epithelial cell co- 
culture model have reported that complexes of bacteria may induce higher levels of pro- 
inflammatory mediators (Bodet et al., 2006). Therefore, further studies would be useful 
to investigate cytokine regulation in in vivo infection models using current technologies 
such as microarrays. Preliminary experiments using T denticold as a stimulant in 
Monomac-6 cells showed that culture supernatants elicit only a very small level of IL-la 
production on their own, but are highly synergistic when combined with other 
periodontal pathogenic species (Javier Fernandez, M ClinDent Dissertation, 2006, 
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QMUL, and unpublished data). Since T denticola is strongly implicated as part of the 
pathogenic consortium in the aetiology of periodontitis, further studies would be useful to 
investigate its putative role in IL- Ia regulation (Lakshmyya et al., 2007). 
The failure to find any association with lL-lA genotype and risk of aggressive 
periodontitis is similar to findings from some other studies but in contrast to other studies 
showing associations between IL-I genotype and risk of aggressive periodontitis (Hodge 
et al., 2001). The relationship between genotype and periodontal disease remains unclear, 
partly due to the absence of carefully controlled large studies. A more definitive 
approach to these studies requires additional large population studies (e. g. of the order of 
2000-3000 racially defined subjects and matched controls) with careful disease 
phenotyping using standard criteria. 
Data from this study also indicates that the SNP 1 (-899) C-*T polymorphism affects the 
transcriptional levels of IL-IA gene, at least in the reporter system, and it might play a 
role in regulating IL-IA gene transcription induced by bacteria. It should be emphasized 
that whereas the data presented in this thesis are compatible with the above 
interpretation, not all components of this hypothesis have been tested experimentally. 
Firstly, the effects of the identifled polymorphisms on the IL-la rnRNA or protein levels 
in response to bacterial stimulants in human monocytes derived from subjects genotyped 
for the identified polymorphisms have not been tested. This could answer functional 
effects of the identified polymorphisms at the translational level. Secondly, since 
periodontal disease is considered as a complex disease, confounding factors such as 
smoking and specific microflora could exert an influence on the outcome by their 
interactions with genotype. It is likely that polymorphisms would interact with 
environmental factors in order to confer susceptibility to disease. Further analysis is 
required to consider these factors. Furthen-nore, the possibility that other polymorphisms, 
linked to the SNP I polymorphism, may influence the expression of IL-la' cannot be 
formally excluded. There is linkage disequilibrium across the IL-I cluster (Cox et al., 
1998; Danis et al., 1995; Diehl et al., 1999; Scapoli et al., 2005), and it is likely that a 
combination of specific alleles is more important than individual alleles (Chen et al., 
2006). Further studies are needed to understand haplotype structure between identifled 
polymorphisms and also test the influence of haplotype context on the molecular function 
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of a polymorphism in a gene promoter. Finally, to further understand differential 
transcriptional activity of individual alleles in the reporter assays, electrophoresis 
mobility shift assay using specific antibodies for these transcription factors would be a 
logical method to use in the future studies. 
The results from this thesis have suggested that doxycycline inhibits the production of 
several cytokines including IL-la by human monocytes. This inhibitory effect does not 
appear to involve regulation of NF-O activity or the suppression of transcription of IL- 
Ia. The inhibitory effects are also independent of the ability of doxycycline to chelate 
metal ions. MAPK signalling pathways play an important role in the translational 
regulation of pro-inflammatory cytokine synthesis (Clark et al., 2003; Fleenor et al., 
2003). Since data from this thesis suggest that regulation is post-transcriptional, rather 
than transcriptional, to determine a mechanism for the cytokine inhibition, MAPK 
signalling pathways such as p38 MAPK protein could be examined. 
The data presented here suggest that low doses of doxycycline below the threshold for 
antimicrobial actions may be useful for treatment of periodontal diseases due to anti- 
inflammatory activity. Although subantimicrobial dose doxycycline has been tested 
clinically as an adjunct for the management of periodontitis, further clinical studies to 
investigate further the role of doxycycline treatment or other IL-1 attenuating therapies in 
the management of periodontitis would be valuable. The possibility of targeting such 
therapies on the basis of levels of IL-I production or IL-1 genotyping may merit 
investigation in the future. 
7.3 CONCLUSIONS 
in conclusion, IL-Ia is a pivotal cytokine involved in periodontal disease and its 
regulation is a complex event governed by bacterial factors, host genetics and 
pharmacological agents. Clear differences in responses to different bacteria and specific 
combinations of bacteria may have particular implications for the understanding of 
disease aetiology and progression. 
It is often difficult to assess SNP function on the basis of nucleotide sequence alone. This 
is particularly true when SNPs do not alter an amino acid or do not disrupt protein 
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function or structure (Rebbeck et al., 2004). The present results demonstrate that SNP I (- 
889) has a novel functional role in IL-la regulation, even if it may not prove to be a risk 
determinant for aggressive periodontitis. An important feature of a complex disease like 
periodontitis is that most susceptible individuals are at elevated risk due to the combined 
effects of several susceptibility alleles and their interaction with confounding factors, 
such as smoking and the presence of a pathogenic flora. From the viewpoint of 
experimental design, further association studies are still required, with larger number of 
cases and controls in homogeneous populations, including analysis of all possible 
confounding factors. New methods are required to consider simultaneously interactions 
between genes and environmental factors. These approaches should be incorporated into 
SNP based associations in periodontal diseases. Such genetic information from those 
approaches would have a potential as diagnostic and prognostic biomarkers for 
periodontal disease susceptibility and possibly, for development of novel therapeutic 
targets aimed at preventing the development of periodontal disease. 
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APPENDIX I Standard buffers and reagents 
Luria Broth (LB) 
10 g bacto-tyrptone 
5g bacto-yeast extract 
10 g NaCl 
Made up to IL with dH20 and pH adjusted to 7.2 and autoclaved. 
LB Agar 
15 g Bacto agar in IL LB 
1.0% Agarose 
Ig of agarose in 100 ml of Ix TAE buffer. Heated in microwave to melt. 
Ethidium Bromide (10% EtBr) 
100 mg of EtBr in I ml dH20. Stored in the dark. 
I Ox Tris Acetate EDTA (TAE) 
48.46 g (0.4 M) Tris base 
3.72 g (0.0 1 M) EDTA-Na2-saIt 
12.01 g (0.2 M) Glacial Acetic Acid 
Made up to IL with dH20. Used at IX by diluting 1: 10 in dH20 and ph adjusted to 8.3. 
Phosphate buffered saline (PBS) 
5.84 g Sodium Chloride 
11.5 g Di-sodium hydrogen orthophosphate 
2.96 g Sodium dihydrogen orthophosphate 
Made up to IL with dHO and pH adjusted to 7.5 
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APPENDIX 11 ELISA ASSAY 
Solutions required 
PBS Phosphate Buffered Saline 
Wash buffer- 0.005 % Tween 20 in PBS. 
Block buffer- I% Bovine Serum Albumin (BSA, >98% electrophoresis, Sigma), 5% Sucrose in 
PBS with 0.05% NaN3 
Reagent diluent- 1% BSA in PBS, 0.2gm filtered. 
Substrate Solution- tetrarnethyl benzidine dihydrochloride (TMB, Sigma-Aldrich) substrate 
dissolved 0.1 M C61-1807P 0- 1M Na2H, 0.00075 % H202 
Stop Solution- 2N H2S04 
Reagent preparation 
1. Dissolve 10 PBS tablets into 1.0 L of deionised, water to prepare wash buffer and add 500ýtl 
of Tween 20 
2. Prepare all solutions required (see above). 
3. Reconstitute the IL-la standard with 1.0 ml of deionised water. This reconstitution produces 
a stock solution of 50 ng/mL. Allow the standard to sit for a minimum of 15 minutes with 
gentle agitation prior to making dilutions. 
4. Pipette 500 uL of reagent diluent into 8 tubes and prepare a dilution series. The 500 pg/mL 
serves as the high standard and reagent diluent serves as the zero standard. 
Protocol 
1. Add 100 pl anti-human IL-la (2mg/ml) antibody into each well for overnight at room 
temperature 100 pl, Assay Diluent to each well. 
2. Aspirate and wash 4 times 
3. Add 300 gL block buffer to each well. Incubate for I hr on the shaker. 
4. Aspirate and wash 4 times 
5. Add 100 ttL Standard or samples to each well. Incubate for 2 hrs at room temperate on a 
horizontal orbital shaker set at 500 rpm. 
6. Aspirate and wash 4 times. 
7. Add 100 gL biotinylated detection antibody to each well. Incubate for 2 hrs on the shaker. 
8. Aspirate and wash 4 times 
9. Add 100 ýtL Streptavidin-HRP to each well. Incubate for 20 min at room temperature 
protected from light. 
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10. Aspirate and wash 4 times 
11. Add 100 RL substrate solution to each well. Incubate for 20 min at room temperature 
protected from light. 
12. Add 50 tiL stop solution to each well. Read at 450 nm within 30 min with a correction at 570 
nm. 
600 y- 529 , 
2X4 - 1220.7X3 + 1008X2 - 214.6x + 19.296 
5001 
R2 - 0.999 
# 
-g 
cn CL. 
400- 
300 - 
200 - 
100- .0 
0.5 1.5 
0 
OD 4501570 
Figure 1A standard curve was generated using a four parameter logistic (4-PL) curve-fit (Microsoft Office 
Excel) for each set of samples assayed. The values of the samples were assigned in relation to the standard 
curve 
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APPENDIX III DNA extraction 
Reagents 
Solution 1 
0.32 M Sucrose (filter sterilised) 
10 mM Tris-Cl, pH 7.6 (sterile) 
5 MM MgC12 (sterile) 
0.02 % Sodium Azide (sterile) 
I% Triton X- 100 
Sterile distilled deionised water to 500 ml 
Solution 2 
50 mM Tris-Cl, pH 8 
20 mM EDTA, pH 8 
2% SDS 
Sterile distilled water to 500 ml 
Solution 3 
Add NaCl to 300ml of sterile distilled deionised water keep adding salt until salt comes out of 
solution. 
DNA Extraction method using salt precipitation 
1. Place an aliquot of solution I of adequate size and some distilled water in the fridge to cool 
before use. 
2. For blood samples of 2ml add distilled water to make up to 12.5 ml 
3. Centrifuge at 2500/3000 revs/min for 15min at 15" 
4. Remove supernatant by pouring gently to leave around I ml (leave pellet plus pink layer). 
5. Add distilled water up to a volume of 4ml and ensure pellet is dissolve (pipette up and down 
if needed to break up pellet) add solution I up to a volume of 8 ml and then add distilled 
water up to a final volume of 12 ml. 
6. Mix thoroughly to disperse pellet. 
7. The above stages result in cell lysis 
8. Incubate on ice for 2min (volume of 12ml) 
9. Centrifuge at 2500/ 3000 rev/min at 4'Cfor 15min 
10. Remove supernatant by pouring gently and saving pellet 
11. Vortex to get pellet of tube. 
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12. This pellet should appear light pink in colour. If a dark red pellet is present, repeat previous 
steps. 
13. Resuspend the pellet in 2,5 ml of solution 2 and vortex vigorously (ensure pellet broken up) 
14. Add proteinase K to supernatant to yield a final concentration of I 00mcg/ml. Incubate at 60' 
with shaking for I hr at 3 WC or overnight. 
15. Incubate on ice for 10min 
16. add I ml of solution 3 
17. Mix by invert several times 
18. Centrifuge at 2000/ 2500 revs/min for 15 min at 20'C 
19. Transfer supernatant using a large bore pipette to a sterile tube which is correctly labelled. 
Precipitate DNA by adding two volumes of 100% ethanol (cool before use) to the supernatant 
20. Invert the tube gently until the DNA precipitates a 'hairball' 
21. This can be stored at -20 OC overnight if necessary 
22. Spin at 2000 rev/min for 15 min 
23. Remove ethanol 
24. Resuspend the DNA in 500ul of TE, gently invert the tube. 
25. DNA samples should be stored at 4*C. 
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Figure T)pical Spectrophotometer plot for DNA quantification 
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Table 1 Spectrophotometer readings for DNA quantification (Patients) 
Patient 
code ng/ul 
Patient 
code nglul 
Patient 
code ngful 
Patient 
code ng/ul 
49 84 249 95 299 32 N145 127.7 
201 54 250 300 7 N146 86.8 
202 78 251 55 301 37 N147 127.8 
203 101 252 38 302 46 N149 59.9 
204 86 253 186 303 2 N149 59.6 
205 81 254 186 304 - NISO 42.6 
206 255 83 305 3.9 NISI 68.7 
207 63 256 96 306 66 N162 18.1 
208 96 257 105 N12 61.9 N164 19.6 
209 86 268 32 N13 55 NISS 80.8 
210 21 259 N14 24.8 N166 90.4 
211 52 260 20 N15 145.8 N157 18.8 
212 68 262 43 N17 105.5 N168 63.7 
213 6.3 263 65 N18 55.9 N159 53.6 
214 12 264 43 N19 33.4 N160 19.7 
215 119 266 32 NIIO 136.9 N162 85.4 
216 87 266 17 NIII 44.2 NIBS 221 
217 66 267 1.2 N112 58.2 NI B7 364 
218 268 '14 N113 54.6 NI B 12 89 
219 26 269 25 N114 34.5 NI B 13 215 
220 116 270 38 N115 32.1 NI B 16 151 
221 271 55 MIS 21.7 NI B 18 177 
222 15 272 12 N117 35.6 NI B 19 145 
223 17 273 9 MIS 29.5 N1 B 20 61 
224 92 274 96 N119 27.3 NI B 23 134 
225 200 2T5 2 N120 42.6 NI B 27 122 
226 17 276 21 N121 79.1 NI B 28 525 
227 74 277 101 N122 86 NI B 29 233 
228 278 5 N123 17.3 NI B 30 193 
229 53 279 32 N124 41.2 NI B 32 113 
230 280 18 N125 32.1 NI B 33 111 
231 18 281 3 N126 85 N1 IB 36 265 
232 108 282 25 N127 85.9 NI B 39 99 
233 27 283 12 N128 131.4 NI B41 156 
234 180 284 5 N129 23.7 N1 B42 653 
235 56 285 1.8 N130 26.7 NI B44 1186 
236 286 36 N131 101.3 NI B45 145 
237 60 287 18 N132 231.4 N1 B 46 84 
238 96 288 1 N133 117.1 N1 B 47 197 
239 70 289 12 N134 112.9 NI 8 48 74 
240 124 290 3 N135 83.5 NI B49 143 
241 135 291 25 N137 152.8 NI B So 183 
242 90 292 N138 80.9 N1 B 51 263 
243 117 293 17 N139 125.5 N1 B 52 586 
44 117 294 44 N140 166.6 NI B 63 1198 
245 7 295 102 N141 63.4 N1 13 54 2Q3 
246 67 296 58 N142 
247 27 10 N143 132.2 
2i4i F iL 149 298 45 N144 54.8 
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Table 2 Spectrophotometer readings for DNA quantification (Controls) 
Healthy code nglul Healthy code 
Healthy 
code nglul 
001 11 048 90.9 094 55.3 
002 4.4 049 70.4 095 43 
003 1 060 14.7 096 41 
004 0.3 051 52.8 097 29.1 
005 8.4 062 68.7 098 114.1 
006 26.2 063 13.4 099 13.3 
007 18.9 055 13.1 100 11.9 
008 1.4 056 24 101 67.1 
009 32.5 067 74.5 1 102 48.2 
010 47.9 068 32 103 11.1 
Oil 3.4 069 25.2 104 39 
012 1.6 
1 060 20.4 106 53.2 
013 40.8 061 543.5 106 91.1 
014 16.9 062 18.5 107 18.5 
015 3.4 063 23.5 108 11.4 
016 13.6 064 26.6 109 26.9 
017 38.6 065 13.1 110 42.9 
018 14.2 066 25.5 111 25.2 
019 2.5 067 15.2 112 18.4 
020 70.7 068 15.4 113 15.6 
021 4.3 069 19.9 114 19.9 
022 22.2 070 37.5 116 39.5 
023 21.2 071 24 116 23 
024 242.2 072 13.2 117 34.3 
025 5.9 073 24.6 
026 21.8 074 16.6 
027 19 075 66.8 
028 27.7 076 25.2 
029 18.8 077 21.7 
030 15.5 078 12.5 
031 4.6 079 19.2 
032 20.7 080 17 
033 18.4 081 19.4 
034 13.6 082 23.8 
035 12.4 083 18.6 
036 16.6 084 14.7 1 
037 14 085 17.9 
038 35 086 37.8 
039 43.2 087 21.4 
040 24.7 088 21.6 
041 15.3 089 29 
042 21.3 090 21.8 
043 q! 60.7 091 091 22.8 
044 17.9 092 092 23.1 
045 12.6 093 093 
W 
27.7 
046 4.5 O 94 45.1 
7 095 
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APPENDIX IV IL-1 A DNA sequence 
Accession number: AF536338 
3841 TACCCAGTAGAGCCCTGCCCAG-, ACOTTC--AC-ýC; -IC--CTTCCCTAGAAGAGGTGACTGTT 
3901 GTTCACAGTCCCAGAAAAGCGGGCTCCCCAAAACAATGCAAGGACCCACCTCTCTCTGAA 
3961 CCTCACCCACCCTAGTTTTCCTTTAAAAATCAATTTACAAGAAGATCATGTGAAGGAAAA 
4021 GGTTGGGTGATATTCTAACCCAAGTTAGCTGTTTCTCAACCAAGTTCTCTTTGAAAAATT 
4081 CAACAACCACCTTTGGGGAATTATTTACAACAGAGGAGTGAGGATGGGACCAGGATAGGT RS3783570 (-2037) 
4141 ATTGCCTATGTTGGTGGAACCAGGGTTTTTTTCCTGGATTACCAAAGAGATGGTATGCAT 
4201 TGCTCCCAGAAGCTAAATATCTTCAGGCTTTCAATGGTGGCCTTCACCTGAAAATGTTAT 
4261 CCCTGTTGAAGCTTTCAAGCCAGTATTTTCATAAGAACTATATTTTCTTTGGTGAACTGA 
4321 GGCATTATAATGATGACTATACAGGTTCTTGAGTGACTGAAGCCATCATTAGCATTGTCA 
4381 TTATTTTTGTTTAGTTGCATCTCCATAGCAGCTCACATTCACAATGTGCTTTGCAATTGT 
4441 TCCTTAGCAATAGCCCTCACAAGATTCTCAGGAGGAGAGGGTTAATCAGGATTAACATTT 
4501 CTGTGTTGCCTAAAGAGGAACCAAGGTAAGCAGAAATGTAGCCAGTTGGCTGGCATCACT RS3783521 (-1607) 
4561 GTTGCTTCAGGATTCATCCTTAGACACCCAAGCTTCTACCCTAGTCTGGTGCTACACTTA 
4621 CATTGCTTACATCCAAGTGTGGTTATTTCTGTGGCTCCTGTTATAACTATTATAGCACCA 
4681 GGTCTATGACCAGGAGAATTAGACTGGCATTAAATCAGAATAAGAGATTTTGCACCTGCA 
4741 ATAGACCTTATGACACCTAACCAACCCCATTATTTACAATTAAACAGGAACAGAGGGAAT 
4801 ACTTTATCCAACTCACACAAGCTGCTTTCCTCCCAGATCCATGCTTTTTTGCGTTTATTA RS1800794 (-1303) 
4861 TTTTTTAGAGATGGGGGCTTCACTATGTTGCCCACACTGGACTAAAACTCTGGGCCTCAA RS3783571 (-1287) 
4 921 GTGATTGTCCTGCCTCAGCCTCCTGAATAGCTGGGACTACAGGGGCATGCCATCACACCT 
4 981 AGTTCATTTCCTCTATTTAAAATATACATGGCTTAAACTCCAACTGGGAACCCAAAACAT 
5041 TCATTTGCTAAGAGTCTGGTGTTCTACCACCTGAACTAGGCTGGCCACAGGAATTATAAA 
5101 AGCTGAGAAATTCTTTAATAATAGTAACCAGGCAACACCATTGAAGGCTCATATGTAAAA RS1800587) (-990) 
5161 ATCCATGCCTTCCTTTCTCCCAATCTCCATTCCCAAACTTAGCCACTGGCTTCTGGCTGA 
5221 GGCCTTACGCATACCTCCCGGGGCTTGCACACACCTTCTTCTACAGAAGACACACCTTGG 
5281 GCATATCCTACAGAAGACCAGGCTTCTCTCTGGTCCTTGGTAGAGGGCTACTTTACTGTA 
5341 ACAGGGCCAGGGTGGAGAGTTCTCTCCTGAAGCTCCATCCCCTCTATAGGAAATGTGTTG 
5401 ACAATATTCAGAAGAGTAAGAGGATCAAGACTTCTTTGTGCTCAAATACCACTGTTCTCT 
5461 TCTCTACCCTGCCCTAACCAGGAGCTTGTCACCCCAAACTCTGAGGTGATTTATGCCTTA 
5521 ATCAAGCAAACTTCCCTCTTCAGAAAAGATGGCTCATTTTCCCTCAAAAGTTGCCAGGAG 
5581 CTGCCAAGTATTCTGCCAATTCACCCTGGAGCACAATCAACAAATTCAGCCAGAACACAA 
5641 CTACAGCTACTATTAGAACTATTATTATTAATAAATTCCTCTCCAAATCTAGCCCCTTGA 
5701 CTTCGGATTTCACGATTTCTCCCTTCCTCCTAGAAACTTGATAAGTTTCCCGCGCTTCCC 
5761 TTTTTCTAAGACTACATGTTTGTCATCTTATAAAGCAAAGGGGTGAATAAATGAACCAAA 
5821 TCAATAACTTCTGGAATATCTGCAAACAACAATAATATCAGCTATGCCATCTTTCACTAT 
5881 TTTAGCCAGTATCGAGTTGAATGAACATAGAAAAATACAAAACTGAATTCTTC' 
5941 A-TCCCCGTTTTGACGACGCACTTGTAGCCACGTAGCCACGCCTACTTAAGA(- 
6001 GCGAAGAAGACTGAC EXON I 
6061 'AAAGGTATTOTCCTCACATCTCTGGCTATTAAAGTATTlý--ý-: --, - 
6121 --. ýý-. -TT-CTCTTTGGCTGTTTTCTCTCACATTGCCTTCTCTAAAGCTACAGCCTCTCCT 
6181 TTC-, TTTCTTGTCCCTCCCTGGTTTGGTATGTGACCTAGAATTACAGTCAGATTTCAGAA 
6241 AATGATTCTCTCATTTTGCTGATAAGGACTGATTCGTTTTACTGAGGGACGGCAGAACTA 
6301 GTTTCCTATGAGGGCATGGGTGAATACAACTGAGGCTTCTCATGGGAGGGAATCTCTACT 
6 361 ATCCAAAATTATTAGGAGAAAATTGAAAATTTCCAACTCTGTCTCTCTCTTACCTCTGTG 
6421 TAAGGCAAATACCTTATTCTTGTGGTGTTTTTGTAACCTCTTCAAACTTTCATTGATTGA 
6481 ATGCCTGTTCTGGCAATACATTAGGTTGGGCACATAAGGAATACCAACATAAATAAAACA 
6541 TTCTAAAAGAAGTTTACGATCTAATAAAGGAGACAGGTACATAGCAAACTAATTCAAAGG 
6601 AGCTAGAAGATGGAGAAAATGCTGAATGTGGACTAAGTCATTCAACAAAGTTTTCAGGAA 
6 661 GCACAAAGAGGAGGGGCTCCCCTCACAGATATCTGGATTAGAGGCTGGCTGAGCTGATGG 
6721 TGGCTGGTGTTCTCTGTTGCAGAAGTCAAGATGGCCAAAGTTCCAGACATGTTTGAAGAC EXON 2 
6781 CTGAAJGAACTGTTACAGGTAAGGAATAAGATTTATCTCTTGTGATTTAATGAGGGTTTCA 
Figure 2. The DNA sequence of the human IL- ]A putative promoter. Yellow highlights indicate positions 
of single-nucleotide polymorphisms. Numbers in brackets indicate base positions with respect to the 
translation initiation site blue highlights indicate the translated region (exon 1). Red underlined sequences 
are both forward and reverse primers DNA sequence. 
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APPENDIX V MOLECULAR BIOLOGY PROTOCOLS 
V. 1 TOPO Cloning Reaction 
Set-uiD 
Fresh PCR product 2pt 
Salt Solution 1PI 
Dilute Salt Solution I PI 
Sterile Water I ýfl 
TOPOV vector lill 
Final Volume 6pl 
V. 2 Performing the TOPO Cloning Reaction 
1. Mix reaction gently and incubate for 5 minutes at room temperature (22-230C). 
2. The reaction was placed on ice and proceeded to transforming competent cells. 
V. 3 Chemical Transformation Protocol 
1.2 pl of the TOPO cloning reaction from the TOPO Cloning Reaction was added into a vial of 
One Shot Chemically Competent E coli and mixed gently. 
2. The cells were incubated on ice for 30 minutes. 
3. The tubes were then placed in a 42T water bath for 30 seconds exactly in order to heat shock 
cells then placed back on ice for 2 minutes. Then 250 VI of SOC broth was added to each tube 
which was placed in an Inova 4000 shaking incubator (New Brunswick Scientific) at 225 rpm 
for -60 minutes at 370C. 
4.10-50 pI of medium was then added to each pre-warmed plate which was evenly spread. The 
plates were then incubated upside down for 16 hours at 37*C and colonies viewed the next 
day. 
IVA Isolation of DNA from agarose 
MinElute Gel Extraction Kit, Quiagene was used to isolate PCR products from agarose gel. 
1. After running the PCR product on an agarose gel, the DNA band was excised from the gel 
using a clean scalpel blade and placed into a 1.5ml centrifuge tube. The volume of the gel 
was then estimated by weight (I g=I ml). 
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2.3 volumes of binding buffer (Buffer QG) was added to the excised gel at aI volume 
equalling the volume of the gel. (100mg-100ml). The mixture was agitated gently and 
incubated in a water bath at 50'C for 10 minutes. The microfuge tube was vortexed every 2-3 
minutes to help dissolve the gel. 
3. After gel slice has dissolved completely, I gel volume of isopropanol was added and the 
mixture placed a MinElute column in a provided collection tube to bind DNA. 
4. The DNA-matrix was pelleted by centrifugation at 13000 rpm in a benchtop minicentrifuge 
for I minute. Supernatant was discarded and the DNA/matrix washed in 500 PI binding buffer 
and centrifuged at 13,000 rpm for I minute. 
5. The supernatant was discarded and the DNA-matrix washed twice further in 750pl wash 
buffer PE and centrifuged at 13,000rpm for I minute. The supernatant was removed 
6. MinElute column centrifuged at 13,000rpm for additional I minute to remove residual 
ethanol from buffer PE. 
7. MinElute column placed into a clean 1.5 ml microcentriffige tube and 10 PI elution buffer 
(Buffer EB) was added and was incubated at RT for I minute and, centrifuge at 13,000rpm 
for I minute. The supernatant was removed again and placed into a fresh 0.5ml microfuge 
tube which was stored at -20'C until required. 
8. The recovery of DNA was estimated by running on a 1% agarose gel and the concentration 
estimated by UV spectrophotometer (A260) where 50 pgImI =I absorbance unit 
(Nanodrop, UK). 
V. 5 Ligation 
4x QS ligase buffer 5 pI 
DNA to be ligated 14 pl (100ng) 
Quick -Stick ligase (3U/pl) I-ILI 
Total volume 20 Id 
The above reaction mixture was incubated at RT for 5 minutes and stored at -200C. 
V. 6 Pouring Luria-Bertani Broth (LB Broth)/Agar plate 
1. The LB/Agar was melted using a microwave and left to cool to about 45T. 
2. When cool to touch, 800 gl of ampicillin (50 mg/ml) was added to the 400 ml of LB/Agar, 20 
ml of which was poured per plate (9 cm diameter Sterilin). The top of the agar was then 
flamed to sterilize and remove air bubbles. 
3. The agar plates were dried upside down in a 37'C incubator for I hour, then wrapped in cling 
film and stored at 4'C until required. 
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V. 7 Transformation of JM 109 Cclls 
1.2 pl of ligation mixture was added into sterile Eppendorf (on ice) tubes followed by 50 PI of 
JM 109 competent cells (Promega) 
2. The ligation-cell mixture was incubated on ice for 20 minutes. The tubes were then placed in 
a 42*C water bath for 47 seconds exactly to heat shock cells then placed back on ice for 2 
minutes. Then 700 jil of 2% LB broth was added to each tube which was placed in an Inova 
4000 shaking incubator (New Brunswick Scientific) at 225 rpm for -60 minutes at 37*C. 
3.50 pl of medium was then added per plate which was evenly spread. The plates were then 
incubated upside down for 16 h at 370C and colonies viewed the next day. 
V. 8 Purification of Plasmid DNA from Bacterial cells 
V. 8.1 Mini-Prep Bacterial Cell Culture 
To each falcon tube containing 3 ml of sterile 2% LB broth, 6 jil of ampicillin (50 mg/ml) was 
added. Sterile pipette tips were then dabbed onto selected colonies and transferred into the LB 
broth. The falcon tubes were placed into a shaking incubator at 225 rpm, at 370C for 16 hours. 
QIA Spin Miniprep Kit DNA (Qiagen) was used. 
1. The 3ml bacterial culture described above (mini-prep) was centrifuged at 40OOrpm, OC for 
15 minutes. The supernatant was then discarded and the falcon tubes blotted upside down on 
paper towel to remove excess media. 
2. The pellet was re-suspended in 250 pl of cell re-suspension solution then the re-suspended 
cells were transferred to a 1.5 ml tube. The cells were then lysed by adding 250 PI of lysis 
solution and inverting the tubes four times. 
3.350 pl of neutralization solution was then added and the tube inverted four times. The lysate 
was then centrifuged at 13,000 rpm in a bench top microcentrifuge for 5 min. 
4. The supernatant from above step was applied to QIA-prep Spin Column by decanting and 
centrifuged at 13,000 rpm in a bench top micro centrifuge for I minute. 
5. The QIA-prep Spin Column was washed by adding 0.5 ml Buffer PB and centrifuged at 
13,000 rpm in a bench top micro centrifuge for I minute. 
6. The column was washed again by adding 0,75 ml Buffer PE and centrifuged at 13,000 rpm 
for 30-60 s. The mini-column was then centrifuged at 13,000rpm in a bench top 
microcentrifuge for 2 minutes to dry the resin. The column was removed and transferred to a 
1.5 ml micro- centrifuge tube. 
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7.50 pl of dH20 was applied to the mini-column which was left for I minute. The DNA was 
then eluted by centrifuging the mini-column -microfuge tube assembly for I minute at 13,000 
rpm. The purified plasmid DNA was stored at -200C until required. 
V. 8.2 Maxi-prep Bacterial culture 
Selected bacterial colonies were cultured in 6 ml of sterile 2% LB broth with 12 pl of ampicillin 
(50mg/ml) for 12 hours. The 6 ml culture was then poured into 500 ml of 2% LB broth with 
ampicillin (100pg/ml) and left overnight in a shaking incubator at 370C, 225 rpm for no longer 
than 16 hours. 
1. The 500 ml bacteria] culture described above was divided into two 250 ml Beckman 
centrifuge tubes and centrifuged at 4,000 rpm for 15 minutes. 
2. The bacterial pellet was then re-suspended in 10ml of buffer PI containing RNAse A. Each 
bacterial suspension was transferred into a 40 ml centrifuge tube (Beckman). 10 ml of buffer 
P2 (lysis buffer) was then added to the bacterial suspension which was then mixed by 
inverting the centrifuge tube four times. The bacterial suspension was incubated at room 
temperature for 5 minutes. 
3.10 ml of chilled buffer P3 (precipitation buffer) was then added to the suspension which was 
mixed by inverting the centrifuge tube four times. The bacterial suspension was then 
incubated on ice for 20 minutes and centrifuged at 12,000rpm for 30 minutes at 4*C. 
4. A QIAGEN-tip 500 column was equilibrated by applying 10 ml of buffer QBT, (equilibration 
buffer) then allowing the column to empty by gravity flow. Both supernatants from the 
original maxi prep were then added to one QIAGEN-tip which was allowed to enter the resin 
by gravity flow. 
5. The QIAGEN-tip was then washed twice with buffer QC and the DNA eluted with 15ml 
buffer QF. Elute was transferred to a 40ml tube and the DNA precipitated with 0.7 volume of 
iso-propanol at room temperature. 
6. The precipitate was immediately centrifuged at 9,500 rpm at 40C for 30minutes. The 
supernatant was then discarded and the DNA washed twice with 5ml 70% ethanol. 
7. The DNA was air dried for 5 minutes and re-suspended in Iml distilled H20. The purified 
plasmid DNA was stored at -20'C until required. 
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V. 9. Restriction Digestion 
DNA x pl (2 tig) 
Enzyme specific buffer 2 pl 
Restriction enzyme 0.5 pl (2-10U) 
dH20 y P, 
Total volume 20 pI 
The above reaction was incubated at 37*C for 3 hours. Restriction products were viewed by 
agarose gel electrophoresis. 
V. 10. DNA precipitation 
1. Sodium acetate was added to the DNA solution, in a 1.5 ml microfuge tube, at a ratio of I 
part DNA to 10 parts sodium acetate (pH 3.0) followed by a 2.5x volume of 100% alcohol. 
2. The solution was left for 60 minutes at 40C and centrifuged for 10 minutes at 13,000 rpm. 
The supernatant was then discarded and the pellet washed with 75% alcohol. 
3. The solution was then re-centrifuged at 13,000 rpm for 5 minutes and the supernatant 
discarded leaving the pellet to dry. 
4. The pellet was redissolved in a suitable volume of water or TE buffer, pH 8.0 
V. 11 Site-Directed Mutagenesis 
V. 11.1 Mutant Strand Synthesis Reaction 
1. Prepare the sample reactions as indicated in Material and Methods Table 5.3. 
2. Cycle each reaction using the cycling parameters outlined in Material and Methods Table 5.4 
3. Following PCF, place the reaction was cooled on ice for 2 minutes and then subjected to 
restriction enzyme digestion. 
VA 1.2 DpnI digestion 
1. Add I til (10 U) of the Dpn I restriction enzyme directly to the PCR reaction 
2. Gently and thoroughly mix each reaction mixture by pipetting the solution up and down 
several times. Spin down the reaction mixtures in a microcentrifuge for I minute and 
immediately incubate each reaction at 370C for 2 hours to allow complete cleavage of digest the 
noranutated supercoiled DNA. 
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V. 11.3 Transformation 
1. Gently thaw K coli cells on ice and aliquot 50 pI of cells to a prechilled 14-ml polypropylene 
round-bottom tube (131) Falcon). 
2. Transform competent E coli with I ml of DpnI-treated DNA. 
3. Swirl the transformation reactions gently to mix and incubate the reactions on ice for 30 
minutes. 
4. Heat pulse the transformation reactions for 45 seconds at 421C and then place the reactions 
on ice for 2 minutes. 
5. Add 0.5 ml of LB broth preheated to 420C and incubate the transformation reactions at 371C 
for I hour with shaking at 225-250 rpm. 
6. Plate between 10 and 50 pl of each transformation reaction on ampicillin agar plates (10 
mg/ml) 
7. Incubate the transformation plates at 371C for 16 hours. 
The desired mutations were verified by sequencing the constructs as detailed in sequencing 
section (V. 14). 
V. 12 Luciferase Reporter Assay 
V. 12.1 Protocol for Preparing Cell Lysates 
1. Lysis buffer was diluted from 5X stock and equilibrated to room temperature. 
2. The growth medium was removed from cells and then cells were rinsed with PBS. 200 PI of 
IX lysis buffer was added to cover the cells and incubated at RT for 30 minutes. 
3. Attached cells were removed from the dish using a scraper and cells were transferred to a 
microcentrifuge tube. 
4. Tubes were placed on ice for 10 minutes and the microcentrifuge tubes were vortexed 10-15 
seconds, and then centrifuged at 12,000 xg for 15 seconds at RT. 
5. The supernatants were transferred new tubes and stored at -700C until used. 
V. 12.12 Luciferase Assay Protocol 
1. The samples were taken out and adjusted to room temperature before experiments. 20PI of 
cell lysate were added to each well and mixed with I 00pl of Luciferase Assay Reagent. 
2. The luciferase activity was measured in relative light units with a luminometer. The 
values determined were subsequently standardized to the amount of input protein and 
are indicated as relative light units per microgram of protein. 
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V. 13 P-Galactosidase Assay 
-Z- buffer: 
I OmM KCI 
60mM Na2HP04 
40mM NaH2PO4 
I mM MgS04 
SOmM P-mercaptoethanol 
Adjust pH to 8 with NaOH at 250C. 
ONPG (4mg/ml in Z buffer) 
IM Na2C03 
1.50 VI of cell extract was added to 250 pI of Z-buffer. 50 pI of ONPG (ortho-nitrophenyl-beta- 
D-galactopyranoside) was added to mixture and vortexed briefly. 
2. Samples were incubated at 37'C for 30 minutes or until a faint yellow color has developed 
and the reaction was stopped by adding 250 pl of IM sodium carbonate and mixed by 
vortexing briefly. 
3. Optically clear 96- well plates were used to read in a plate reader. 100 pI of mixture was 
added to each well and absorbance of samples was read at 405nm in a plate reader. 
V. 14 Direct sequencing 
Exosap 1,5 pl in each well 
a. PCR product 3,5 pl 
b. Total volume =5 pl 
2. Cover 
3. Spin 
4. PCR machine - GC, Exosap (programme), 10 gl (min vol), heated lid, approx 37 min 
5. Make up Big dye master mix; 
a. I til Bigdye 
b. I jil water 
c. 3 pI better buffer 
6.5 gI of this mix per sample 
7. Add I jil of primer (forward or reverse) 
8. Cover and spin 
9. PCR machine -GC, BigDye programme, 10 pl, appox 2.46 hrs. 
10. Ethanol/ ammonium acetate solution - 60 pI per well 
a. Invert several times to mix and centrifuge at 3100 rcf, 41C 30 min 
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11. Prepare spreadsheet for 3700 
12. Add Cold 70% ethanol - 100 ýtl per well and spin for 2 min at 3 100 rcf at 41C 
13. Repeat step 12 
14. Remove ethanol spin for I min at 250 rcf at 4'C 
15. Leave to dry 10 min 
16. Resuspend in 10 pl water 
17. into fresh microplate add 8 pl hydide formamide 
18. Transfer 10 pl of sample into microplate and mix by pipetting 
19. Spin for 2 min 3 100 rcf 
20. Place in 3700 in holder and run for 4 hours 
DNA sequences obtained were analysed for sequence identity with known human genomic DNA 
sequences using the BLAST online search engine (http: ý', ',, kw",. ncbi. nlm. nih. ý,, ov/ BLAST). Below 
figure shows an example of BLAST sequence match obtained. 
V. 15 Example of an electropherogram obtained form sequencing PCR or plasmids 
120 130 140 150 160 
lk7AT TC TAA CC CAAG T TAG CT GT TT CT C AAC CAA GTTC TC TTTG AAA A Al 
Figure 3 Part of an electropherogram of DNA sequenced from a PCR product 
V. 16 Example of BLAST search results obtained from plasmid sequences 
Referene 
Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schtiffer, inghui Zhang, Zheng Zhang, 
Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation 
of protein database search programs", Nucleic Acids Res. 25: 3389-3402. 
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RID: 1172009972-32520-153901653553. BLASTQ3 
Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST. STS, GSS, environmental 
samples or phase 0,1 or 2 HTGS sequences) 5,001,276 sequences; 19,821,175,605 total letters 
Taxonomy report 
Distribution of 38 Blast Hits 
Sequences producing significant alignments: Score E 
(bits)value 
6122385323161AF536338. Iý Homo sapiens interleukin 1, alpha 1423 0.0 
jzijl43l83951gbiAC079Z53.7j Homo sapiens BAC clone RPI 1-671-14 1423 0.0 
jzil2831737OItpeIBNO00002. IIHSA000002 TPA: TPA 
- 
exp: Homo sapiens 1409 0.0 
gi1201438311gbIAC112235.41 Homo sapiens BAC clone RPI 1-285DI 1409 0.0 
izil33785lembIX03833. I IHSIL I AG Human gene for interleukin I alpha 165 3e-37 
gil32823251gblAFO 10237.11 Mus musculus interleukin- I alpha gene, 107 7e-20 
Alignments 
>qiJ223853231gb1AF536338.11 Homo sapiens interleukin 1, alpha (IL1A) 
gene, complete cds 
Length=18446 
Score = 1423 bits (718), Expect = 0.0 
Identities = 788/799 (98%), Gaps = 5/799 (0%) 
Strand=Plus/Plus 
AAACAATGCAAGGACCCACCTCTCTCTGAACCTCACCCACCCTAGTTTTCC 
AAACAATGCAAGGACCCACCTCTCTCTGAACCTCACCCACCCTAGTTTTCC 
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